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From within their ecologic niches, zoonotic viruses emerge from animal reservoirs into the edges and 
centers of human habitation to exploit opportunities for unabated transmission within 
immunologically–naïve populations.  Our understanding of where, in whom, and how these viruses 
emerge is under direct challenge, driving the evolution of modern infectious disease epidemiology 
within a rapidly-connected global community.  The studies presented herein are based on analyses of 
both aggregate and case-level data, which, we argue, provide unique insight into the complexities of 
transmission, co-infection, and clinical sequelae occurring within, and arising from, epidemics of 
emerging zoonotic viruses.  In Chapter II, we investigate differences in disease severity between single- 
and multi-serotype dengue virus infections, and examine the clinical presentation of patients with 
dengue versus patients with dengue virus-Leptospira co-infection.  Our objective was to construct a 
diagnostic algorithm to aid clinicians in the early recognition and treatment of patients with multi-
pathogen infections.  In Chapter III, we reconstruct a six-person transmission chain of Ebola virus 
disease in Liberia.  We analyze the individual behaviors and epidemic control measures that 
contributed to, and interrupted, transmission.  Finally, in Chapter IV, we present a case series of pain 
profiles and functional disability among survivors of Ebola virus disease, a contribution to the newly-
recognized post-Ebola virus disease syndrome.   
 
Our research contributes three principal implications for clinical and public health practice.  In Norte 
de Santander, Colombia, we provide the first prevalence estimates of dengue virus multi-serotype 
infection and dengue virus-Leptospira co-infection.  Identifying the reservoirs of pathogenic Leptospira 
spp. in Los Patios, and initiating public and clinical education campaigns, will be important 
interventions to mitigate environmental persistence, prevent additional cases, and encourage early 
initiation of antibiotic therapy.  From case investigations in Liberia, we identify sweat as an under-
recognized driver of the Ebola virus disease epidemic, and discuss the importance of social distancing 
to interrupt transmission.  Finally, we describe the clinical symptoms and longitudinal disability 
experience of three Ebola virus disease survivors to contribute to the growing evidence of a post-viral 




INTRODUCTION TO THE RESEARCH AND REVIEW OF THE LITERATURE 
 
Approximately 75% of new diseases emerge from animals.1  At the human-animal interface, a complex 
set of eco-evolutionary pressures induces changes in a virus’ genome, and, therefore, the RNA or DNA 
architecture.  These architectural modifications enable expansion of the viral host range2, and confer 
transmission and replicative advantages within immunologically-naïve populations.3 Genomic changes 
are the result of interdependent evolutionary pressures from diverse ecosystems, physiologic processes, 
population changes, social dynamics, and human behavior.4  Understanding the confluence of these 
pressures informs changes in the global risk surface,5 that is geographies with conditions, pathogens, 
and ecologies rife for emergence events.  The Institute of Medicine developed the Convergence Model 
to characterize four principle categories of evolutionary pressures that drive emergence events.6   
 
1) Genetic and Biological Factors 
Genome mutation, recombination, and reassortment optimize routes of transmission and exploit 
pathways of suppression and/or avoidance of the host immune response.7-9  Particularly for error-
prone RNA viruses, these changes may encode a new protein or receptor, expanding the host range 
of the pathogen, such as the human adaptation of HIV from non-human primates (NHPs) to 
human,10 pandemic influenza H1N1 from birds,11 and Plasmodium falciparum from gorillas.12  
 
2) Physical and Environmental Factors 
Deforestation and road construction create threads for human travel through previously 
impervious forests, providing opportunities for spillover from animal reservoir to human host.13  
The repurposing of land for large-scale agricultural production, particularly for palm oil 
production, gives rise to food insecurity by removing food-source species habitats, driving changes 
in hunting practices and consumption of NHPs,13,14 which share genetic similarities with humans.7  
 
3) Ecological Factors 
Rising atmospheric temperatures increase the amount of rainfall, which provides pools of standing 
water for mosquitos breeding sites, and changes the density and diversity of vegetation and resident 
species.15 Warmer temperatures and higher humidity permit expansion of mosquito vectors into 
new regions;16 increase biting rates, which ultimately increases the risk to humans of mosquito-
borne viral and parasitic infections. 
 
4) Social, Political, and Economic Factors 
Urbanization, mining, political instability, and environmental degradation create conditions of 
poverty, social inequality,17 and human susceptibility to emerging viruses.6  The absence, or 
decline, of public health infrastructure in the developing world has created regions in which the 
detection and control of an emergence event is weakened or nonexistent,18 such as the West Africa 





INTRODUCTION TO THE RESEARCH AND RATIONALE FOR THE USE OF CASE-STUDY 
METHODOLOGY 
 
Shoe leather epidemiology has been replaced by the use of mathematical models for large-scale 
predications for epidemic response.19  These models necessarily rely upon the accuracy and amount of 
data used to inform model parameters that attempt to identify and explain causal links and pathways.5  
The ability to detect and predict emergence events requires targeted surveillance among susceptible 
populations, combined with the ability to rapidly deploy a robust, appropriate, and adaptive public 
health response.  A multidisciplinary engagement of basic science, medicine, social science, and policy 
is required to address transnational health issues and mitigate the consequences of epidemics. Working 
within these complexities requires integration of empirical evidence, the underlying mechanisms of 
transmission, clinical management, and preventive strategies for global public health practice. 
 
The case study, or naturalistic approach, has a long tradition in clinical practice, medical research, and 
infectious disease epidemiology.  The central tenet of a case study is a need for in-depth, multi-faceted 
explorations of complex scientific and anthropologic phenomena within their natural context.20  In 
contrast to the experimental design, in which predictor variables are manipulated to explore 
associations with an outcome of interest, the case study approach is based in interrogation, an approach 
that submits to examination of the critical events, interventions, policies, and consequential human 
and pathogen responses.  The case study approach lends itself, with limitations, to in-depth analysis 
of complex events and associations when human behavior is an essential—and under-appreciated—
influence on pathogen behavior.  The case study affords granular insight into gaps in control strategies, 
microscale drivers of transmission, and cultural factors that determine the success or failure of 
transmission control strategies. 
 
 
ORGANIZATION, HYPOTHESIS, AND RESEARCH OBJECTIVES  
 
DENV is the most common arbovirus infection, increasing in both its global distribution and 
profound burden of disease, primarily due to the co-circulation of the four serotypes.21  EBOV, once 
said to be a ‘bit player in the global drama of emerging diseases’,22 has demonstrated its ability to cause 
widespread morbidity and mortality, and its potential for regional destabilization and interruptions to 
global transportation and commerce.  The foci of this research are dengue virus and EBOV, identified 
by the World Health Organization (WHO) as two of ten greatest threats to global health in 2019.23  
We present investigations into the epidemic transmission, co-infection, severity, and clinical sequelae 
of hyper-endemic circulation of dengue viruses (DENV) in northeastern Colombia and the 2014 
emergence of Zaire ebolavirus (EBOV) in West Africa.   
 
The overarching hypothesis of these studies is that case-study methodology is uniquely able to: 
1) Identify changes in clinical severity related to multi-pathogen infections;  
2) Describe the contextual drivers of viral transmission and estimate key transmission 
parameters for use in predictive modeling; and 
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3) Characterize post-viral symptomology and disability after infection with an emerging 
zoonotic virus. 
 
 Chapter II.  Dengue Virus Multi-Serotype Infection and Leptospira Co-Infection 
 
We performed a hospital-based serosurvey of patients with acute febrile illness (AFI) in Norte de 
Santander, Colombia during the epidemic years of 2013 and 2014. 
 
 Research Objectives   
1) To estimate the prevalence of DENV multi-serotype infection (MSI) and DENV-
Leptospira co-infection in Norte de Santander. 
2) To examine differences in clinical severity and identify indicators associated with 
differential clinical presentation among patients with DENV MSI compared to patients 
with DENV single-serotype infection (SSI), and patients with DENV-Leptospira co-
infected compared to patients with DENV only.  
3) To develop a diagnostic algorithm for use by clinicians in DENV-endemic areas lacking 
diagnostic capabilities. 
 
 Chapter III.  Familial Transmission of Zaire ebolavirus 
 
Using an instrumental case study approach,24 we investigated the transmission events, progression of 
EVD, and the clinical outcomes of a six-person cluster in Liberia.  
 
 Research Objectives   
1) To describe the individual behaviors, settings, modes and routes of EBOV transmission, 
highlighting the circumstances of single-day exposure and transmission events. 
2) To estimate, with greater precision, the key transmission parameters of EBOV using 
individual exposure-transmission data. 
3) To illustrate protective measures used by the family and local health workers to prevent 
community transmission, whilst describing deficiencies in the international response. 
 
 Chapter IV.  Post-Ebola Virus Disease Syndrome 
 
To investigate physical complaints and associated disability among survivors of the EVD cluster 
described in Chapter III, we conducted serial physical examinations and measured changes in 
functional ability by applying intrinsic case study methodology24 specific to the exploration of unique 
phenomena.  
 
 Research Objectives   
1) To perform a comprehensive history and physical examination. 
2) To identify and examine the anatomical locations of pain. 
3) To measure functional ability between pre-EVD and at two post-EVD timepoints. 
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REVIEW OF THE LITERATURE—DENGUE VIRUS  
 
Dengue is a complex viral illness transmitted among humans by Aedes mosquitoes.  It is one of 53 
human-pathogenic flaviviruses, which include Japanese Encephalitis virus (JEV), West Nile virus 
(WNV), Yellow fever virus (YFV), and Zika virus (ZIKV), each of which have historical or emerging 
global distribution.25,26  First identified during WWII in Southeast Asia among military personnel,21 
its emergence and persistence have made it one of the leading causes of tropical morbidities.27  There 
have been episodic outbreaks and epidemics since the 18th century.28  As climate change alters weather 
patterns and increases ambient temperatures, rainy seasons are lengthening, and the mosquito vector 
is expanding from its tropical regions to temperate climates with naïve populations.  Between 1990 
and 2013, the incidence of dengue doubled each decade, from 8.3 million apparent cases in 1990 to 
58.4 million in 2013.27  In 2010 alone, the total global burden of dengue was estimated at 390 million 
cases, of which more than 75% (294 million) cases were undiagnosed and untreated.29  In 2019, nearly 
40% of the world’s population is at risk of infection with a dengue virus, a disease with a mortality 




DENV (family Flaviviridae, genus Flavivirus)30 is a positive-sense, single-stranded RNA virus of 11-
kilobases (kb).  During translation, the genome is cleaved into ten proteins to yield three structural 
proteins and seven non-structural proteins (Figure 1).31  E, on the virion surface, is the principle 
inducer of antigenicity and thereby the primary target for the human antibody response.32  E also 
forms the basis of classification of the four DENV serotypes (DENV-1-4), which share ~70% sequence 
homology but differ at the E protein in sequence and structural translation.33  The homology of the 
sequences and similarity in protein structure form the basis of temporary cross-protection of antibodies 




DENV has both a sylvatic transmission cycle and a human transmission cycle.  While considered to 
be of the same evolutionary origin, the two cycles are now maintained separately in different ecologies, 
with different strains, and with different mosquito species.35  Sylvatic dengue transmission occurs 
 
Figure 1. Dengue Virus Genome 
The viral particle is encoded by structural proteins C (capsid), E (envelope), 
and M (membrane); nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, 
NS4B, NS5) control replication.   
Reprinted from Guzman MG. Lancet. 2014;385(9966):453-465.   
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among forest-dwelling non-human primates (NHPs) and Aedes luteocephalis and furcifer in Sub-
Saharan Africa, and Ae. niveus spp. in Southeast Asia.35  The human transmission cycle is maintained 
primarily by the anthropophilic Ae. aegypti, which utilize water-storage containers for oviposition and 
remain inside dwellings for frequent blood meal acquisition.36  Their introduction to the Neotropics 
during the Age of Sail likely occurred by slave and commerce vessels traveling from West Africa to the 
Caribbean.37,38  During the construction of the Panama Canal from 1903-1914, the morbidity and 
mortality from YFV threatened progress of its construction.25 Public health efforts focused on 
eradicating the mosquito vector, and transmission of the virus ended in 1906.  However, when 
eradication efforts failed in Cuba, Venezuela, and the Caribbean Community, the species returned.  
Today, Ae. aegypti are endemic throughout the tropics, with climate change driving their expansion 
into temperate regions.15 
 
 Multi-Serotype Infection 
A mosquito acquires infection with more than one DENV serotype by acquisition of a single blood 
meal from a human with an MSI, or multiple blood meals from differentially-infected humans.39-42  
Human MSI results from one or more bites by a mosquito infected with multiple DENV serotypes, 
or by consecutive bites from differentially-infected mosquitoes.43,44  The first report of a DENV MSI 
occurred in Puerto Rico in 1982.45  Since then, MSIs are reported with increasingly frequency and of 
and expanding global distribution (Figure 2, Appendix B), with India and Brazil reporting the majority 
of cases.  The scholarship of the clinical implication of DENV MSI is sparse; some studies report and 
describe the clinical severity of MSI patients, while others wholly exclude them from analyses and 
provide no clinical data.  
 
Among case reports of MSIs and studies of MSIs as the primary outcome,46,47 the evidence is 
inconclusive.  In one study of MSIs in a Malaysian cohort,46 DENV-1/2 and DENV–1/3 
combinations were associated with at least one severe dengue manifestation.  Patients with DENV-
1/2 had severe thrombocytopenia (<50.0 x 109 platelets/L), pleural effusion, and fluid accumulation 
with respiratory distress.  Hemorrhagic manifestations have been observed with greater frequency in 
patients with MSIs (Appendix B).47,48 MSIs will be detected with increasing frequency, and 
understanding how they modulate disease and contribute to the modern epidemiology of dengue will 





Figure 2. Number of Published Reports of Dengue Virus Multi-Serotype Infections, By Country, 1985-2018 
Corresponding references are listed in Appendix B by country and author’s last name. 
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 Human Infection and Disease 
 
Dengue is a systemic and dynamic disease with a clinical spectrum encompassing asymptomatic 
infection to a critical illness.49 Its severity is influenced by host genetics, pre–existing immune 
repertoires, and nutritional factors.31  Following an incubation period of three to seven days, the course 
of illness follows three phases—febrile, critical, and recovery (Figure 3).49   
 
 Febrile Phase 
The initial symptom of dengue is characterized by a temperature ≥38.5°C and then sudden onset of 
headache, myalgia, and arthralgia.49  The patient will develop thrombocytopenia, leukopenia, and 
elevations in hepatic transaminases.   
 
 Critical Phase 
Between days post-illness onset (DPO) 4-7, the stable patient can deteriorate suddenly to the critical 
phase is marked by evidence of endothelial compromise (i.e., increasing hematocrit, lethargy, 
abdominal pain, hypotension, rapid pulse), severe thrombocytopenia, and diffuse ecchymoses.49  These 
signs and symptoms of hemodynamic collapse precede cardiopulmonary shock and death. 
 
Not all patients with dengue progress to the severe forms of disease; however, early diagnosis of DENV 
infection enables identification of at-risk patients, and is critically important for initiation of 
supportive therapies.49   
 
Figure 3. Phases of Clinical Dengue, with Clinical Symptoms and 
Laboratory Changes  
Reprinted from WHO. Dengue: guidelines for diagnosis, treatment, 
prevention and control: new edition. 2009.  
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Molecular detection of DENV RNA is the gold standard for laboratory diagnosis of acute dengue, 
but, for the majority of affected countries, not available.  Therefore, diagnosis is symptom-based, 
although rapid antibody-detection kits increasing available, largely through WHO initiatives to 
expand laboratory capacity in developing countries.18  
 
 Recovery Phase 
Recovery begins when IgM and IgG concentrations approach their peak (Figure 3). Endothelial 
compromise is reversed, and symptoms quickly resolve.  A profound fatigue lasting up to a month has 
been reported in up to 50% of patients,50 and has been associated with age and female sex.51,52 
 
  Immune Response to DENV Infection 
Disease progression and outcome are determined by the balance of the protective and pathologic 
immune responses (i.e., suppression of viral invasion) (i.e., pro-inflammatory).53  In the primary 
immune response, the immune system has its first encounter with a DENV serotype.  Production of 
IgM antibodies produced by plasma cells and memory B-cells neutralizes the virus, which is cleared 
by the lymphatic system.31,54  Serotype-specific IgG antibody confers life-long immunity to infection 
by the same serotype, with temporary cross-protection against infection by a heterologous serotype.55   
 
A unique aspect of dengue is the potential to have up to four infections with each of the four serotypes 
during a lifetime.  The primary DENV infection is the first encounter of the immune system with the 
virus, producing IgM and serotype-specific IgG antibodies.31,54  Recovery occurs when the virus is 
neutralized and removed by the lymphatic system.  Secondary infection, however, has the potential to 
invoke a more complicated immune response, and, therefore, a critical clinical progression of disease.  
Sequential infection by one of the four serotypes is the immunopathology of the critical phase of 
dengue.  Referred to as original antigenic sin,34 and antibody dependent enhancement (ADE),56 this 
critical state is characterized by systemic, excessive immune activation of pro–inflammatory cytokines 
produced in response to a second infecting serotype. Due to their sequence homology and 
conformational similarities at the E receptor site, pre-existing antibodies produced during the patient’s 
primary infection are stimulated by a secondary serotype.56 Rather than mount a new, energy-
expensive, highly-specific immune response, expression of viral epitopes activates pre-existing memory 
B- and T-cells. 56  Cross-protection  leads to cross-induction, resulting in suboptimal binding avidity 
and only partial neutralization of the secondary, heterologous serotype.  Incomplete neutralization of 
viral replication results in excessive cytokine release, systemic inflammation, endothelial disruption, 
and hemodynamic instability.34,57   
 
 
REVIEW OF THE LITERATURE—ZAIRE EBOLAVIRUS  
 
The ebolaviruses (Filoviridae) are enveloped, non–segmented, negative–stranded RNA viruses.58  
Paleoviral dating places their existence on Earth since the early Miocene period,59 approximately 23.8 
to 5.3 million years ago.60 There are six recognized species61: Zaire ebolavirus (EBOV), Sudan ebolavirus 
(SUDV), Taï Forest ebolavirus (TAFV), Bundibugyo ebolavirus (BDBV), Reston ebolavirus (RESTV), 
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and Bombali ebolavirus.62,63 At present, EBOV, SUDV, TAFV, and BDBOV are known to be 
pathogenic in humans.  In the Philippines, where RESTV has been found in bats colonies,64 the virus 
caused outbreaks in laboratory NHPs65,66 and domestic swine.67 In both outbreaks, animal handles 
developed antibody evidence of exposure to the virus, but none developed clinical symptoms.68,69  The 
newly-identified Bombali ebolavirus can mediate entry into human cells but has not been associated 
with human disease.63   
 Virology  
 
The EBOV genome is seven linearly-arranged genes of 16-19 kb (Figure 4).58 Nucleoprotein (NP) 
forms the helical filaments that encapsidate the viral RNA and confer protection from nucleases and 
products of the innate immune response. 58  Viral proteins (VP) 35 and 30 are transcription activation 
factors and interferon antagonists and suppressors of innate immune-cell signaling.70 Soluble 
glycoprotein (sGP) circulates at high levels early in infection and is thought to impair the humoral 
immune response by binding and steric impedance of neutralizing antibodies.71 VP40 is required for 
assembly and budding of viral particles from infected cells, and is the most abundant protein in the 
virion.72  VP24 is an interferon antagonist, and, L, the RNA-directed RNA polymerase responsible for 




The fruit bat Rousettus aegyptiacus is a recognized reservoir of Marburg virus, a filovirus progenitor of 
the ebolaviruses.73,74  Historically, Central African outbreaks of ebolavirus have been linked to human 
contact and consumption of bats and sick or dead NHPs (Appendix A) within remote, densely-
forested regions in Central Africa (Figure 5) often associated with mining activity.75  In areas where 
NHPs are rare or absent, fruit bats serve as an alternative protein source.76,77  
 
In perhaps the germinal paper of the 2013-2016 West Africa EBOV outbreak, a two-year-old boy, 
known to play inside a large tree stump that hosted a bat roost, was identified as the index case of the 
West Africa epidemic.78  In 2018, a partial sequence of EBOV was identified from a Greater Long-
fingered bat in Nimba County, Liberia,79 an area with mining activity.80  In the same year, the full 
genome of Bombali ebolavirus was isolated from an Angolan freetail bat colony in the Bombali District 
of Sierra Leone,63 also a mining region.80  Given these recent findings, the long-standing hypothesis 
implicating Chiroptera bat species as reservoirs of filoviruses is gaining traction.73,81,82  
 
 
Figure 4. Filovirus Genome Structure 
Reprinted from Messaoudi, I. Nat Rev Microbiol. 2015;13:663–676 
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 Epidemiology  
 
Emergence History of the Ebolaviruses 
The first recognized spillover of an ebolavirus, SUDV, into humans occurred in June 1976 in present-
day Republic of South Sudan in a cotton factory worker who had consumed bushmeat.83  The second 
spillover event, also of SUDV, occurred in August 1978, near the Ebola River in DRC, in a man who 
had consumed bushmeat.84 He attended a local health clinic and received an injection. The 
contaminated needle was subsequently used to administer injections to other patients at the clinic, 
which infected 318 people (CFR 88%).  In 1979, an outbreak of SUDV among 34 people (CFR 65%) 
occurred in the same region of the Republic of South Sudan as the 1976 outbreak.85  Following a 
quiescence of 15 years, TFV was isolated in 1994 from an ethnologist working in the Taï Forest in 
Côte d’Ivoire who received a percutaneous needle stick while performing a necropsy of a chimpanzee.86 
In 1994, EBOV was identified as the causative ebolavirus species of three separate outbreaks in Gabon 
(n=52, CFR 60%), each linked to alterations in the forest canopy by mining activity, gorilla mortality, 
and the butchering and consumption of a sick chimpanzee.87  From this same outbreak, a Gabonese 
 
Figure 5. Geodistribution of Human Ebolavirus Outbreaks and Putative Bat-Reservoir Species, Sub-
Saharan Africa 
Reprinted from Spengler JR. Emerg Infect Dis. 2016;22(6):956-963 
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HCW became infected, was transferred to South Africa, and infected a South African HCW.88 In 
1995, a charcoal maker in DRC was the index case of an outbreak of EBOV that infected 315 people 
(CFR 81%).89  Between 2000 and 2012, there were ten outbreaks in Uganda, Republic of Congo, 
DRC, and the Republic of South Sudan (Appendix A).  During this period, the newest ebolavirus 
species, BDBV, emerged in Uganda in 200790-92 and DRC in 2012.93    
 
Epidemic Parameters  
The incubation period for a pathogen, defined as the interval from exposure to onset of clinical 
symptoms, is a function of the intensity and nature of contact.94  Therefore, the incubation period is 
dependent on the infectious dose (e.g., viral load), route of infection (e.g., percutaneous, inhalational, 
contact), and the duration of exposure (i.e., single contact or prolonged exposure periods).  For 
outbreaks of ebolavirus, the incubation period is a key epidemic parameter used for determining the 
timing and length of isolation and quarantine, length of enhanced syndromic surveillance, and for 
declaring the end of an outbreak.19,95  The current incubation interval used for epidemic monitoring 
is 2-21 days, which is derived from the first outbreak of SUDV in 1976.96,97 Across all species and 
modes of transmission, the mean incubation period is 3.4-12.7 days (range 1-21 days).98  By species, 
the incubation period for EBOV is 5.3-12.7 days (range 1-21 days),19 3.35-12 days (range 1-16 days) 
for SUDV,19 and 6.3-7 days (range 2-20 days) for BDBV.91,92  For single-day exposures, which provide 
greater precision but are rarely documented, the mean incubation period is 6.22 days (SD ± 1.57 days) 
across all species.95 Needle-stick transmission had a mean incubation period of 6.3 days, compared to 
9.5 days for contact with blood and bodily fluids.89,97,99-101  
 
The Changing Epidemiology of Ebolavirus Outbreaks 
In December 2013, a two-year-old boy in Guinea set off an historic outbreak in West Africa that 
infected at least 28,616 people (CFR 39.5%).78 For the first time in history, an ebolavirus outbreak 
had broached a highly-populated urban center. Then, in 2017, the DRC experienced its eighth 
outbreak of EVD when the index case butchered the wild boar at the same market where an NHP was 
butchered and sold.103  In 2018, two separate outbreaks the DRC would herald a watershed event for 
outbreaks of ebolavirus: transmission in an active war zone.104 Today, transmission continues 
unabated, with no evidence of slowing transmission or decreases in cases. 
 
 Human Ebola Virus Disease 
 
Sources and Modes of Transmission   
Ebolavirus transmission to humans occurs by contact with the blood, body fluid, or infectious carcass 
of a NHP, bat, antelope, and other forest mammals.73,105  Human-to-human transmission occurs by 
contact with infectious body fluids of a living or deceased human. Historically, an index case is a male 
member of a remote forested community who works in mining or logging, or who recently hunted 
and butchered an infected animal (Appendix A).  An index case sets in motion an outbreak through 
two primary transmission pathways. In the first transmission pathway, female family members, who 
serve as primary caregivers in traditional African cultures, provide bedside care for the index case. Stool 
and vomitus are the primary sources of transmission during outbreaks, as high viremia and viral 
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shedding through fluid loss coincide with the phase of illness when patients require care.106  Additional 
secondary cases arise among community members who travel to provide care, attend a religious 
ceremony, or participate in funereal rituals. In the second transmission pathway, HCWs who are 
infected when the index case seeks care at a local or regional facility. For smaller, localized outbreaks, 
an index case infects an HCW at a rural facility, who generates tertiary cases among family members 
and a smaller number of patients who reside in the surrounding village.  For larger outbreaks, an index 
case infects an HCW at a larger health facility, which serves a large population center. Tertiary 
transmission occurs within the hospital among patients and family members, who return to distant 
villages and homes within larger cities. Percutaneous exposures (i.e., needle-stick, scalpel injury, 
injection using a contaminated needle) are associated with a high infectious dose and high mortality.  
Among patients exposed by use of contaminated needles during the 1976 outbreak, the case fatality 
rate was 100%, versus 80% among patients exposed to infectious body fluids.107 
 
EBOV has been detected in saliva, sweat, urine, breast milk, synovial fluid, spinal fluid, ocular fluid, 
stool, vomitus, and semen.108  The contribution of saliva, sweat, urine, breast milk, and products of 
conception to transmission during an outbreak is unknown.109 There are no documented reports of 
human transmission from aerosols, but the role of aerosols110 and virus persistence on fomites has been 
suggested.111-113   
 
Until the West Africa outbreak, human transmission was considered restricted to the symptomatic 
period of EVD, and the risk of transmission following recovery was, theoretically, zero.109  However, 
in July 2015, two separate chains of transmission, one in Liberia114,115 and one in Guinea,116 were 
linked by molecular analyses to sexual intercourse with male survivors whose semen was EBOV-
positive.  It is now recognized that harborage of virus in immune-privileged sites is an ongoing risk for 
potential outbreaks in the region. 
 
 Clinical Progression 
The latent period, or dry phase, is symptomatic onset fever, headache, myalgia, arthralgia, sore throat, 
and a distinguishingly profound weakness.117  In the first three days post-illness onset (DPO), the viral 
load increases exponentially in blood, from undetectable to >105 viral particles/mL, and continues 
within the vascular system for another 3-7 days.118  The infectious period, or wet phase, begins with 
onset of vomiting and diarrhea and shedding of virus through fluid loss.  It corresponds to peak viral 
loads, and, for some, progression to hemorrhage and fatal sequelae.  Pregnancies will spontaneously 
abort during this phase.119  Diaphoresis is remarkable; extensive fluid loss from vomiting and per-
rectum peristaltic expulsion is estimated at 3-10 L per day.117  If present, hemorrhage appears first at 
the gum line at intravenous catheter and injection sites, with progression to subconjunctival 
hemorrhage, melena, petechiae, and diffuse ecchymoses.120 Loss of electrolytes, most critically 
potassium and calcium, causes muscular rigidity, confusion, alterations in consciousness, cardiac 
dysrhythmias, hypovolemia, and vascular collapse.106  In the absence of timely, supportive care, organ 




 Disease Outcomes 
Viral load is a predictor of clinical severity and outcome.121  The West Africa outbreak provided a large 
dataset from which analyses of prospective and retrospective associations could be investigated.  From 
these data, a clearly-defined, divergent course for survivors and decedents emerged based on the 
differences in the amount and kinetics of their viral loads.121-128  Patients who survive EVD have slower 
viral replication, lower peak viral loads (Figure 6), and a shorter duration of less severe symptoms.117  
In contrast, patients who succumb to EVD have higher viral loads and demonstrate rapid increases 
and a prolonged symptomatic period of increasing severity.117 In an analysis of viral loads in 65 patients 
in Sierra Leone, patients who presented with fewer than <100,000 EBOV copies/mL of serum had a 
CFR of 33%, whereas those with a viral load of >10 million EBOV copies/mL of serum had a CFR 
of 94%.128 Importantly, patients with higher viral loads have rapid onset of severe, debilitating 
symptoms. As patients become bedridden, requiring total care by family and community members, 
prolonged contact with highly-infectious body fluids dramatically increases the risk of infection for 
caregivers. 
 Immune Response 
While surviving EVD is multifactorial, the governing principles is inactivation of replicating virus by 
the humoral immune response.118,123  The natural portals of virus entry are the mucosal surfaces and 
the skin, where macrophages and dendritic cells, the primary cellular targets of ebolaviruses, promote 
dissemination to multiple cell types throughout the body fluids and tissues,58 including sites previously 
considered immune-privileged (e.g., central nervous system [CNS],129 ocular chamber130).  
 
 
Figure 6. Viral Load Kinetics, Distribution of Virus in Body Fluids, and Antibody Response 
Reprinted from Malvey D. Lancet. 2019;393:936-948. 
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Severe EVD is characterized by an intense inflammatory response with by high concentrations of pro-
inflammatory mediators.131  Simultaneous immune suppression and overactivation results in global 
immunosuppression, a complex pathogenesis of insufficient and deranged innate and adaptive 
immune responses.132,133  Systemic and uncontrolled viral replication causes apoptosis, tissue necrosis, 
coagulopathies, and compromise of the vascular endothelia.134-136 
 
There is no licensed treatment for EVD.  Survival is achieved by rapid and balanced humoral and 
cellular immune responses.137  Aggressive rehydration with concomitant electrolyte replacement can 
support cell and tissue function until development of the antiviral immune response.131 In Africa, 
treatment for EVD is limited to oral rehydration salts, oral nutrition, intravenous fluid recessitation, 
paracetamol, and presumptive treatment for malaria.138 In the absence of such therapies, multiple 
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CLINICAL SEVERITY AND IDENTIFICATION OF DIAGNOSTIC DISCRIMINATORS IN 
PATIENTS WITH DENGUE VIRUS MULTI-SEROTYPE INFECTIONS AND  
DENGUE VIRUS-LEPTOSPIRA CO-INFECTION, NORTE DE SANTANDER, COLOMBIA 
 
The clinical presentation of dengue as a non-specific AFI is indistinguishable from other tropical 
etiologies, which constitute an already heavy burden of disease in endemic areas. In the tropics, viruses, 
bacteria, and parasites occupy similar ecological niches, and infection is not restricted to one pathogen.  
For regions of hyperendemic circulation of all four DENV serotypes, such as Colombia, concurrent 
infection with more than one serotype, or MSI, occurs from the bite of a single mosquito infected 
with multiple serotypes,1,2 sequential mosquito bites from differentially-infected mosquitoes, as the 
presence of two DENV serotypes in one mosquito has been demonstrated.3,4 as has simultaneous 
infection with two arboviruses.5  Since 2003, Colombia has been hyperendemic for co-circulation of 
all four serotypes,6 yet there are no published reports of MSIs in Colombia.   
 
Leptospirosis is a bacterial disease caused by one or more of 250 pathogenic leptospire serovars.7 The 
burden of disease is known to be high but is undefined.8  Untreated disease can lead to kidney and 
liver failure, with death in 5-15% of cases.9 The bacteria are responsive to treatment with readily 
available, cost-effective antibiotics, including doxycycline; therefore, early diagnosis is critical to 
improving patient outcomes.10 Because of overlapping geographies and the similarity of acute 
presentation, leptospirosis is often misdiagnosed as dengue.11,12  In Colombia, the seroprevalence of 
anti-Leptospira antibodies is as high as 76%.13,14   Among 53 patients in Córdoba given the diagnosis 
of dengue, more than half were retrospectively reclassified as cases of leptospirosis.15  As a high-
consequence pathogen,16 these findings highlight the global need for clinical education, laboratory 
diagnostic capacity, and the early  for the accurately diagnose and treat disease.  
 
Despite similarities in their clinical presentation, dengue, an intracellular virus,17 and the pathogenic 
leptospires, which are extracellular bacteria,18 differ in their underlying pathophysiology, such that 
divergent host responses, including clinical presentation, may have utility in developing clinical 
algorithms to discriminate differences in their laboratory profiles. We hypothesized that clinical and 
laboratory indicators exist to differentiate between these infections, and we therefore aimed to develop 
a diagnostic algorithm for use in clinical settings. 
 
MATERIALS AND METHODS 
 
 Population Screening and Enrollment 
 
The State of Norte de Santander (Figure 7) lies within the northeast region of Colombia along a 
common border with Venezuela.  The region hosts the Pan American Highway, an artery of vehicular 
and commercial traffic connecting the Caribbean, Venezuela, and internal regions of northern Latin 
America.19  The capital city, Cúcuta, hosts a border-crossing of the Pan American Highway and was 




As part of a larger study of serotype diversity and transmission ecology in Norte de Santander, we 
conducted a cross-sectional seroprevalence study of DENV and pathogenic Leptospira among patients 
with an AFI presenting for care at Hospital Erasmo Meoz, a 700-bed referral and teaching hospital in 
Cúcuta, and the Hospital de Los Patios, a multi-service referral center in the Cúcuta suburb of Los 
Patios.  An AFI was defined as a fever >38.0°C of unknown etiology.  Continuous enrollment occurred 
from January 2013 to October 2014, which coincided with an epidemic of dengue in Colombia.21  
Adults (>18 years) who agreed to participate in the study provided written informed consent for use 
of clinical and laboratory data, and use of a serum aliquot for research testing at Louisiana State 
University (LSU).  Children (7-17 years of age) provided verbal informed assent, with written 
informed consent from a parent or guardian; informed consent was provided by a parent or guardian 
for children <7 years of age. 
 
Patients were interviewed for history of present illness.  Clinical and laboratory data were extracted 
from medical records.  De-identified data were transmitted  electronically to LSU for analysis.  Serum 
aliquots were maintained at -80o C by study personnel.  Temperature integrity was monitored and 
maintained during international shipping to LSU.    
 
Norte de Santander, Colombia 
 
Figure 7. Regional Map of Mexico, the Caribbean, and Northern Latin America 
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 Ethics Statement 
The study protocol was approved by the Instituto Departamental de Salud of Norte de Santander, and 
ethics review boards at the Hospital de Los Patios, the Hospital Erasmo Meoz, and the LSU Human 
Subjects Institutional Review Board (IRB) (Appendix D).  Serum aliquots were obtained in 




Detection of Dengue Virus RNA 
Molecular testing for DENV serotypes 1-4 RNA was performed at the LSU School of Veterinary 
Medicine, Department of Pathobiological Sciences, by multiplex RT-qPCR targeting the DENV-
specific NS1 gene, as previously described.22  RNA was extracted using the MagMaxTM-96 Viral RNA 
Isolation Kit (Ambion/Life Technologies, Carlsbad, CA) and detected by RT-qPCR with the 
Superscripts III® Platinum® One-Step RT-qPCR system (Life Technologies, Carlsbad, CA) on the 
LightCycler 480 (Roche Diagnostics Corp., Indianapolis, IN).  Extracted samples were tested using 
the following protocol: (1) reverse transcriptase step (1 cycle) at 48°C for 2 minutes and 95°C for 2 
 
Figure 8. Seroprevalence Study Enrollment Flowchart, Norte de Santander, Colombia 
Abbreviations: DENV, dengue virus; N, total number of enrolled patients; n, number of patients 
per group.  Numbers within parentheses correspond to percentages (%).  
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minutes; (2) amplification and data recording step (40 cycles) at 95°C for 15 seconds and 60°C for 30 
seconds.  Primers and probes specific to each DENV serotype23 were designed and obtained through 
Integrated DNA Technologies, Inc. (Coralville, IA). 
 
Detection of Pathogenic Leptospira spp. DNA 
Detection of the pathogenic gene LipL32 was performed according to the protocol developed by 
Stoddard, et al.24  Leptospira DNA was extracted using the MagMaxTM-96 DNA Multi-Sample Kit 
(Ambion/Life Technologies, Carlsbad, CA).  The reference standard for LipL32 was Leptospira 
interrogans serovar icterohaemorrhagiae from culture-extracted DNA (Dr. Sreekumari Rajeev, 
University of Georgia, College of Veterinary Medicine, Veterinary Diagnostic Laboratory).  The 
primers and the probe were obtained from Integrated DNA Technologies according to the sequences 
used by Stoddard, et al.24 The amplification protocol (LightCycler 480, Roche Diagnostics 
Corporation, Indianapolis, IN) consisted of 8 minutes at 95 °C, by 45 cycles of amplification (95 °C 
for 10 seconds and 60 °C for 30 seconds), finishing with a cool cycle of 45 °C for 5 minutes.  Serial 
dilutions of cDNA, probes, and primers were performed to achieve a desired concentration 
approximating the expected concentration of the target gene in human sera.24   
 
Measurement of Anti-Dengue Virus IgM and IgG Antibody Concentrations 
Anti-DENV IgM and IgG was detected by MAC-ELISA (InBios International, Inc., Seattle, WA).  
The assay was optimized for each DENV serotype as previously described.22  Briefly, 96-well plates 
were coated with 1 μg/mL of Flavivirus capture antibody 4G2 at 4°C overnight, blocked for 1 hour 
with 5% dry milk in PBS at 37°C, and incubated with each of the serotypes or uninfected cell culture 
(media control plate) for 2 hours at 37°C.  Diluted human serum (100 µL/well) was incubated for 2 
hours at 37°C on a shaker.  Plates were washed 3 times with PBS and 0.1% Tween, and then incubated 
at 37°C for 1 hour with 100 µL/well of goat anti-human IgG antibody diluted 1:1,000 horseradish 
peroxidase-conjugated antibodies (Caltag Laboratories, Burlingame, CA).  
Colorimetric development was obtained as follows: 100 µl/well tetra-methyl-benzidine incubated for 
10 minutes at room temperature.  The reaction was stopped with 100 µL/well of 1 M phosphoric stop 
solution, and absorbance was measured at 450 nanometers.  Each sample was tested in triplicate with 
three controls per plate: 1) control blank: 2 wells without 4G2 or DENV to control for nonspecific 
induction of color for any of the reagents used in the assay; 2) negative control: 2 wells with 4G2 and 
no DENV to control for any nonspecific color induction of the coating antigen; and 3) positive control 
from human serum with a known concentration of anti-DENV IgG antibodies. 
 
 Clinical and Etiologic Definitions 
 
A dengue case was defined as a patient with molecular detection of DENV RNA, of any serotype, by 
RT-qPCR, without consideration of anti-DENV IgM or IgG antibody status.  Patients were classified 
according to their infection status in by the following PCR-outcome categories: 
 
DENV-negative Patients without molecular detection of DENV RNA 
DENV-positive Patients with molecular detection of DENV RNA 
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DENV SSI DENV-positive patients with infection by 1 serotype  
DENV-1 DENV-positive patients with infection due to DENV-1 only 
DENV-2 DENV-positive patients with infection due to DENV-2 only 
DENV-3 DENV-positive patients with infection due to DENV-3 only 
DENV-4 DENV-positive patients with infection due to DENV-4 only 
DENV MSI DENV-positive patients with infection by >1 serotype 
Leptospira-positivePatients with molecular detection of gene LipL32 
 
Clinical and laboratory data were collected using the information queried by the CDC Dengue Case 
Investigation Report (Appendix F).  Due to the lack of population-standardized hematotologic indices 
for the Colombian adult or pediatric populations, we applied the clinical reference ranges published 
by the American Board of Internal Medicine for adults, and those used by Texas Children’s Hospital 
Department of Anesthesiology and Pediatrics (Appendix G) for pediatric patients.   
 
 Research Objectives 
 
Hypothesis 1:  The means of the identified hematologic indices will be different and indicative of 
greater clinical severity in DENV MSI versus DENV SSI, such that: 
 
Hox: ?̅?𝑥Group 5 = ?̅?𝑥Group 4 Hoy: 𝑦𝑦�Group 5 = 𝑦𝑦�Group 4 Hoz: 𝑧𝑧̅Group 5 = 𝑧𝑧̅Group 4 
Hax: ?̅?𝑥Group 5 < ?̅?𝑥Group 4  Hay: 𝑦𝑦�Group 5 < 𝑦𝑦�Group 4 Haz: 𝑧𝑧̅Group 5 > 𝑧𝑧̅Group 4 
 
Rationale 
Hematologic indices are clinical predicators of severity.  We identified the following endpoints to 
define clinical severity:    
1) Leukocytes (x) = where ?̅?𝑥 is the mean leukocyte count; 
2) Platelets (y) = 𝑦𝑦� is the mean platelet count; and 
3) Hematocrit (z) = where 𝑧𝑧̅ is the mean hematocrit. 
 
The central importance of these indices in DENV pathogenesis and clinical presentation is supported 
by the following observations: 
1) Leukopenia, defined by WHO as <5.0 x 109 leukocytes/L for adults,25 is a hallmark feature of 
the early phase (i.e., DPO 2-10) of dengue.  It occurs in 76-100% of dengue cases and is 
associated with viral destruction or inhibition of mononuclear lineage cells. 
2) Thrombocytopenia, defined by WHO as <100.0 x 109 platelets/L for pediatric and adult 
patients,25 is a major clinical manifestation of moderate-severe dengue occurring DPO 3.5.  
The estimated prevalence of thrombocytopenia is 26-50%.25  It is associated with capillary 
permeability secondary to endothelial dysfunction in the progression of dengue from the 
febrile to the critical phase. 
3) Hemoconcentration, defined by WHO as a change in hematocrit >20% above baseline for 
adults.25  It is a major clinical manifestation of moderate-severe dengue and an indicator of 
dysfunction of the endothelial barrier and plasma leakage into the perivascular space.25 
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Hypothesis 2:  One or more clinical characteristics or hematologic indices differentiating DENV-
Leptospira co-infected patients from DENV-positive patients can be incorporated 
into a clinical algorithm for use in under-resourced clinical settings. 
 
Ho: Due to the identical clinical presentation of dengue and leptospirosis in the acute phase (i.e.,  
DPO <7), no clinical characteristic or hematologic index is able to differentiate DENV-
Leptospira co-infection from DENV SSI and provide decisional support for clinicians without 
access to comprehensive diagnostic testing. 
 
Ha:  Despite the identical clinical presentation of dengue and leptospirosis in the acute phase (i.e.,  
DPO <7), one or more clinical characteristic(s) or hematologic index(ices) is able to 
differentiate DENV-Leptospira co-infection from DENV SSI to provide decisional support 
for clinicians without access to comprehensive diagnostic testing. 
 
 Rationale   
Leptospirosis is a differential diagnosis for tropical AFI,26 and leptospirosis is frequently misdiagnosed 
as dengue.13 A case-control study in Bucaramanga, Colombia,27 demonstrated significant differences 
in leukocyte and platelet counts between patients with dengue and patients with leptospirosis, 
supporting the utility of these indices as part of a diagnostic algorithm.  The central importance of 
investigating DENV-Leptospira co-infections is supported by the following:  
1) Dengue and leptospirosis have overlapping geographic regions of endemnicity28; 
2) Dengue and leptospirosis have identical acute clinical presentations27; 
3) Laboratory diagnosis of leptospires is highly technical, lengthy, and not readily available 29; 
4) Leptospirosis is a disease of high consequence but is treatable by cost-effective, readily-available 
antibiotics.9,12 
 
 Statistical Analyses 
 
Frequency of Demographic and Clinical Characteristics 
The prevalence of demographic characteristics was expressed as numbers and percentages. Categorical 
variables (i.e., clinical characteristics) were expressed as numbers and percentages.  Group comparisons 
were performed using X2 test or Fisher’s exact tests, as appropriate for the sample sizes under 
comparison.   
  
 Comparison of Means for Hematologic Indices 
Parametric One-way ANOVA was used to compare the means of continuous variables (i.e., 
hematologic indices).  Between-group mean differences were compared using the Student’s t test and 
the Mann-Whitney U test (Wilcoxon rank sum test) where applicable.   
 
 Logistic Regression 
Logistic regression was used to model the relationship between DENV infection status. Crude and 
adjusted odds ratios (OR) were used to assess measures of association.   
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 Post-Hoc Analyses 
Two types of post-hoc analyses were performed.  First, restricting the analyzable cohort to only 
DENV-positive patients, we used a case-case approach30 with DENV-positive patients as the case-
control and differentially-infected subgroups (i.e., SSIs and MSIs) as case-case groups.  Due to both 
zero values and small samples sizes in the outcome subgroups, case-case analyses could not be 
performed or failed to approach statistical significance.  A second approach was a principal component 
analysis aimed at detecting signals of association between variables, particularly the interrelated 
hematologic indices.     
 
Statistical analyses were performed in SAS version 9.4 ® (Cary, NC).  P values were based on 2-sided 




 Participant Demographics  
 
Between January 2013 and October 2014, 216 patients with an AFI were enrolled and underwent 
molecular testing for DENV and Leptospira spp.  Los Patios (n=124, 57.4%) and Ocaña (n=50, 
23.4%) were overrepresented in the enrolled cohort; 64.1% (n=66) of DENV-positive patients were 
from Los Patios (Table 1, Figure 8).  Although recruitment was continuous, 50% of patients were 
enrolled between October and December of 2013, presenting for care a mean of 3.6 DPO (range 2.0-
8.0 days).  Timing of presentation for care did not differ by infection status (DPO 3.6 for DENV-
positive versus DPO 4.0 for DENV-negative, p=0.1508), nor did admission to hospital (16.8% for 
DENV-positive versus 27.2% for DENV-negative, p=0.2003). Twenty-eight (27.2%) patients were 
hospitalized; 18 (64.3%) were pediatric patients.  There were no differences between SSI and MSI 
patients for timing of presentation for care or admission to hospital. 
 
Female patients comprised 44.4% (n=96) of the enrolled cohort; there were no pregnancies. Co-
morbid conditions—trisomy 21 and hepatitis B virus (HBV)—were recorded for two patients (0.9%). 
The mean age for the enrolled cohort was 20.0 years (range <1-92 years), compared to 19.8 years 
(range 1-87 years) for the DENV-positive cohort.  Pediatric patients (<18 years) comprised 63.0% 




One hundred and three (47.7%) patients were positive for DENV (Figure 8).  SSIs (n=88) accounted 
for 85.4% of DENV-positive infections and MSIs (n=15) 14.6% of all DENV-positive infections.  
Three patients were tested positive for infection with a pathogenic Leptospira spp., providing a cohort 
infection prevalence of 1.4%.  Anti-DENV IgM and IgG antibody data were available for 91.2% 
(n=103) of DENV-negative patients and 49.5% (n=51) of DENV-positive patients.  However, the 
data did not form the basis of classification of infection status, nor was it used to infer associations 
between acute etiology and clinical data. 
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 Single- and Multi-Serotype Infection   
DENV-2 was the predominate SSI (n=34, 38.6%), followed by DENV-3 (n=24, 27.3%), DENV-1 
(n=21, 23.9%), and DENV-4 (n=9, 10.2%) (Figure 8).  DENV-2/4 (n=5) accounted for 41.7% of 
MSIs, followed by DENV-2/3 (n=4, 33.3%), DENV-3/4 (n=2, 16.7%), and DENV-1/2 (n=1, 8.3%).  
Triple-serotype combinations were DENV-1/2/3 (n=1), DENV-1/3/4, (n=1), and DENV-2/3/4) 
(n=1). 
 
 Clinical Presentation 
 
Headache (52.3%) and myalgia (49.1%) were the most frequently reported symptoms for all enrolled 
patients, similar to DENV-negative patients (headache 79.3%, myalgia 75.0%) (Table 2). DENV-
positive patients reported headache (52.4%), myalgia (49.5%), and vomiting (27.2%).  Abdominal 
pain was reported by 46.2% (n=6) of patients with DENV-1 SSI, and DENV-2 SSI patients reported 
retro-orbital pain (n=11, 52.6%).  Signs of bleeding were observed in seven (6.8%) patients (Table 3). 
  
Figure 9. Patients with Dengue and Leptospirosis, by 
Municipality of Residence 
Numbers inside colored indicate number of patients. 







Table 1. Seroprevalence Survey Descriptive Data for Dengue-Positive 





All Participants DENV-positive DENV-negative
N (%) N (%) N (%)
 Abdominal pain 33 (15.3) 17 (16.5) 15 (25.9) 0.1832
 Arthralgia 35 (16.2) 14 (13.6) 17 (29.3) 0.3030
 Diarrhea 7 (3.2) 5 (4.9) 2 (3.5) 0.3075
 Epistaxis 4 (1.9) 2 (1.9) 2 (3.5) 0.5283
 Gingival bleeding 1 (0.5) 1 (1.0) 1 (1.7) 1.0000
 Headache 113 (52.3) 54 (52.4) 46 (79.3) 0.5493
 Icterus 1 (0.5) 1 (1.0) 0 (0)  †
 Hospitalized 53 (24.5) 28 (27.2) 25 (22.1) 0.9800
 Hypotension‡ 1 (0.5) 1 (1.0) 0 (0)  †
 Myalgia 106 (49.1) 51 (49.5) 15 (75.0) 0.3418
 Oliguria 3 (1.4) 3 (1.4) 0 (0)  †
 Petechiae 6 (2.8) 1 (1.0) 3 (5.2) 0.4364
 Rash 26 (12.0) 12 (11.7) 13 (22.4) 0.0783
 Retro-orbital pain 58 (26.9) 24 (23.3) 27 (46.6) 0.1946
 Tachycardia§ 1 (0.5) 1 (1.0) 0 (0)  †
 Vomiting 46 (21.3) 28 (27.2) 14 (24.1) 0.7528
Abbreviations: DENV, dengue virus. 
* Fisher's exact X 2 p -value significant at < 0.05.
† Not applicable due to zero values.
‡ Blood pressure <90/60 mm Hg.
§ Heart rate >100 beats per minute.
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DENV-1 only DENV-2 only DENV-3 only DENV-4 only MSI only
N (%) N (%) N (%) N (%) N (%)
 Abdominal pain 6 (46.2) 4 (21.1) 4 (23.5) 2 (25.0) 1 (6.7)
 Arthralgia 2 (15.4) 5 (26.3) 4 (23.5) 2 (25.0) 1 (6.7)
 Diarrhea 1 (7.7) 1 (10.5) 1 (5.9) 0 (0) 0 (0)
 Epistaxis 0 (0) 3 (15.8) 0 (0) 0 (0) 0 (0)
 Gingival bleeding 0 (0) 0 (0) 0 (0) 0 (0) 1 (6.7)
 Headache 8 (61.4) 17 (89.5) 13 (76.5) 8 (100.0) 8 (53.3)
 Icterus 0 (0) 0 (0) 1 (5.9) 0 (0) 0 (0)
 Hospitalized 4 (30.8) 11 (57.9) 5 (29.4) 3 (37.5) 3 (20.0)
 Hypotension* 0 (0) 1 (10.5) 0 (0) 0 (0) 0 (0)
 Myalgia 9 (69.2) 14 (73.7) 15 (76.5) 8 (100.0) 7 (46.7)
 Oliguria 1 (7.7) 1 (5.3) 1 (5.9) 0 (0) 0 (0)
 Petechiae 0 (0) 1 (5.3) 2 (11.8) 0 (0) 0 (0)
 Rash 2 (15.4) 3 (15.8) 2 (11.8) 1 (12.5) 4 (26.7)
 Retro-orbital pain 4 (30.8) 10 (52.6) 6 (35.3) 2 (25.0) 2 (13.3)
 Tachycardia † 0 (0) 0 (0) 1 (5.9) 0 (0) 0 (0)
 Vomiting 0 (0) 7 (36.8) 7 (41.2) 3 (37.5) 5 (33.3)
Abbreviations: DENV, dengue virus; MSI, multi-serotype infection; SSI, single-serotype infection. 
* Heart rate >100 beats per minute.
† Blood pressure <90/60 mm Hg.
                
    
Clinical Feature





Table 4. Mean Hematologic Indices, by Dengue Virus Infection Status 





































































































































                    
  
Index P  value
Abbreviations: DENV, dengue virus; L, liter; g/dL, grams per deciliter; L, liter; MSI, multi-serotype infection' SD, standard deviation.
* N=1.     





 Hemoglobin and Hematocrit 
Despite the correlation between hemoglobin and hematocrit, and their dual-dependence on whole 
blood and plasma volume,31 this biological correlation did not hold in our analyses.  DENV-2 had the 
highest mean hemoglobin (15.0 + 16.4 g/dL), consistent with hemoconcentration, but there were no 
significant between-group differences (Table 5).   
 
The mean hematocrit for the enrolled cohort (40.8%) was statistically equivalent across all groups 
(p=0.9616, data not shown), while the mean hemoglobin was significantly different across all groups 
(p=0.0232) (Table 4).  In the principle component analysis, no significant associations emerged, 
including between hemoglobin and hematocrit.  The extent of missing data (Appendix I), particularly 
for DENV-negative patients, likely contributed to this counterintuitive finding. 
 
 Leukocytes 
The mean leukocyte count for all enrollees was 3.9 x 109 cells/L, which falls just below the lower limit 
of the adult clinical reference range of 4.0 x 109 leukocytes/L (Appendix G).  The DENV-2 SSI group 
did not have leukopenia (?̅?𝑥leukocyte count = 4.4 ± 2.1 x 109 cells/L) and was the only infection group with 
a mean leukocyte count exceeding the cohort mean (4.4 ± 2.3 x 109 cells/L), although the difference 
was not statistically significant (p=0.5382) (Table 4).  In regression analyses (Table 6), only DENV-1 
was marginally associated with leukopenia (OR 2.85; 95% CI 1.05-7.74), which, when adjusted for 
age (aOR 2.82; 95% CI 1.02-7.79) and DPO (aOR 2.84; 95% CI 1.05-7.72) weakened but remained 
significant.   
Group 1 Group 2
(g/dL)
  95% CI*
DENV-2 DENV-negative 2.1 0.90-3.22
DENV-2 DENV-1 2 0.33-3.63
DENV-2 DENV-3 2.2 0.61-3.86
DENV-2 DENV-4 1.81 -0.42-4.03
DENV-2 DENV MSI 1.9 0.09-3.70
Abbreviations: DENV, dengue virus; g/dL, grams per deciliter.
         Difference between mean values of group 1 and group 2.
*t -test significant at p <0.05. 
?̅?𝑥1-?̅?𝑥2 
?̅?𝑥1-?̅?𝑥2






All enrolled patients met the clinical criteria for thrombocytopenia (<150.0 x 109 platelets/L) with a 
cohort mean of 102.3 + 43.5 x 109 platelets/L.  We observed no overall association between platelet 
count and DENV infection status (p=0.1559).  DENV-2 SSI patients had the lowest mean platelet 
count (81.8 + 47.3 x 109/L), and DENV-3, the highest (110.1 + 40.8 x 109 /L).  However, there were 
between-group differences for DENV-2 SSI patients.  Compared to DENV-negative patients, DENV-
2 SSI patients had a significantly lower platelet count (?̅?𝑥=28.3 platelets, CI 6.70-49.91), as did DENV-
3 SSI patients when compared to DENV-2 SSI patients (?̅?𝑥=18.1 platelets, CI 2.42-33.75) (Tables 4 
and 7).  Neither SSI nor MSI predicted severity of thrombocytopenia.   
 
 
Model Parameter OR (95% CI) P  value
DENV infection status x leukocytes DENV-1 2.85 (1.05-7.74) 0.0394
DENV infection status x leukocytes
     Adjusted for Age
DENV-1 2.82 (1.03-7.69) 0.0432
DENV infection status x leukocytes
     Adjusted for DPO
DENV-1 2.84 (1.05-7.72) 0.0401
DENV infection status x leukocytes
     Adjusted for Sex
DENV-1 2.76 (1.02-7.51) 0.4640
Abbreviations: DENV, dengue virus; L, liter.
X2 p -value significant at <0.05.
Table 6. Predictive Models of Leukopenia and Dengue Virus Serotype 1 
 
Group 1 Group 2 N
(109/L)
95% CI*
DENV-2  DENV-negative 68 28.3 6.70-49.91
DENV-2  DENV-3 147 18.1 2.42-33.75
Abbreviations: DENV, dengue virus; g/dL, grams per deciliter.
          Difference between mean values of group 1 and group 2.
* t -test significant at p <0.05. 
         




Table 7. Between-Group Differences in Mean Platelet Counts 
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Multi-Serotype Infection and Clinical Severity 
 
 Adult Patients   
The three adult patients were infected with a serotype combination that included DENV-2, and each 
patient had thrombocytopenia and monocytosis (Table 9).  Clinical symptoms at presentation were 
documented for only one patient, a 62-year-old female (DENV-2/3) from Los Patios who presented 
for care on DPO 4 complaining of headache and myalgia.   
 
 Pediatric Patients 
Twelve of 15 (80.0%) MSIs were in patients <15 years of age (median 8.5 years, range 1-15 years) 
(Tables 10-12).  Males accounted for 75.0% (n=9) of pediatric MSIs.  Ten (83.3%) resided in Los 
Patios, followed by Teorama (n=3, 25.3%) and Ocaña (n=2, 16.7%) (Figure 9).  They presented for 
care a median of DPO 3 (range 3-4 days).  DENV-2/4 was the most frequent serotype combination 
(n=4, 33.3%) (Table 11).  Three patients <16 years of age were simultaneously infected with three 
serotypes (Table 12).  Headache (n=6, 50.0%) and myalgia (n=6, 50.0%) were recorded for half of 
the pediatric MSIs  (Tables 10-12).  All 12 had thrombocytopenia; nine (75%) were classified as mild, 
two (16.7%) moderate, and one (8.3%), a three-year-old male, with borderline severe 
thrombocytopenia.  Gingival bleeding was documented in a two-year old male with a platelet count 
of 75.0 x 109 cells/L.  Leukopenia (n=10, 83.3%) was the second most frequently observed condition, 
followed by anemia (n=4, 33.3%).  
 
 Leptospira-Positive Patients 
 
Table 13 provides demographic, clinical, and hematologic data for Leptospira-positive patients.  Each 
of the three patients was a resident of Los Patios, and two patients were co-infected with DENV.  
Arthralgia, myalgia, thrombocytopenia were common to the three patients; the DENV-negative and 
DENV-2 co-infected patients had moderately severe leukopenia.  Based on the hematologic indices, 
there are indicators of additional etiologies other than those for which we conducted molecular testing.  
The DENV-negative patient, who presented with eosinophilia, could have a parasitic infection or 
other systemic inflammatory process.  The patient co-infected DENV-2, who was the only patient 
admitted to hospital, had a clinical presentation consistent with a hematologic malignancy.  Finally, 
the patient with DENV-3 and HBV had a clinical picture consistent with HIV infection, liver 






Little is known about the processes and consequences of DENV MSI, including their frequency and 
impact on regional transmission dynamics.  In Norte de Santander, which includes the Colombian-
Venezuelan border, neither the prevalence of MSIs nor the prevalence of leptospirosis have been 
determined.  Employing hospital-based surveillance methodology, we tested the sera of 216 AFI 
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patients presenting for care in at two referral centers.  We confirmed 103 cases of dengue, of which 
14.6% were MSIs, and three cases of leptospirosis, of which two were in patients with dengue.  To 
our knowledge, this is the first study to report DENV MSIs and dengue-leptospirosis co-infection in 
this region of Colombia.        
 
DENV-2 and -3 were detected with greater frequency than the other serotypes during our study period 
from 2013-2014.  A study conducted one year later in Norte de Santander, from 2015-2016, identified 
DENV-2 and -1 as the dominate serotypes in circulation for that period.33  As an aside, this study, 
which used hospital-based serosampling, also detected DENV-CHIKV and DENV-ZIKV co-
infections in 40% of serum samples.  Three patients were acutely infected with all three arboviruses. 
 
 Indicators of Clinical Severity  
 
As a clinical syndrome, AFIs present both a diagnostic and treatment challenge for clinicians, 
particularly in developing countries.  Dengue has long been identified as a clinical syndrome identified 
initially presenting with fever, myalgia, and headache.29  The difficulty, therefore, in diagnosing 
dengue has been the non-specific presentation of symptoms that mirror other AFIs.  
Thrombocytopenia and leukopenia were prevalent in this study population, including among the 
DENV-negative patients.  Further, headache and myalgia, the most frequently reported symptoms by 
DENV-positive patients, did not differ by individual serotype of between SSIs and MSIs. Our findings 
underscore the challenge of dengue diagnosis: clinical presentation alone is insufficient.   
 
Overall, no patterns emerged within the MSI cohort to indicate differences in either magnitude or 
severity.  Clinically, the pediatric population is distinct from the adult population, and we were 
underpowered to detect differences between adult and pediatric patients.  Due to small sample sizes, 
which limited statistical power, we grouped patients by infection status, ignoring sex-linked 
physiologic differences that contribute to clinical outcomes for infection diseases.  In case-level 
examination, however, pediatric thrombocytopenia did not appear to differ by SSI or MSI, nor did 
the other hematologic indices.  A larger study, powered to detect differences by age-sex groups, will be 




The National Public Health Surveillance Center for Colombia has one documented case of 
leptospirosis in Norte de Santander, which was in 2007.34  Ours is the second report of leptospirosis 
in Norte de Santander, and the first to identify co-infections with DENV.  We estimate the prevalence 
of leptospirosis to be 1.4%, which is almost certainly an underestimation of the true burden of disease 
in the region.   
 
Arthralgia, myalgia, and mild thrombocytopenia were the common characteristics of Leptospira-
positive patients.  Leukopenia was observed in the one patient with DENV co-infection and in the 
DENV-negative patient.  Leukopenia has been suggested as a potential clinical discriminator between 
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dengue and leptospirosis,12,27 although our findings do not reflect this relationship.  Conversely, the 
patient with dengue, leptospirosis, and HBV did not have leukopenia, but he did have neutrophilia.  
In a comprehensive case report of fatal DENV-Leptospira co-infection in Puerto Rico, 
thrombocytopenia, leukocytosis, with neutrophilia were each observed.12  Neutrophilia is a common 
finding in patients with HBV and, together with the neutrophil-to-lymphocyte ratio, is a 
prognosticator of HBV-associated mortality.32  This patient highlights the difficulty for clinicians in 
interpreting clinical data and determining differential diagnosis.  This unexpected finding further 
emphasizes the ability of case-level data to examine how co-infection can alter the clinical presentation 
of disease. 
 
Our results are subject to a number of limitations and should be considered within the context of 
logistical limitations inherent in global health partnerships.  The main challenge to data analysis was 
the amount of missing data (Appendix I).  Although initially powered for detecting differences among 
the study groups, enrollment fell short of the planned samples sizes, for reasons not related to 
enrollment or study-site participation.  Our use of hospital-based convenience sampling in Norte de 
Santander limits the generalizability of the results to the general population of Colombia, as patients 
seeking treatment may have increased severity, including underlying comorbidities, greater that the 
experience of the general population.  Finally, our study was not designed for a pediatric population, 
nor did we use pediatric specialists to evaluate these patients.  For example, the finding of retro-orbital 
pain in a pre-verbal pediatric patient should be considered with in this context.    
 
A major strength of this study was the examination of hematologic values to evaluate disease severity.  
This enabled identification of clinical indicators that would be of utility at presentation for care, and 
thereby mediate a shorter interval between onset of illness and inhiation of supportive or antibiotic 
therapies.  Further, our use of PCR platforms for diagnosing dengue and leptospirosis avoided the 
ambiguity of antibody response and increased the specificity of inferences about pathogen-specific 
presentation.  However, we did not perform additional testing for other etiologies, and therefore we 
cannot rule out confounding by other chronic and infectious conditions.   
 
 Implications for Clinical and Public Health Practice 
 
Our objectives for this study were twofold: 1) to establish the first prevalence estimates of DENV 
MSIs and Leptospira co-infections in Norte de Santander; 2) to design an algorithm to discriminate 
between the clinical presentations of dengue SSI and MSI, and dengue and dengue-leptospirosis.  Our 
rationale for these objectives is the increasing frequency of co-infections and the need to explore how 
these infections alter disease severity.  Although dengue has no pharmaceutical therapy, leptospirosis 
is treatable with readily-available antibiotics.  Because of the small numbers of both types of infection, 
we identified case-level data as a source of granularity not achieved by the use of aggregate data. 
 
We provided estimates, with limitations, of the prevalence of DENV MSI and DENV-Leptospira co-
infections, but we were unable to conclude that a difference in clinical severity between the acute 
presentation of dengue SSI is different than that of dengue MSI.  While we detected serotype-specific 
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clinical features that invariably present across the spectrum of dengue, including leukopenia and 
thrombocytopenia, we failed to identify clinical features or hematologic measures of clinical severity 
in the MSI patient, although assessment of this relationship using a larger cohort of patients is 
warranted.  The clinical data presented herein will be of utility for background information for pooled 
analyses for future studies of infection severity. 
 
Under-diagnosis and under-reporting of leptospirosis may be due to a lack of clinician awareness of 
the prevalence of disease and environmental reservoirs, and consideration should be given to public 
campaigns and medical education throughout endemic regions. In Colombia, diagnosis of 
leptospirosis requires submission of acute and convalescent sera to private or referent laboratories for 
testing, a cost-prohibitive option for the patient and one too lengthy for delaying treatment.  Increasing 
the availability of rapid diagnostics will be essential for defining the prevalence of leptospirosis, 





Multi-pathogen infections will continue to occur as emerging tropical viruses move into population 
centers where other diseases of poverty and urban density constitute an already high burden of disease.  
The broadening application of molecular technologies for clinical diagnosis, including the use of next-
generation sequencing for describing the intra-host pathogen landscape, will detect these infections 
with increased frequency, requiring clinical interpretation for the treating clinician.  In Norte de 
Santander, Colombia, we estimated the prevalence of multi-serotype dengue disease to be 14.6% and 
the prevalence of leptospirosis to be 1.4%.  We identified co-infections of DENV with pathogenic 
Leptospira spp. and HBV.  While we were unable to identify clinical or laboratory predictors of severity 
associated these co-infections, the implication of multi-pathogen infection on disease pathogenesis, 
clinical manifestation of disease, and pathogen-pathogen interaction should be the subject of targeted 




























































No † 3.8↓ 11.6↓ 37.0↓ 97.0↓ 62.0 36.0 † † 2.0
Abbreviations: Admit, admission to hospital; Baso, basophils; Ct, cycle 
threshold; DENV, dengue virus; DPO, days post-illness onset; Eos, eosinophils; 
Eryth, erythrocytes; Hb, hemoglobin; Hct, hematocrit; IgG, anti-DENV IgG 
antibody; IgM, anti-DENV IgM antibody; Leu, leukocytes; Lymph, 
lymphocytes; Mono, monocytes; ND, none detected; Neut, neutrophils; Plt, 
platelets; and Yr, years.
Above (↑) or below (↓) laboratory reference for age and sex. See Appendix 8 for adult and pediatric 
reference ranges.
† Missing value  












Table 10. Pediatric Dengue Virus Multi-Serotype Infections 

























































IgG+ 4         † Yes † 2.7↓ 12.9 41.0 110.0↓ 57.0 43.0 †
Above (↑) or below (↓) laboratory reference for age and sex. See Appendix # for 
adult and pediatric reference ranges.









Abbreviations: Admit, admission to hospital; Baso, basophils; Ct, cycle threshold; 
DENV, dengue virus; DPO, days post-illness onset; Eos, eosinophils; Eryth, 
erythrocytes; Hb, hemoglobin; Hct, hematocrit; IgG, anti-DENV IgG antibody; 
IgM, anti-DENV IgM antibody; Leu, leukocytes; Lymph, lymphocytes; Mono, 




Table 11. Pediatric Multi-Serotype Infections with Dengue Virus Serotypes 2 and 4 
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Yes † 3.0↓ 11.8 38.0 161.0↓ 55.0 45.0 †
Above (↑) or below (↓) laboratory reference for age and sex. See Appendix # for adult and 
pediatric reference ranges.
† Missing value  









Abbreviations: Admit, admission to hospital; Baso, basophils; Ct, cycle threshold; DENV, 
dengue virus; DPO, days post-illness onset; Eos, eosinophils; Eryth, erythrocytes; Hb, 
hemoglobin; Hct, hematocrit; IgG, anti-dengue virus IgG antibody; IgM, anti-dengue virus 
IgM antibody; Leu, leukocytes; Lymph, lymphocytes; Mono, monocytes; ND, none detected; 


















































Yes † 1.3↓ 13.0 40.0 110.0↓ 52.0 48.0 † † †
Abbreviations: Admit, admission to hospital; Baso, basophils; Ct, cycle 
threshold; DENV, dengue virus; DPO, days post-illness onset; Eos, 
eosinophils; Eryth, erythrocytes; Hb, hemoglobin; Hct, hematocrit; IgG, 
anti-dengue virus IgG antibody; IgM, anti-dengue virus IgM antibody; 
Leu, leukocytes; Lymph, lymphocytes; Mono, monocytes; ND, none 
detected; Neut, neutrophils; Plt, platelets; and Yr, years.
Above (↑) or below (↓) laboratory reference for age and sex. See Appendix # for adult and pediatric 
reference ranges.
† Missing value  






























Negative IgG+ 3 No
Arthralgia
Myalgia
2.6↓ 13.8 43.9 106.0↓ 63.0 29.0↓ 8.0↑
M, 21 yr
Los Patios




2.8↓ 13.4↓ 43.0 112.0↓ 22.0↓ 76.0↑ 2.0
M, 33 yr
Los Patios







4.4 12.6↓ 38.8↓ 117.0↓ 85.0↑ 15.0 †








Clinical Features Hematologic Indices
Abbreviations: DENV, dengue virus; DPO, days post-illness onset; 
Eos, eosinophils; Hb, hemoglobin; Hct, hematocrit; IgG, anti-
DENV IgG antibody; Leu, leukocytes; Lymph, lymphocytes; Neut, 
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INDIVIDUAL BEHAVIORS, SOCIAL PRESSURES, AND FAILURES OF EPIDEMIC 
CONTROL MEASURES THAT CONTRIBUTED TO TRANSMISSION OF ZAIRE 
EBOLAVIRUS AMONG GEOGRAPHICALLY-DISPERSED FAMILY MEMBERS, LIBERIA 
 
A single introduction of EBOV can set off a chain of rapid transmission that accelerates through 
interconnected populations through unregulated border crossings, and all undetected due to a lack of 
public health infrastructure.  In December 2013, EBOV emerged for the first time in West Africa.  
The index case, a two-year-old child in a rural village near the international borders of Guinea, Sierra 
Leone, and Liberia, was that single introduction (Figure 10).1  In March 2014, the first cases of EVD 
were detected in Lofa County, Liberia, with onward transmission to rural villages and the capital city, 
Monrovia.  On 23 March 2014, MSF notified WHO of the outbreak, which had overwhelmed 
humanitarian efforts to isolate and care for cases, and sent affected communities into social turmoil.2  
Not until 139 days later did the WHO respond, on 8 August 2014, with an issuance of a ‘public 
health emergency of international concern’.3  The most extensive and protracted outbreak of EBOV 
unfolded, infecting at least 28,616 people.4 Community resistance,5 the collapse of an already 
inadequate public health system, and a grossly inadequate supply of isolation beds contributed to 
unabated transmission through urban centers and rural areas,6 in a location and on a magnitude 
previously inconceivable.  
 
We reconstructed a chain of transmission of EBOV that originated in a single source and spread to 
five, geographically-dispersed family members.  Through the use of case-level data, we describe the 
physical contacts with the source patient, the circumstances of those contacts, and rarely-documented 
single-event contact between and infected source and secondary cases.  We provide estimates of 
epidemiologic parameters of transmission to inform outbreak dynamics, providing granular 
knowledge applicable to current and future outbreaks of ebolaviruses.  Coupled with case-level data, 
we explain how an inadequate capacity of isolation beds early in the outbreak, at the most crucial 
intervals, perpetuated transmission and contributed to community mistrust and resistance, violence, 
and refusals to accept control measures intended to interrupt outbreak progression.  Finally, we 
identify underrecognized modes of transmission, which may account for EVD in persons with no 
identifiable risk factors, that should be the subject of community education efforts in future outbreaks 





 Ethical Considerations 
 
This study was conducted during the international Ebola emergency response, in which the 
investigators participated in outbreak response efforts, direct patient care, clinical diagnostics, and 
infection prevention and control.  The cases described herein were known to the investigators as part 





Figure 10. Map of Guinea, Liberia, and Sierra Leone International Borders 
Yellow arrowhead indicates the home village of the West Africa epidemic index case.  Lofa 
County, where the first cases appeared in Liberia, is encircled in orange.  Red arrows indicate 
spatial transmission into and through Liberia to the capital city, Monrovia.  Bomi County is 
indicated by the blue circle and within the inset.  The yellow circles identify the Klay checkpoint, 
where the source patient died at the roadside, and Tubmanburg, the location of the isolation and 
treatment centers, respectively. 




evaluations of post-EVD sequelae.  Human subjects approval was granted by the LSU IRB (Appendix 
J), and data collection conformed to all relevant General Principles of the Declaration of Helsinki.7   
Cases and family members were informed of the purpose of the study, that their privacy would be 
protected, and that the findings would be shared within the international community to aid in 
understanding the events and behaviors that contribute to the transmission of EBOV.  Written 
informed consent was obtained and witnessed by a third party.  Cases were interviewed in their homes, 
alone or in the presence of family and community members, as per choice.   
 
 Constructing the Chain of Transmission 
 
Detailed information was collected by standardized questionnaire; open interviews with cases, family 
and community members; and by interviews with staff and review of medical records at the district 
health clinic (DHC).  We investigated, and cross-checked among varied data sources, exposure to the 
source patient, history of local and regional travel, contacts and types of physical interaction, dates of 
symptom onset, progression of clinical illness, and treatments.  To create the fullest possible resolution 
of the chain of transmission, these data were supplemented by information collected from anecdotal 
reports, medications, and receipts obtained during health-seeking events by the cases.  An exposure 
was defined as any physical contact with the source patient during the course of her illness, including 
contact with her body fluids and soiled linens.   
 
 Clinical Descriptors and Definitions of Phases of Ebola Virus Disease 
 
We describe the evolution of EVD by exposure, onset of clinical symptoms, evolution of clinical 
disease, and outcome.  We categorized EVD phase as dry and wet, according to the guidelines and 43-
year history of use by Médecins Sans Frontières,8 the global humanitarian experts on viral hemorrhagic 
fever response and clinical management.  Dry-phase symptoms include fever, myalgia, arthralgia, 
weakness, malaise, headache, and conjunctivitis.  Wet-phase symptoms, including vomiting, diarrhea, 
abdominal pain, hemorrhage, profuse diaphoresis, subconjunctival hemorrhage, and mucosal 
bleeding.   
 
 Definition of Key Epidemiologic Parameters 
 
To describe the transmission dynamics of EBOV in our cohort, we calculated the key intervals that 
correspond to transmission risk associated with the presence of virus in body fluids and tissues,9-11 and 
describe the clinical progression and outcomes of the six cases.  The incubation period was calculated 
as the number of days between exposure to the source patient and symptom onset.  For multi-day 
exposures, we used the first date of contact with the source patient during the wet or infectious phase 
of her disease.  This was an intentional restriction to reflect the biological risk (i.e., probability) of 
virus transmission when virus is contained within the vascular system versus when virus is present in 
the tissues and extravascular fluids.10-11 The clinical onset serial interval (COSI) is the time between 
contact with the source patient in her wet phase and onset of dry-phase symptoms in a secondary case.  
The infectious period was determined by the date of wet-symptom onset to clinical outcome (i.e., 
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recovery or death).  Under epidemic conditions, recovery is necessarily defined as the date of discharge 
from the ETU, as real-time testing for the resolution of viremia was not, and could not, be performed 
in West Africa.  Onset to clinical assessment for an epidemic of EVD is intended to define the number 
of days, and therefore approximate risk of ongoing transmission, that a symptomatic person spends in 
the community before recognition by a health care provider.11  We selected the onset of wet symptoms 
to more precisely describe the risk period of transmission using the same rationale for determination 
of the incubation period.  Hospitalization to recovery/death was determined as the number of days 
between admission to the isolation unit and clinical outcome.  Finally, the CFR was determined by 
dividing the number of deaths by six, corresponding to the number of cases in our chain of 
transmission. 
 
 Data Analysis 
 
Due to our sample size of six persons, we calculated the median value where appropriate.  The 
median for even-numbered data points was calculated by ranking the values in ascending order, 
averaging the two middle values, and dividing the sum by 2.  For odd-numbered data points, the 





 Evolution of the West Africa Outbreak in Liberia 
 
The first case of EVD in Liberia was reported in March 2014 in Lofa County, where five of six districts 
reported transmission.12 The virus reached the capital city of Monrovia in Montserrado County, 
seeding intense transmission and multiple focal outbreaks in rural and remote areas within and around 
Monrovia.13,14 By August 2014, Monrovia reported more than 200 incident cases of confirmed EVD 
per week,15 and Liberia recorded 2,080 suspected, probable, and confirmed cases for the month of 
September.16  By November, incident cases were concentrated in Monrovia and in smaller clusters in 
rural locations.  In Bomi County, the markets and health centers were closed, and clinical staff was 
assigned to operate surveillance checkpoints.  At the time of this transmission chain, there were no 
known sick persons in Bomi County.  Only one source of exposure was reported by each of the 
surviving cases and by the family proxies for the decedent cases.  Our investigation revealed the 
following sequence of events. 
 
 The Source Patient (Index Case) 
On 27 September 2014 (Figure 12), the source patient, a 42-year-old female trader originally from 
Lofa County, traveled 15 km by taxi from her village north of Monrovia to the Red Light District in 
Monrovia to attend the weekly market of traders traveling from Lofa County to sell their highly-prized 
palm oil.  Four days later, on 1 October, she complained of feeling weak while selling goods in a nearby 
village.  On 3 October, she was examined by the district health nurse (DHN), who recorded fever, 
weakness, and myalgia in the clinical dossier.  She reported travel to Monrovia the week prior, but 
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denied contact with sick persons or attending a burial.  The DHN suspected EVD because of her 
connection to Lofa County.  No isolation beds were available in Monrovia or in Bomi County, and 
there were no options for testing.  She was prescribed paracetamol and artesunate-amodiaquine in case 
of malaria.  She was instructed to remain inside her home and contact the DHN in three days if her 
symptoms had not improved.   
 
On 6 October, the source patient grew increasingly weak and developed a persistent, severe headache.  
She walked one km to visit the local roadside druggist in a neighboring village (Figure 11), where she 
purchased additional paracetamol and drugs indicated for malaria.  Her symptoms continued to 
worsen, and her children left her house to stay with the grandmother, approximately 10 feet from the 
home of the index case.  On 8 October, she began to have uncontrolled vomiting and diarrhea and 
was unable to walk.  Her husband remained the sole care provider, and he did not allow anyone to 
enter the home.  Family placed food and water on the porch, but there was no physical contact between 
the source patient and husband with outside persons.   
 
On 13 October, the source-patient’s mother arrived to assist in her care.  On October 15, the husband 
and mother took the source patient by taxi to a private medical clinic at Point Four Junction in the 
West Point area of Monrovia.  The husband slept at a family home in Monrovia where there were no 
sick persons, and the mother slept on the clinic floor next to the source patient.   The index case was 
administered three bags of IV fluids, doxycycline 200 mg daily, cimetidine 800 mg daily, and iron 
400 mg daily for her diagnoses of typhoid fever, malaria, and a bleeding ulcer.  The husband and 
mother reported that the clinic staff told them that the source patient tested negative for EBOV.  
 
On 17 October, the source patient, husband, and mother traveled by taxi approximately 20 km from 
Monrovia to the DHC.  Learning of her arrival, the DHN and district health officer (DHO) brought 
an ambulance to transport her to the isolation center in Tubmanburg.  The family explained that the 
patient has tested negative for EBOV at the Monrovia clinic, and they ardently refused the ambulance 
because they ‘make people disappear.’  The index case remained at the mother’s home.  Believing the 
 
Figure 11. Location of Roadside Druggist, Bomi County, Liberia 
Copyright © 2019 by the author. 
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source patient to be EBOV-negative, her niece provided bedside care by wiping saliva and vomitus 
from her face, and her sister cleaned buckets of vomitus and hand-washed soiled linens in the creek.  
The niece reported washing her face with a cup of water used by the source patient and receiving paper 
money from her to purchase soap.   
 
On 18 October, a brother-in-law arrived to assist the source patient and husband to travel by taxi to 
the isolation center in Tubmanburg.  The brother-in-law assisted the index case into the back of the 
taxi, next to the husband, and then seated himself in the front passenger’s seat.  The DHN spotted 
the source patient in a taxi and stopped the car.  He noted no vomiting or diarrhea by the source 
patient, but noted she was profusely diaphoretic and had bright-red eyes that confirmed she was in the 
hemorrhagic phase.  They again refused transport by ambulance and continued by taxi to the CCC in 
Tubmanburg.  At Klay checkpoint five km from Tubmanburg, the source patient was denied passage 
and instructed to wait on the roadside for an ambulance.  The brother-in-law assisted the source 
patient out of the taxi and hired a motorbike to return to his home in Tubmanburg.  He did not wear 
a helmet, and no information is available about the motorbike operator.  The source patient and 
husband waited separately from the crowd of people gathered at the Klay checkpoint.  The source 
patient experienced intractable vomiting and died four hours later.  The husband carried her body 
behind the checkpoint station and waited one hour for the burial team.  The body of the source patient 
was placed in a body bag, the grounds were sprayed by the attendants, and the husband and body were 
transported in their vehicle to the mother’s home.  A safe burial was performed immediately, followed 
by a wake inside the mother’s home.  Postmortem oral swabbing was not performed.      
 
 Husband 
On 22 October, four days after the death of the source patient, the husband (aged 40 years) 
experienced onset of fever, weakness, and myalgia.  He purchased gentamicin from a village trader and 
took the remainder of his wife’s medications for malaria and typhoid fever.  On 26 October, the 
husband began to have vomiting and diarrhea.  He remained self-sequestered in his home with no 
contact with family members, but he ran into the palm forest directly behind his home when the 
DHN made surveillance visits.  On 29 October, due to a worsening of his condition, the husband 
agreed to be transported by ambulance to the isolation unit in Tubmanburg.  He was confirmed 
EBOV-positive on 6 November and discharged on 21 November. 
 
 Mother 
On 26 October, 8 days after the death of the source patient, the mother (aged 53 years) had onset of 
both diarrhea and ‘heavy weakness’ without fever.  She denied having symptoms during surveillance 
visits by the DHN.  She remained alone in her home until her admission to the Tubmanburg isolation 





Figure 12. Evolution of the Familial Cluster of Ebola Virus Disease: Disease Progression and Events 
Abbreviations: CCC, community care center; DHC, district health clinic; sx, symptomatic. 
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 Sister and Niece 
On 5 November, the sister (aged 38 years) presented to the DHC (Figure 12) with fever, abdominal 
pain, vomiting, diarrhea, subconjunctival hemorrhage, and inability to walk.  She refused ambulance 
transport to the isolation center.  On 6 November, the DHN and the DHO brought an ambulance 
to her home, where the niece (aged 23 years) reported a headache, anorexia, chills, and weakness.  Both 
were transported to the isolation center.  The sister died on 8 November.  The niece progressed to wet 
symptoms, recovered, and was discharged on 23 November.   
 
 Brother-in-Law 
On 23 October, five days after the death of the source patient, the brother-in-law (aged 33 years), had 
onset of fever, headache, and weakness.  He remained in the presence of his family until 27 October, 
when he experienced vomiting and diarrhea.  He isolated himself within a bedroom without contact 
with his family.  On 30 October, he self-presented to the isolation unit and died on 3 November. 
 
 Clinical Course 
 
We resolved the chain of transmission of one source patient and five secondary cases with dates of 
symptom onset and clinical outcome (Figure 15).  The source patient died in the community and is 
classified as a probable case; the five secondary cases, who were each admitted to the isolation unit, 
were laboratory-confirmed as positive for EBOV.  Contact tracing identified no additional cases of 
secondary transmission or tertiary cases, including the taxi driver from the day the source patient died.   
 
The median age was 39 years (range 23-53); three (50%) were female (Tables 14 and 16).  All six cases 
had direct physical contact with the source patient or her body fluids.  The most common mechanism 
of contact was through bedside care, which accounted for transmission in three cases (50%).  One case 
(17%) had contact only with soiled linens and body fluids, and one case (17%) had only skin-to-skin 
contact. 
 
Clinical features (Table 14 and 16) at presentation were nonspecific and included weakness or 
profound weakness in six cases (100%), fever and headache in four cases (67%), myalgia in three cases 
(50%), anorexia in two cases (33%), and one case each had chills (17%) and conjunctivitis (17%).  In 
the wet phase of disease, all six cases (100%) had diarrhea, five (83%) had vomiting, three (50%) had 
subconjunctival hemorrhage, two (33%) had abdominal/epigastric pain, and one case each had 
diaphoresis (17%), melena (17%), and muscular rigidity (17%).  Evidence for hemorrhage was 
available for three cases (50%), of which two were decedents.  The clinical course of the brother-in-
law in the isolation unit was relayed by the husband without dates of onset.   
 
 Epidemic Transmission Parameters 
 
The incubation period is used for monitoring contacts, isolation and quarantine, and  for determining 
a region to be free of transmission following an outbreak.17 The median incubation period for the six 
cases was 6.5 days (range 4-14 days).  For survivors, the median incubation period was 8 days (range 
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8-14 days), possibly suggesting an association between slower disease progression and survival.  For 
the three decedents, the incubation period was 4 days (range 4-5 days) (Table 14).  For single- and 
multi-day exposures, the median incubation periods were 5 days (range 4-8 days) and 11 days (range 
8-14 days), respectively.  The COSI was 21 days (range 20-24 days), which highlights the importance 





Table 14. Demographics and Frequency of Clinical 
Symptoms, by Dry and Wet Phases of Illness 
Abbreviation: n = number of observations. 
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The infectious period is a risk measure of secondary transmission.  We calculated the infectious period 
from onset of wet symptoms to survival or death.  The median infectious period was 11 days (range 
7-32 days) (Tables 15 and 17).  The infectious period could not be determined for the niece, because 
we could not determine the date of wet-symptom onset.   
Onset to clinical assessment (Tables 15 and 17) is an indicator of how early in disease (i.e., time interval 
following symptom-onset) a potentially infectious person is identified in the community for 
intervention.  For the five cases assessed by the DHN, the median onset to clinical assessment was 17 
days (range 3-22 days).  The source patient was the first to seek care, which occurred on her third day 
of symptoms (3 October).  Active case monitoring by the DHN was initiated on 17 October, when 
the source patient returned to the area from Monrovia.  The mother, niece, and sister were initially 
assessed at 20, 21, and 22 days, respectively, post-symptom onset. For the three survivors, the median 
number of days from hospitalization to discharge was 18 (range 17-24 days). Three patients died (CFR 
50%). The source patient died in the community after an 18-day infectious period.  The median 
number of days from hospitalization to death was 15 (range 12-18 days) for the two secondary cases 





 Epidemic Response in Liberia 
 
With the WHO declaration of a public health emergency of 8 August 2014, the Armed Forces of 
Liberia established checkpoints to restrict the movement into and out of affected regions.18  Coincident 
*Calculated for the five secondary cases. 
Table 15. Epidemic Transmission Parameter 
Estimates, Ebola Virus Disease Familial Cluster 
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with the arrival of WHO to the region, the Ebola Response Incident Management System identified 
isolation of persons with EVD as the ‘immediate and overriding objective’ of all response activities in 
Liberia.19  From there, the international response was structured to address the Four Pillars19: (1) early 
detection, isolation, and treatment; (2) safe patient transport; (3) safe and dignified burial; and (4) 
IPC.  Mobilization of district-level surveillance, both within the community and at road checkpoints, 
proved essential for identifying sick persons and maintaining awareness of travel into and out of the 
Bomi County.  The source patient made three separate trips to Monrovia during this time period, 
each of which was by public taxi.  First, on 27 September, she traveled to attend the Lofa market in 
the Red Light District, followed by the second trip on 15 October to seek care at a  private clinic.  Her 
third trip was to seek admission to the isolation center in Tubmanburg.  The husband recounted their 
travel southwest from their village, back to and through Monrovia, and then northeast, because they 
wanted to avoid temperature checkpoints stationed along the main larger roads.   
 
 Isolation and Bed Capacity 
In March 2014, a holding unit was erected adjacent to the county hospital in Tubmanburg with the 
purpose of isolating symptomatic patients and then transporting infected patients to the MSF ETU 
in Monrovia.20 In July, however, concern over HCW infections and the lack of IPC within the holding 
unit led to its closure, and closes of the county hospital and all 23 clinics in the Bomi County 
Community Health Department.20 Then, on August 18 and October 9, two new isolation units 
opened again in Tubmanburg adjacent to the county hospital.  Treatment was limited to oral 
hydration solution, and nurses entered only twice daily to carry in the food dropped off by family 
members. The only diagnostic laboratory was in Monrovia at the MSF ETU, and transport of blood 
samples and results required a motorcycle courier to make the two-hour drive to the laboratory.  
Patients often remained inside the holding unit for days without knowing their infection status, while 
being exposed to patients with EVD.   
 
Between July and December, 2014, 93% of secondary cases were generated by patients who died in 
the community, compared to only 7% from patients who died inside an ETU.14 The failure of the 
WHO to respond rapidly to the epidemic allowed unchecked transmission throughout the affected 
countries.21 While the bed capacity expanded greatly in latter 2014 and into 2015, many treated only 
one or two patients, while others were fully constructed but never commissioned for use.19,22  
 
 Surveillance and Community Resistance 
Initial recognition by the DHN of illness in the source patient would prove critical, because the time 
spent in the community beyond the fourth day of illness presents the greatest—and increasing—risk 
for community transmission.23  The source patient sought care early in her illness (onset to clinical 
assessment=3 days).  Had an isolation bed been available, the five cases of secondary transmission could 
have been prevented.  However, repeated attempts to isolate cases, however, were frustrated not only 
by the lack of isolation beds, but later by the abject refusal of the family to ride in an ambulance.  
Despite decades of response to smaller VHF outbreaks in Central Africa, and the identification of key 
elements of a response, the West Africa epidemic again highlighted a gap in operationalizing a large-
scale response: the fundamental importance of establishing a relationship with the communities 
63 
 
concerned and the public at large.24  Missteps early in the epidemic, in which teams were forcibly 
removing children and family members from their homes, contravened closely-held cultural beliefs in 
honoring the death with burial rites.5,25  Among impoverished populations scarred by histories of 
colonialization and civil war, a disbelief in the existence of ‘Ebola’ thwarted both local and 
international efforts to control the outbreak (Brown H).  Notably, the DHN and DHO, trusted 
members of the community, ended the chain of transmission by bringing the ambulance directly to 
the homes of the husband, mother, sister, and niece (Figure 13).  A flattening of hierarchy24 was not 
understood by leaders of the Ebola response, who had encouraged enforcement rather than 
cooperation to control transmission.6   
 Social Distancing 
Children were not among the secondary cases in this cluster, due to cultural practices of not including 
them in the care of sick family members24,26 and self-sequestration by the cases, noted by Faye et al.9 
as an effective strategy that contributed to interrupting transmission in Guinea.  Social distancing (e.g., 
‘no-touch’ policies), curfews, and prohibitions on large gatherings were announced by radio.12,19 This 
influenced the source patient, husband, and brother-in-law to self-sequester and have no physical 
contact with family.  Of note, the inability to find treatment was a risk factor for transmission in our 
study, particularly the travel and three-day stay of the source patient and mother at the private clinic 




Figure 13. County Ambulance and Chlorine Sprayer, Liberia 
Copyright © 2019 by the author. 
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desperately under-resourced, used the same pair of gloves to treat multiple patients, likely an attempt 
to maintain a barrier between themselves and the many patients under their care.  We cannot rule out 
the clinic as the source of infection for the husband and mother, nor could we determine if the source 
patient infected other patients or family members in the clinic.  If they were exposed to virus in the 
clinic, however, it likely superimposed latent infections from the care provided to the source patient 
once she progressed to the wet phase of EVD. 
 
 Exposures and Transmission 
 
Although we cannot exclude the possibility of EBOV transmission from sources not disclosed or 
discovered, our extensive efforts to precisely identify the time and place of transmission failed to 
uncover other sources of transmission for the source patient or secondary cases than those proposed.  
As a schoolteacher, the brother-in-law was at home because of school closures, and there were no 
known sick persons in his hometown of Tubmanburg.  We were unable to obtain information on his 
travel history.  The index case and husband could not identify a known exposure event to which they 
could attribute her illness.  Without a risk history, and in combination with the negative diagnosis 
received at the Monrovia clinic, they attributed her illness to another etiology.  Interestingly, the 
husband stated that people in their village did not believe the virus could reach their community, 
despite its close proximity to Monrovia.  It is important to note that at this time, ‘Ebola’ was 
synonymous with bleeding,5 as it was in the West.  Contact with a bleeding person would be subject 
to recall, but contact with a sick person who appeared weak and sweating would not be an unusual 
event during the Liberian rainy season, particularly given the background burden of disease from 
malaria and other mosquito-borne diseases.   
 
We considered the epidemiologic link of the source patient to Lofa County, known for their prized 
production of palm oil.  Palm oil and the fruits were regularly purchased by the source patient.  Palm 
plantations have been the setting of previous outbreaks in the DRC,27 as some bat species roost in the 
trees for fruit.  The possibility of fallen fruits contaminated with bat saliva or guano was explored by 
Leroy et al. (2009),27 and has been proposed as a potential source of spillover of ebolaviruses from 
frugivorous bats to NHPs and humans.28  Recently, EBOV RNA was isolated from a bat (Miniopterus 
inflatus) caught in Nimba County, Liberia,29 a straight-line distance of 50 miles from Guéckédou, 
Guinea. 
 
Our findings raise an important question about the role of sweat in EBOV transmission.  Zaki et al.30 
demonstrated the presence of EBOV and antigen within and around sweat glands in 14 of 14 axillae 
and neck biopsies.  Based on those findings, they proposed that skin may service as a site of viral 
replication, not merely viral secretion.  Sweat was identified as the mode of transmission between an 
infected father with only mild illness to his infant during a three-hour walk bush walk.27  Dowell et 
al.31 (1999) concluded sweat-based transmission was an ‘intriguing explanation’ for transmission 
events for which no risk factor could be identified.  Based on our findings following exhaustive efforts 
to identify other modes of transmission or exposures not previously accounted for, we hypothesize that 
the source patient and brother-in-law were infected by skin-to-skin contact with the source patient, in 
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which sweat was transferred from an infected person to a susceptible person.  We support the proposal 
of Zaki et al.30 to establish a skin surveillance system to explore the role of direct physical contact in 
transmission of the virus.   
 
Infection of expatriate humanitarian workers provided the opportunity for real-time monitoring of 
EBOV viral loads in tissues and fluids in patients undergoing treatment in high-containment 
biofacilities in the US and Europe.  In two patients, EBOV was detected in axillary sweat on day 24  
and from axillary, inguinal, and forehead sweat from during days 20-40 of EVD.32 Moreover, 
anecdotal reports of skin-to-skin contact also implicate sweat as the mode of transmission, including 
as the source of the virus for the Liberian man who died of EVD in Dallas.33  Prior to his death, he 
recalled that his only contact with a sick person was when he assisted a sick pregnant woman into a 
taxi the week before leaving for the US.  In 2015 in the Red Light District in Monrovia, two cases of 
EVD were diagnosed in two people who helped a sick person into a taxi.34   
 
The growing evidence of sweat in the epidemiology of EVD warrants further examination as an under-
recognized mode of transmission, particularly for outbreaks in densely-populated urban environments 
of tropical Africa.  Risk communication, and the promotion of social distancing, should include an 
awareness of skin-to-skin contact—not just contact with blood, stool, and vomitus—as opportunities 





The time, setting, and mechanism of EBOV transmission events are key observations upon which an 
epidemic response is operationalized.  Reconstruction of chains of transmission provides the 
opportunity to examine person-level transmission and assess the effectiveness of control measures.  We 
described the key transmission events that contributed to secondary transmission, and determined that 
the lack of isolation beds, coupled with fear and mistrust, contributed to secondary transmission to 
five family members of the source patient.  Importantly, self-sequestration by three of the cases 
prevented additional secondary prevention and generated no cases of tertiary transmission.  This was 
particularly important given the household setting and the presence of children.   
 
After exhaustive efforts to identify a source of EBOV transmission to the source patient and the 
brother-in-law, we excluded all modes and sources of transmission except sweat.  This is an important 
finding with implications for driving ongoing and unrecognized virus transmission.  Risk 
communications for social distancing should be instituted immediately in future outbreaks.  Our data 
join a limited number of descriptive studies in which single-day transmission events, and the precise 
dates of clinical onset, are documented.  Together, our data provide estimates of epidemic transmission 
parameters with the greatest precision possible from an epidemic context.  Our informed estimates 
will better characterize the epidemiology of EVD, improve spatiotemporal modelling of EBOV 











Table 16. Demographic Characteristics, Transmission Events, Symptoms, and Outcomes, EVD Cluster 
*Less than 24 hours of exposure to the source patient. 
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Table 17. Estimations of Case-Specific Incubation and Infectious Periods 
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CLINICAL SEQUELAE AND FUNCTIONAL DECLINE AMONG SURVIVORS OF  
EBOLA VIRUS DISEASE, BOMI COUNTY, LIBERIA 
 
The West Africa EVD epidemic, unexpected and protracted, heralded a new era of ebolavirus 
epidemiology.  No longer a disease of hemorrhage and death, more than 17,000 people survived 
infection with a virus once considered to be nearly always fatal.1  Post-Ebola sequelae were first 
described following the 1976 SUDV outbreaks.2  Among survivors,  a constellation of consistent, 
frequent, and debilitating symptoms, which encompass a spectrum of non-descript clinical sequelae 
of poorly understood pathogenesis without prescriptive treatments.   Designated as post-Ebola virus 
disease syndrome (PEVDS),3 arthralgias, disabling fatigue, ocular complications, hearing loss, and 
neuropsychiatric symptoms are among the most commonly-reported sequelae, some persisting more 
than 20 years after infection.4-6  PEVDS presents a challenge to individual and national recovery, with 
a continued threat to global health security.  The consequences of lost productivity, food insecurity, 
and the breakdown of cohesive community structures has the potential to maintain the enfeebled state 
of the affected countries, creating and maintaining large regions of susceptibility to future emergence 
events.     
 
We conducted physical examinations and evaluations of functional status to investigate the clinical 
symptoms reported by three survivors from the transmission chain described in Chapter III.  Our aim 
was to characterize, as fully as possible, and within the limitations of ongoing EBOV transmission, the 
physical and psychiatric symptoms, patterns of distribution by body system, and impact on 
longitudinal regain-of-function or increasing disability.  We further present proposed mechanisms of 
pathophysiology with results of advancing studies conducted in the wake of the epidemic.  
 
 
MATERIALS AND METHODS  
 
 Ethics Approval 
 
All interviews and physical examination were conducted in the home village of each participant while 
active EBOV transmission was occurring in Liberia, and therefore occurred during the international 
Ebola emergency response.  Data collection conformed to all relevant General Principles of the 
Declaration of Helsinki.7  Human subjects approval was granted by the LSU IRB (Appendix J).   
 
 Case Ascertainment and Informed Consent 
 
The survivors presented in this case series were patients discharged from the ETU where the 
investigators provided direct patient care for EBOV-infected persons, and then participated health-
system strengthening and community reintegration efforts.  During June and July 2015, the  
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investigators resided in a rural village approximately 15 km northeast of Monrovia, the capital city of 
Liberia, to investigate the events of EBOV transmission and post-Ebola sequelae.  Survivors and family 
members were informed of the purpose of the study, that their privacy would be protected, and that 
the findings would be shared with the international community to aid in understanding how EBOV 
is transmitted among family and community members, and to understand the symptoms associated 
with PEVDS.  Written informed consent was obtained and witnessed by a third party.  Cases were 
interviewed in their homes alone or in the presence of family and community members, as per choice.   
 
 Data Collection and Analyses 
 
 Definitions 
A survivor was defined as a laboratory-confirmed case of EVD who was admitted to the Bomi County 
ETU, recovered from EVD, and discharged to their home community.  Discharge from the ETU was 
based on two criteria: (1) serial laboratory-confirmed EBOV-negative blood samples, and (2) 
resolution of EVD-associated symptoms (e.g., afebrile, cessation of diarrhea).  An additional criterion 
was the ability to perform self-care within their homes.   
 
 Interviews 
Following informed consent, each survivor was interviewed and examined in their homes in English 
using an open-ended format (Appendix L).8  Survivors were asked about their activities, exposures and 
knowledge of EVD prior to disease onset and throughout the course of illness into the convalescent 
period.  Initial (t1) interviews and physical exams occurred in February 2015 (90 days post-discharge).  
Secondary interviews (t2) and physical exams took place in June 2015 (120 days post-discharge).  We 
dichotomized the convalescent period as acute (i.e., discharge to <90 days) and subacute (i.e., >90 days 
after discharge).   
 
 Physical Examination 
Data collection was performed by one investigator, who is a clinician and infectious disease 
epidemiologist with experience in West African cultures.  Vital signs (i.e., blood pressure, heart rate, 
pulse oximetry, temperature) were obtained using portable durable medical equipment.  The physical 
examination conformed to the methodology outlined by Campbell et al.,9 including 18-tender point 
exam, utilized by the American College of Rheumatology for assessment of symmetrical pain 
distribution.10  Direct physical examination of the urogenital and reproductive systems was deferred 
but remained part of the oral interrogation (Appendix M).   
 
 Patient-Specific Functional Scale 
We selected the Patient-Specific Functional Scale11 (Appendix C), used previously in a Guinean 
survivor cohort,12 to obtain longitudinal global functional changes. The instrument requires 
participants to identify high-priority activities essential for daily living, and to rate their ability to 
perform the activities over a specified internal of time, based on a scale of 0 to 10 (i.e., ‘0’ corresponds 
to wholly unable to perform the activity, ‘10’ corresponds to being fully able to perform the activity.  
At 90 days post-discharge (t1), survivors were instructed to rate their loss or gain in functional ability 
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based on their pre-EVD ability (t0).  At 120 days post-discharge (t2), survivors were instructed to rate 
gains or losses in their functional ability based on their abilities at t1.  An incremental change, from 
23, for example, represents a 10% gain of function; a 31 rating represents a 20% loss of function.  
Final scores were calculated as percentages of recovery based.  For example, a premorbid score of ‘10’ 
for four activities corresponds to a total possible score of 40.  The functional ratings of each activity 
for t1 were added together, divided by 40, and multiplied by 100 to score the functional ability in the 





A full history and physical examination for each survivor is detailed in Table 18.  The mother is the 
grandmother of the niece, and the husband is the surviving spouse of the mother’s daughter, the source 
patient for their infections.  The median age of the survivors was 40 years (range 23-53 years).  None 
of the survivors had a history of chronic disease.  The mother was born with bilateral exotropia that 
had not affected her vision.  All three survivors experienced weight loss as a result of their disease.  This 
was least extreme in the 23-year-old and most profound in the 53-year-old, who, despite a normal 
BMI, appeared cachectic and weak. 
 
 Categories of Disease Severity 
 
We classified the severity of EVD as mild, moderate, and severe, based on their clinical manifestations 
during their admission to the ETU.  Mild disease was unexpectedly observed in the 53-year-old 
mother, who was afebrile, had simultaneous onset of diarrhea and profound weakness, and did not 
manifest signs or symptoms of hemorrhage.  The niece was classified as having moderate disease, based 
on her fluid losses from diarrhea and vomiting and conjunctivitis.  The husband was admitted with 
signs of hemorrhage and was classified as having severe disease.   
 
 Musculoskeletal Pain 
 
Each of the three survivors identified pain as the greatest obstacle to performing activities of daily 
living, reintegrating with the community, earning an income, and farming for food.  In all cases, pain 
was symmetrical and mechanical, defined by: (1) pain with activity and improvement with rest, (2) no 
pain during the night, and (3) morning stiffness  and pain <30 minutes duration .13  Arthralgias were 
persistent and polyarticular of both large and small joints. Direct physical examination of the joints 
and skin were without evidence of an inflammatory process.    
 
Despite having mild disease, the mother demonstrated the most extensive profile of severe pain. Results 
of the 18 tender-point assessment10 demonstrated severe, symmetrical pain at each of the 18 sites 
(Figure 15). She had marked guarding and withdrawal to palpation of the joints.  She unable to rotate 
her head (i.e., horizontal cervical rotation) >45 degrees in either direction.  She could not form a closed 
first with either hand. 
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Table 18. History and Physical Examination Summaries, EVD Survivors 
Abbreviations: BMI, body mass index; BP, blood pressure; cm, centimeters; H, height; HR heart rate; kg, 
kilogram; LROM, left range of motion; O2 sat, oxygen saturation in blood; OD, right eye; OS, left eye; 
ROM, range of motion; T, temperature; W, weight; WNL, within normal limits.   
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The niece, whose disease would be classified as moderate, described severe bilateral myalgia in the recti 
femorus, vasti lateralis, and vasti medius.  She recounted pain of such severity that she was unable to 
walk her usual distances between villages to sell items for an income.  Finally, the husband, who had 
severe disease, described articular pain severe in the morning and moderate during the day.  Pain was 
localized to the cervical spine and symmetrically distributed among the glenohumeral joints; 
tibiofemoral joints; and the distal, medial, and proximal phalanges of the hands and feet.  Sagittal 
cervical rotation was limited to <30 degrees in flexion and extension.  The glenohumeral joints were 
limited at 90 degrees for vertical flexion and abduction.  The tibiofemoral joints full flexion and 
extension but with pain.  Pain of the phalanges of the hands and feet was described as moderate and 
relieved with motion. 
 Neuropsychiatric Sequelae 
 
The most severe neurologic symptom was reported by the niece (moderate disease), who reported 
persistent headaches that began after discharge from the ETU and continue more than two days each.  
The severity of the headaches left her bed-bound and unable to perform any activity of daily living. 
Figure 15. Examination of Musculoskeletal Pain Site in an Ebola Virus Disease 
Survivor 
Identification of painful joints without evidence of local pathology. 




Assessment of anxiety and depression in the mother and niece was limited to their willingness to discuss 
this type of symptom.  The district health nurse characterized the mother as ‘acting depressed’ since 
her daughter died in October 2014.  The husband described an inability to fall asleep and stay asleep.  
He said he has ‘racing thoughts’ and ‘feels grief’ over his wife’s death.  He stated he was shunned by 
friends and community members upon his return from the ETU who refused to visit him or shake his 
hand.  He said he felt ‘no reason to live’ upon arriving home and discovering the contents of his home 
had been burned. 
 
 Opthalmic Sequelae 
 
The mother, who had mild EVD, and the husband, who had more severe EVD, both reported 
opthalmic sequelae.  The mother described photophobia during peak daylight hours that require her 
to remain indoors.  The husband described changes in visual acuity changes, pain, and hyper-
lacrimation of the left eye during his ETU admission, which worsened after discharge.  In the acute 
recovery phase, he had complete loss of vision and continuous hyperlacrimation. Subacutely, he 
regained vision but with a deficit of acuity that prevented him from performing community 
construction activities.  In the physical examination, he had evidence of hyperlacrimation and 
demonstrated an inability to discern at a distance of 0.3 meters.  In confrontational visual field testing, 
he demonstrated peripheral deficits of the left eye (Table 18, Appendix M).   
 
 Functional Assessments 
 
The essential activities for daily living are listed in Table 19.  Survivors were asked to associate a clinical 
symptom with their inability to perform their identified activities.  Functional limitations among the 
three survivors were predominantly associated with arthralgias and myalgias.  None of the survivors 
identified a psychiatric symptom as impeding their functional abilities, although the husband did 
report insomnia and nightmares about the loss of his wife and his time in the isolation unit.   
 
Despite having mild disease, the mother demonstrated the most marked loss of function.  Her 
premorbid function was rated at 100%, followed by 0% in the acute phase (t1) and 10% in the 
subacute phase (t2).  She identified arthralgia as the reason for her loss of function, followed by fatigue 
and myalgia as secondary factors.  She described an inability to hold farming tools due to pain and 
weakness of both hands.  She was unable to make a fist and could not hold a knife or ladle to prepare 
food.  On the days when her arthralgia was less severe, fatigue limited her functional ability. 
 
The niece, who had moderate disease, had acute loss of function similar to the husband, 25% and 
28%, respectively, but her subacute score was 53%, compared to 43% for the husband.  She identified 
myalgia of the bilateral quadriceps muscles as the primary reason for functional decline, followed by 
fatigue and persist, debilitating headaches. In contrast, the husband attributed his function losses to 
an inability to see in his left eye, which improved from 0% in the acute recovery phase to 20% in the 
subacute recovery phase.  Fatigue and weakness were prevented him from walking and farming, while 







Following the 1995 outbreak in Kikwit, DRC, survivors reported arthralgias, myalgias, abdominal 
pain, hearing loss, extreme fatigue, and anorexia up to six months after the outbreak.6  At 21 months 
after the same outbreak, more than 60% of the survivors continued to experience symmetric 
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polyarthropathies and myalgias.6  A more recent study conducted 22 years after the outbreak detected 
abnormal neurological exams, lower cognitive scores, and depression in survivors compared to their 
household controls.14  High viral titers cause sustained immune activation, with cell and tissue damage 
secondary to apoptosis and necrosis.15  These pathophysiologic processes have been postulated as the 
biologic bases of both the development and severity of PEVDS, but a causal mechanism or biomarker 
has yet to be identified.1,16   
 
 Musculoskeletal Sequelae 
 
Arthralgia and myalgia constitute the majority of reported complaints of pain and disability among 
survivors of the West Africa epidemic.13,17  Remarkably, the same symptom profile of arthralgias and 
large-muscle myalgias has been reported with consistence by survivors across all outbreaks of 
ebolaviruses.4,18,19  Arthralgia alone has been documented in up to 87% of survivors across three cohort 
studies.12,20,21  In nearly all cases, the patterns of arthralgia are symmetrical and involve multiple small 
and large joints.  We observed the same pattern of symmetric pain distribution in the mother, whose 
18 tender-point exam was positive at each of the 18 examined joints and, to a lesser extent, in the 
husband, who experienced severe cervical arthralgia and symmetrical arthralgia of the patellofemoral 
joints.  Both had disabling pain that limited their cervical range of motion.   
 
Two hypotheses have been proposed to explain the underlying pathophysiology of PEVDS.  The first 
is that patients with high viral loads during the course of illness have persistence of RNA within 
immune privileged sites.22  This first hypothesis is contradicted by the recent finding that viral load on 
admission was not predictive of symptom frequency nor severity.17  A second hypothesis, which is 
more consistent with the distribution of symptoms both in the body and in those with less severe 
disease, is that EVD results in an overwhelming immune activation, including the destruction of cells 
and tissues that sustain damage from inflammatory cytokines.21,23  Other causalities have been 
proposed.  In an animal study, double-stranded DNA, which is released from cells during destruction 
of tissues (e.g., rhabdomyolysis), and the presence of heat shock proteins in the synovium were 
associated with higher titers of autoantibodies.24  However, the underlying pathophysiology of 
musculoskeletal complaints in survivors remains unknown.   
 
 Neuropsychiatric Sequelae  
 
Quiescent infection, recurrent neurologic disease, and post-EVD sequelae demonstrate an emerging 
range of neurovirulence and incomplete immune privilege of the CNS against EBOV.25  EBOV RNA 
has been detected in CSF25,26 and ocular fluid.27  Headaches28,29; short-term memory impairment20; 
tinnitus and hearing loss4,6,25; altered sense of taste and smell12; and confusion and hallucinations have 
been documented in survivors, with the most disabling symptoms noted in patients known to have 
had severe EVD.30  
  
Neurologists working with survivor cohorts have diagnosed localized deficits, such as homonymous 
hemianopia, tremors, gait abnormalities, muscle laxity, abnormal reflexes, and asthenias, which are 
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generally observed in post-stroke patients.30,31  Computed tomography imaging in Sierra Leone32 
demonstrated inflammatory changes, including middle cerebral artery gliosis25; meningoencephalitis26; 
ischemic changes26,33; atrophy of the cerebellar, parietal, and temporal lobes; and ventriculomegaly and 
hemorrhagic encephalitis.32  Each of these findings has the potential to be profoundly disabling.  The 
broad range of neurosequelae cannot be attributed to one pathology.  Viral persistence within the 
CNS, post-inflammatory nerve damage, and observational associations of altered consciousness, 
hemodynamic collapse, and cerebral hypoperfusion have been suggested.31 
 
 Psychiatric  Sequelae 
Chronic pain contributes to the frequency and severity of anxiety,34 a finding upheld by the World 
Mental Health survey, which found an association between the number of painful body sites and 
generalized anxiety disorder.35  In post-epidemic studies, computed tomography imaging detected 
evidence of atrophy in the cerebellar, parietal, and temporal lobes, all with the potential to be 
profoundly disabling and contributory to a depressive affect.32  Depression, anxiety, insomnia, grief, 
and fear are frequently reported by survivors who experience social isolation due to an inability to work 
and contribute to their communities.1,4,12,29,36,37  Finally, the history of the region cannot be overlooked.  
Superimposed on the traumas from decades of civil war, the prolonged and chaotic nature of the 
epidemic and loss of family and community members are certain to compound—and confound—
post-EVD sequelae and recovery.   
 
 Opthalmic Sequelae 
 
The complexity of diagnosing opthalmic pathology lies in the requirements for visualization of the 
external and internal structures of the eye.  Identification of lesions or structural abnormalities requires 
not only a clinical specialist, but advanced equipment and drugs.  In African survivors, lesions of the 
retinal structures and along the axonal body of the optic nerve have been described,27,38 which are 
consistent with the development of conjunctivitis, uveitis, hyperlacrimation, and loss of visual 
acuity.5,22,39  In a Sierra Leonean cohort, 60% of survivors reported ocular symptoms at 121 days after 
discharge,21,31 and nearly 20% of survivors in West Africa experience vision problems.40  EBOV is 
neuroinvasive and causes widespread CNS inflammation.  No conclusive evidence exists to determine 
the cause of ocular symptoms.  Whether due to RNA persistence within the ocular chamber, or are 
the consequences of infection and inflammation, intermediate treatments and long-range therapies 




Assessment of physical symptoms is subject to bias on the part of the patient and the investigator.  The 
interpretation of pain and disability involve personal perceptions of health and, therefore, are subject 
to inherent cultural biases.  Our unique approach of residing in the village with the survivors was our 
attempt to overcome these biases by directly observing the context in which they experienced and 




Due to the emergency nature of the response, we were unable to perform clinical laboratory analyses 
to identify elevations in inflammatory biomarkers or cellular suggestive of immune-mediated disease 
processes.  Additionally, we did not have access to the Ct values of the survivors from which to infer 
the association between viral load, EVD severity, and the development of symptoms.  However, a 
recent finding from Wing, et al.17 found no association of viral load with development of PEVDS.   
 
 The Research Agenda for Post-Ebola Virus Disease Syndrome 
 
 Longitudinal Cohort Studies 
The largest ever number of survivors from the West Africa epidemic was absolutely unanticipated at 
the outset of the epidemic, and the global cohort of survivorship will continue to expand as outbreaks 
of ebolavirus grow larger and more frequent.  Our understanding of EVD is incomplete but our 
knowledge is evolving.  Concerted efforts are underway in each of the West African countries to 
describe the syndrome, determine its causality, and identify treatment modalities.  Areas of active 
investigation into the etiology(ies) of PEVDS include the role of global immune activation in cellular 
and tissue damage, the deposition of immune complexes in large and small joints, and the ability of 
EBOV to persist in immune-protected body sites, include the central nervous system.  In Guinea, the 
French-led PostEboGui Study, a prospective, multidisciplinary cohort study, is investigating the long-
term clinical, psychosocial, and viral outcomes of survivorship.13,29,41  Public Health England and the 
UK Ministry of Defence are operating survivor clinics throughout Sierra Leone, in addition to clinical 
trials to assess the safety and efficacy of favipiravir for the clearance of EBOV RNA from immune-
privileged sites,42 and the use of convalescent plasma for treatment of PEVDS.43  The National 
Institute of Allergy and Infectious Diseases initiated the PREVAIL III trial in 2015 for longitudinal 
studies of survivors in Liberia,44 and an additional study, PREVAIL IV, is currently enrolling male 
survivors to assess the ability of experimental drug GS-5734 to eliminate EBOV RNA from semen.45  
Understanding disease pathogenesis and identifying acute and chronic co-morbidities (e.g., malaria; 
history of stroke, diabetes, exposure to heavy metals) will identify endpoints in the clinical course of 
EVD for administration of therapies to mitigate disease severity and post-EVD sequelae.   
 
 Therapeutics 
Treatment for the PEVDS is currently supportive and there is no definitive cure. Beyond recognizing 
the clinical features that are manifested as part of PEVDS, efforts must shift toward therapeutic 
measures that might be initiated during acute infection to minimize the incidence and severity 
symptoms among survivors. In addition, the scientific community must focus on effective therapeutic 
measures that may be useful in managing symptoms of PEVDS. Since the pathogenesis of the PEVDS 
is thought to be related to systemic injury resulting from the original infection, a sustained immune 
response, autoimmune-like inflammatory state, and viral persistence in specific anatomical locations 
(i.e., eye, brain, testes), treatment strategies directed at the inflammatory cascade and the immune 
system have been proposed as initial targets for new therapies.46 In 2015, the National Institute of 
Allergy and Infectious Diseases initiated the PREVAIL III trial47 to facilitate long-term follow-up of 
survivors and household contacts in Liberia. From this group, they are recruiting subjects for the 
PREVAIL IV trial, which will examine the ability of an experimental compound, GS-5734, to clear 
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persistent EBOV RNA from the semen in male survivors.45  In the immediate future, West African 





Post-Ebola virus disease syndrome is a constellation of multi-system, chronic debilitating symptoms 
experiences by survivors of infection with ebolaviruses, and is now reported in the majority of the 
17,000 survivors of the West Africa epidemic.48  Research among EVD-infected patients and survivors 
reveals both acute and post-infectious complications, with no gains in defining the underlying 
pathogenesis.  Our results provide person-level data on the experience of PEVDS, with an emphasis 
on the extent of disability associated with the symptoms.  Together with other studies, these findings 
underscore the need for the international clinical and public health communities to continue 
investigations into the post-viral phase of infections with emerging tropical viruses.  Through 
investment and development of health care and public health infrastructures for at-risk populations, 
we will expand our knowledge of EVD pathophysiology, identify therapeutic targets, and gain key 
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SUMMARY OF RESULTS AND CONTRIBUTION TO PUBLIC HEALTH PRACTICE 
 
SUMMARY OF RESULTS 
 
 Chapter II.  Multi-Pathogen Infections of Dengue Virus   
 
Dengue presents as an AFI, typically characterized by fever, myalgia, and headache,1 and is 
indistinguishable from other tropical diseases, including leptospirosis, during the early-onset of 
symptoms.  The difficulty, therefore, in diagnosing dengue has been the non-specific presentation of 
symptoms that mirrors other AFIs.  We conducted a cross-sectional serosurvey of febrile patients 
presenting for treatment at two facilities in the Colombian State of Norte de Santander.  Our objectives 
for this study were (1) to establish the first prevalence estimates of DENV MSIs and DENV-Leptospira 
co-infections in Norte de Santander, (2) identify hematologic indices associated with clinical severity, 
and (3) to construct a diagnostic algorithm to provide decisional support for clinicians in under-
resourced settings. 
 
 Key Findings and Contribution to Public Health Practice 
1) We estimated the prevalence of DENV MSI to be 14.6% and the prevalence of leptospirosis to be 
1.4% in our hospital-based convenience sample.  These are the first prevalence estimates for Norte 
de Santander, and our findings provide evidence of their presence in the pathogen landscape.  
However, our findings cannot estimate the burden of disease.  Enhanced surveillance and research 
are required, yet laboratory capacity is the critical piece to addressing these issues. 
 
2) We found no differences in clinical severity by SSI, MSI, or among patients co-infected with 
Leptospira.  However, we found co-infections with multiple DENV serotypes, pathogenic 
Leptospira spp., and with HBV.  An unexpected finding of a patient with dengue, leptospirosis, 
and HBV highlights the utility of case-study data to detect multi-pathogen infections, which 
contribute to alterations in the expected clinical presentation of disease.  The impact of intra-host 
co-infection on clinical severity, and its potential to contribute to viral emergence, deserves further 
consideration.  Larger studies, powered to detect differences by age-sex groups, are required to 
further explore the clinical impact of MSIs.   
 
3) We were unable to construct a diagnostic algorithm to assist in clinical diagnostics in areas without 
laboratory capacity.  Our findings underscore the challenge of dengue diagnosis: clinical 
presentation alone is insufficient.  Increasing the availability of rapid diagnostics will be essential 
for initiating early treatment and defining the incidence of co-infections.  Further, the study of 
coinfection must move beyond laboratory systems and examine the outcomes of disease among 
persons with complex immunologic profiles.  The expanding application of molecular technologies 
for clinical diagnosis, including the use of next-generation sequencing, will detect and define the 
intra-host pathogen landscape.2  The clinical interpretation of the findings, and their translation 
into public health practice, will be required.   
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 Chapter III.  Familial Transmission of Zaire ebolavirus 
 
We reconstructed and fully resolved the transmission events of EBOV transmission among 
geographically-dispersed family members in Liberia.  The objectives were to (1) describe the how 
single-day exposures can potentiate an epidemic, and (2) elucidate the underlying ecological 
determinants (i.e., human behaviors and movement) that contribute to the dynamic nature of 
epidemic EBOV transmission.   
 
 Key Findings and Contribution to Public Health Practice 
1) We defined key epidemiologic transmission parameters using individual exposure, transmission, 
and clinical data.  We estimated the incubation period for multi- and single-day exposures to be 
6.0 and 7.0 days, respectively.  Our estimates are aligned with those calculated from a meta-analysis 
of available data up to the West Africa epidemic,3 which determined an incubation period of 6.22 
days for all exposures.  With the limitations inherent in small sample sizes, our estimates provide 
additional measures to contribute to the pool of existing resources from which transmission 
parameters can be estimated with increasing precision.   
 
2) We identified how the inability to obtain an isolation bed for the source patient resulted in health-
seeking behavior and long-range travel into and out of her community during her peak infectious 
phase of fatal EVD.  Admission to a treatment center was a critical aspect of decelerating the 
incidence of EVD in West Africa.4-7  Between the months of July-November 2014, in regions 
where focused contact tracing was combined with patient isolation, the average time from 
detection to isolation decreased from 6.0 days to 1.5 days,8 the number of generations from a single 
source decreased from four to two, the median duration of localized outbreaks decreased from 53 
to 25 days, survival increased from 13% to 50%.5-6  Our results provide the granular data to explain 
the individual-level and impact of these interventions, and support their use for future outbreaks 
of EVD. 
 
3) We described how the cases, when they proceeded to the infectious phase of EVD, isolated 
themselves from large numbers of family members.  They were provided food and water during 
their self-sequestration but did not generate additional secondary or tertiary infections.  This was 
a critical intervention employed by the family and the community, as children were kept separate 
from sick parents.  The care of a sick child is a resource-intensive endeavor, one in which many 
generations of family and community members become involved.  It was a sick child that was the 
source of an outbreak in the DRC,9 and a sick child was the index case for what are probably in 
excess of 30,000 cases of EVD in West Africa.10  We argue that our results demonstrate the utility 
and effectiveness of home- and community-based isolation for future outbreaks, but it should be 
an emergency measure only during an interim waiting period for creation and expansion of 
isolation and treatment capacity. 
 
4) Our unexpected finding of the probable contribution of sweat to epidemic transmission highlights 
an under-recognized mode of transmission.  The assumption has been that EBOV transmission is 
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limited to blood and body fluids, without consideration of sweat.  Previous reports have described 
a high concentration of virus in and around sweat glands.11  Together, this is an important finding 
with implications for driving ongoing and unrecognized virus transmission.   
 
 Chapter IV.  Post-Ebola Virus Disease Syndrome 
 
Post-Ebola virus disease syndrome is a constellation of multi-system, chronic debilitating symptoms 
experiences by survivors of infection with ebolaviruses, and is now reported in the majority of the 
17,000 survivors of the West Africa epidemic.12  Incomplete recovery from tropical virus infection 
may contribute to additional transmission, poor case management, and functional decline amongst 
vulnerable populations lacking public health infrastructure and diagnostic methodologies. We 
conducted physical examinations and evaluations of functional status investigate clinical symptoms 
and chronicle the post-EVD disability among three survivors from the transmission chain described 
in Chapter III.  Within the limitations of ongoing EBOV transmission, our aims were to characterize 
as fully as possible (1) the physical and psychiatric symptoms, (2) patterns of distribution by body 
system, and (3) impact on functional ability.   
 
 Key Findings and Contribution to Public Health Practice 
1) We used repeated physical examinations to identify symptoms and provide highly-detailed 
descriptions of each affected body site.  These data add to the accumulating evidence from ongoing 
investigations in West Africa and the US, and will contribute to systematic reviews and meta-
analyses for future investigations of PEVDS among affected populations.   
 
2) In concert with other studies, we, described a symmetrical distribution of pain consistent 
suggestive of an immune-mediated arthritis.  These findings add epidemiologic support to the 
hypothesis that post-viral symptoms have a pathophysiologic bases in the immune-mediated aspect 
of EVD.   
 
3) We used a vetted functional scale sensitive to cultural-specific measures of disability to assess 
functional decline between pre-EVD baseline status and 90- and 120-day intervals after discharge 
from ETU.  Our results describe chronic sequelae and loss of function, emphasizing the need for 
clinical and public health engagement to elucidate the full spectrum of PEVDS.  Understanding 
the patterns of disability among EVD survivors will our knowledge of EVD pathophysiology and 





Despite decades of research into dengue and the ebolaviruses, we lack the ability to fully explain, 
forecast, and prevent the emergence of these viruses and those to come.  The risk of human infection 
from animals is persistent, wide-spread, and unpredictable.  Until human exposure to infection can be 
more accurately predicted or prevented, the approach to managing future outbreaks will center on the 
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classic, response approach to control: early case detection and isolation; contact tracing and 
community engagement; environmental assessment and mitigation; and effective, equitable clinical 
care.  Within its limitation and criticism of lacking scientific rigor, particularly with respect to 
generalizability,13 case study data are informative estimates from which clinical care is coordination, 
research plans developed, and policy decisions are made.   
 
A vital next step is deliverable financial support for the development and sustainment of health services 
in the countries at risk for emerging zoonotic viruses.  The Commission on a Global Health Risk 
Framework for the Future has underscored the importance of resilient national public health services 
as the first line of defense against future epidemics of EVD or other diseases.14  They recommended 
investment in essential health services with an emphasis on primary prevention and treatment, at an 
annual cost of $4.5 billion,14 to both strengthen the ability to recognize and respond to outbreaks, 
with also have sustained investment for the next generation of technologies for prediction, detection, 
and control.  No country exists in isolation; borders are too porous, and travel too rapid.  Containment 
and isolation are inadequate public health strategies.  We do not lack the science to understand the 
consequences of maintaining weakened nation-states.   In perhaps the greatest ongoing struggle, global 
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PUBLISHED REPORTS OF DENGUE VIRUS MULTI-SEROTYPE INFECTIONS,  
BY COUNTRY AND AUTHOR 
      Author 
      (Year) 
Diagnostic 
Methodology Serotypes (Frequency ) Disease Severity 
Bali      
     Megawati, D.  
     (2017)  PCR  
DENV-1/2    (NS) 
DENV-1/3    (NS) NS 
Belgium  ex. Thailand      
     Cnops, L.  
     (2014)  PCR  DENV-1/2    (n=1) Mild disease 
Brazil      
     Andrade, EH. 
     (2016) 
 PCR  
DENV-2/3    (n=2) 
DENV-2/4    (n=1) 
DENV-3/4    (n=1) 
DENV-2/3/4 (n=2) 
NS 
     Araújo, FM. 
     (2006)  
IFA 
PCR  DENV-2/3    (n=1) Mild disease 
     Colombo, TE.  
     (2013) 
 ELISA 
PCR 
DENV-1/4    (n=1) Mild disease 
     de Bruycker-Nogueira, F. 
     (2018) 
Cell culture 
PCR DENV-1/4    (n=1) NS 
     dos Santos, CLS. 
     (2003) PCR  DENV-2/3    (n=1) NS 
     Figueiredo, RM. 
     (2011) 
IFA 
PCR  DENV-3/4    (n=4) NS 
     Marinho, PE. 
     (2017)  PCR  
DENV-2/3    (n=1) 
DENV-1/2/3 (n=1) No increased severity 
     Rocco, IM.  




DENV-1/2    (n=1) Mild disease 
Abbreviations: ELISA, enzyme-linked immunosorbent assay; ex., exported from; IFA, immunofluorescence assay; NS, not 
specified; PCR, polymerase chain reaction.  
* References are listed by author last name at conclusion of table. 
Table continued on page 94. 
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     Author 
     (Year) 
Diagnostic 
Methodology Serotypes (Frequency) Disease Severity 
China ex. Sri Lanka 
   
     Meiyu, F. 
     (1997) 
Cell culture 
PCR DENV-2/4    (n=8) NS 
     Peng, W. 
     (2005) 
IFA 
PCR DENV-2/3    (n=1) No increased severity 
India 
   
     Anoop, M. 
     (2010) PCR 
DENV-1/2    (n=2) 
DENV-2/3    (n=18) 
DENV-1/2/3 (n=1) 
NS 
     Bharaj, P. 
     (2008) PCR 
DENV-1/3     (n=4) 
DENV-1/4     (n=2) 
DENV-2/3     (n=1) 
DENV-3/4     (n=1) 
DHF: 6/9 (67%)  
     Das, B. 
     (2013) PCR DENV-2/3     (n=14) NS 
     Khan, SA. 
     (2013) 
ELISA 
PCR 
DENV-1/3     (n=11) 
DENV-1/4     (n=1) 
DENV-2/3     (n=1) 
NS 
     Mehta, TK. 
     (2018) PCR 
DENV-1/2     (n=2) 
DENV-2/3     (n=10) 
DENV-3/4     (n=1) 
Mild disease; lab values WNL 
     Rao, MRK. 
     (2018) PCR 
DENV-2/3     (n=74) 
DENV-1/2/3  (n=3) 
DHF: 17/28 (60.7%), including 
3/3 (100%) triple-serotype 
infections  
Abbreviations: DHF, dengue hemorrhagic fever;  ELISA, enzyme-linked immunosorbent assay; ex., exported from; IFA, 
immunofluorescence assay; NS, not specified; PCR, polymerase chain reaction; SD, severe disease; WNL, within normal limits.  
* References are listed by author last name at conclusion of table. 




      Author 
      (Year) 
Diagnostic 
Methodology Serotypes (Frequency) Disease Severity 
India (continued)    
     Reddy, MN. 
     (2017) PCR 
DENV-1/3         (n=9) 
DENV-2/3         (n=7) 
DENV-1/2/3      (n=8) 
DENV-1/2/3/4   (n=2) 
NS 
     Savargaonkar, D. 
     (2018) PCR 
DENV-1/2          (NS) 
DENV-2/3          (NS) 
DENV-2/4          (NS) 
DENV-3/4          (NS) 
DENV-2/3/4       (NS) 
DENV-1/2/3/4   (n=1) 
NS 
     Tazeen, A. 
     (2017) 
PCR DENV-1/2          (n=21) SD: 3/21 (14.3%)  
     Vaddadi, K. 
     (2017) 
ELISA 
PCR 
DENV-1/2          (n=7) 
DENV-1/3          (n=1) 
DENV-2/4          (n=5) 
DENV-3/4          (n=2) 
SD: 12/15 (80%) 
 
DENV-2/4: 5/5 (100%) 
classified DWWS 
     Vinodkumar, CS. 
     (2013) PCR 
DENV-1/2          (n=3) 
DENV-1/3          (n=2) 
DENV-2/3          (n=11) 
DENV-2/4          (n=1) 
DHF: 11/17 (64.7%) 
Indonesia    
     Lardo, S. 
     (2016) PCR DENV-2/3          (n=1) SD 
Malaysia    
Dhanoa, A. 
     (2016) PCR 
DENV-1/2          (n=34) 
DENV-1/3          (n=5) 
DENV-2/3          (n=1) 
SD more frequent among 
MSI patients 
Abbreviations: DHF, dengue hemorrhagic fever; DWWS, dengue with warning signs; ELISA, enzyme-linked immunosorbent 
assay; ex., exported from; MSI, multi-serotype; NS, not specified; PCR, polymerase chain reaction; SD, severe disease.  
* References are listed by author last name at conclusion of table. 
Table continued on page 96. 
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     Author 
     (Year)  
Diagnostic 
Methodology Serotypes (Frequency) Disease Severity 
Mexico 
     
     Requena-Castro, R. 
     (2017)  
ELISA 
PCR  
DENV-1,2         (n=9) 
DENV-2/4         (n=2) 
DENV-1/2/3      (n=1) 
DENV-1/3/4      (n=1) 
DENV-1/2/3/4   (n=1) 
NS 
Mexico ex. Indonesia      
     Loroño-Piño, MA. 
     (1999)  PCR  
DENV-1/2         (n=2) 
DENV-1/3         (n=4) 
DENV-1/4         (n=2) 
DENV-2/3         (n=2) 
DENV-2/4         (n=1) 
DENV-3/4         (n=1) 
DHF: 3/12 (25%)  
Puerto Rico      
     Gubler, DJ. 




 DENV-1/4         (n=1) Mild disease 
New Caledonia      
     Laille, M. 
     (1991)  PCR  DENV-1/3         (n=6) NS 
Peru      
     Mamani, E. 
     (2010)  PCR  DENV-1/3         (n=6) DHF: 1/6 (16.7%)  
Sri Lanka      
     Dissanayake, V. 
     (2011) 
 PCR  DENV-1/3         (n=9) NS 
Abbreviations: CF, complement fixation; DHF, dengue hemorrhagic fever; ELISA, enzyme-linked immunosorbent assay; ex., 
exported from; IFA, immunofluorescence assay; NS, not specified; PCR, polymerase chain reaction; PRNT, plaque reduction 
neutralization assay.  
* References are listed by author last name at conclusion of table. 




      Author 
      (Year) 
Diagnostic 
Methodology Serotypes (Frequency) Disease Severity 
Thailand      
     Sriprapun, M. 
     (2015) 
PCR (urine) DENV-2/4      (n=1) DHF 
     Maneekarn, N. 
     (1993) 
ELISA 
PCR DENV-1/2      (n=2) NS 
     Chinnawirotpisan, P. 
     (2008) 
PCR  
DENV-1/2      (n=1) 
DENV-2/4      (n=1) 
DENV-1/2/3   (n=1) 
DHF: DENV-2/4 only 
     Pongisiri, P. 
     (2012)  PCR  DENV-3/4      (n=1) NS 
Taiwan      
     Wang, SF. 
     (2016) 
 PCR  DENV-2/3      (n=2) NS 
Vietnam      
     Binh, PT. 
     (2009)  PCR  
DENV-1/4      (n=17) 
DENV-2/3      (n=1) 
DENV-3/4      (n=1) 
No increased severity 
Abbreviations: DHF, dengue hemorrhagic fever; ELISA, enzyme-linked immunosorbent assay; NS, not specified; PCR, 
polymerase chain reaction. 
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PATIENT-SPECIFIC FUNCTIONAL SCALE 
 
The Patient Specific Functional Scale 
This useful questionnaire can be used to quantify activity limitation and measure functional outcome 
for patients with any orthopaedic condition. 




I am going to ask you to identify up to three important activities that you are unable to do or are 
having difficulty with as a result of your  problem.  Today, are there any activities that you are unable 
to do or having difficulty with because of your   problem? (Clinician: show scale to patient 
and have the patient rate each activity). 
 
Follow-up Assessments: 
When I assessed you on (state previous assessment date), you told me that you had difficulty with 
(read all activities from list at a time). Today, do you still have difficulty with: (read and have 
patient score each item in  the list)? 
 
Patient-specific activity scoring scheme (Point to one number): 






(Date and Score) 
Able to perform 
activity at the 
same level as 
before injury or 
problem 
 
Activity Initial      
1.       
2.       
3.       
4.       
5.       
Additional       
Additional       
 
Total score = sum of the activity scores/number of activities 
Minimum detectable change (90%CI) for average score = 2 points 
Minimum detectable change (90%CI) for single activity score = 3 points 
PSFS developed by: Stratford, P., Gill, C., Westaway, M., & Binkley, J. (1995). Assessing disability and 
change on individual patients: a report of a patient specific measure. Physiotherapy Canada, 47, 258-
263. 
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COLOMBIA SEROPREVALENCE STUDY ADULT CONSENT AND PEDIATRIC ASSENT 
FORMS, ENGLISH AND SPANISH 
 
ADULT CONSENT FORM (ENGLISH) 
Flesch–Kincaid Readability Scores: 6.0 
 
Heterogeneity of Vector Exposure Alters Dengue Virus Transmission and Disease Risk Patterns 
 
Description 
You had been invited to participate in a study for an investigation about dengue virus and its vector.  We are 
planning to study the virus serotypes and the antibodies against the virus that could be circulating in your blood. 
 
Procedures 
Your doctor has requested a diagnostic test to confirm an infection with dengue virus in your blood. We would 
like to request your permission to use the REMAINING serum in our research. Normally, this serum is 
discarded after the test is done. However, it will be of great use in our investigation and the results of this 
investigation will not change the treatment that your doctor has decided to give you. IF YOU ARE 
PREGNANT YOU WILL NOT BE INCLUDED IN THIS STUDY. 
 
After completion of our main experiments, we would like to store part of your sample for future studies related 
to dengue. This sample will be frozen and stored with a CODE, your NAME WILL NOT BE INCLUDED 
on any material collected for this investigation. You can decide NOT to continue in this research at any moment 
and, all samples collected from you will be destroyed. 
 
We would also like to have your permission to include the results of additional test (platelet count, red blood 
cell count) requested along your dengue confirmation test. We will not record any clinical procedure, treatment, 
past diseases or any identifiable information from your files. You may reject the access of your tests results at 
any time. 
 
It is possible that in the future we can obtain new information, new products, or have any discoveries with 
potential commercial value. Any donor, in this case serum donor, will not be entitled to property rights on this 
information, product or discovery. 
 
The results of this investigation will be obtained only for research purposes. You will not know the results of 
the test we will perform on your sample. 
 
Risks and Benefits 
We do not anticipate any risk or secondary effect for participating in this study. Since this study will not include 
any treatment, you will not receive any direct benefit for your participation. We cannot guarantee you will 
receive any benefit from this research. 
 
Privacy 
Your privacy will be protected to the extent legally possible. Information from this study may be published. We 
will not publish your name, address, or other information that would identify you personally or link your name 









You will not receive any payment for participating in this study. 
 
Whom to call for questions: You can call Carolina Cardenas at 317 300 4517 any time if I have any 
questions about study. 
 
Participant 
When I signed this form, it means that the study has been explained to me in the language that I understand.  
If I decide to take part of this study, I will receive a signed copy of this information and a written summary 
about the study.  I will have the opportunity to ask questions about the study.  My questions will have to be 
answer to my satisfaction before I signed this form.  I can choose not to participate in the study, or I can quit 
the study at any time.  
 
I know what will be done as part of the study.  I also know the good and the bad (benefits and risks) that could 
happen if I take part in the study. I know that I can stop been part of the study and I will keep getting the usual 
medical attention. 
 
I consent that my sample ____or other tests results ____will be used in this research. 
 
I do NOT consent that my sample ____ or other test results ____will be used in this research. 
 
I consent that my sample will be stored for future investigations. ____ 
 
   
Printed Name of Participant 
 
 
 Date of Birth    








 Signature of Person Conducting Consent Interview 
Printed Name of Witness  Witness Signature  Date 
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CONSENTIMIENTO INFORMADO PARA ADULTOS (SPANISH) 
 
Descripción: Usted está invitado para participar en un estudio de investigación sobre el dengue y su vector. 
Nosotros planeamos estudiar los serotipos de dengue y los anticuerpos en contra del virus y de la saliva del 
vector encontradas en su sangre. 
 
Procedimientos: A usted se le ha solicitado un examen de sangre para confirmar la infección por el virus del 
dengue. Nos gustaría que nos diera su permiso para estudiar el suero RESTANTE O QUE SOBRE de la 
realización de dicho examen. Ese suero sobrante normalmente es eliminado. Este estudio de investigación no 
cambiará su tratamiento médico. SI ESTAS EMBARASADA NO SERAS INCLUIDA EN ESTE ESTUDIO. 
 
Después de completar nuestros exámenes iniciales, quisiéramos guardar el suero sobrante para hacer futuras 
investigaciones sobre el dengue. Ese suero sería congelado y almacenado con un número o CÓDIGO y NO SE 
INCLUIRA SU NOMBRE. En cualquier momento del estudio usted puede retirarse, y en ese caso su suero 
sería desechado. 
 
Al mismo tiempo, quisiéramos su permiso para acceder a los resultados de otros exámenes que se pidieron junto 
con en examen de confirmación del dengue, con el UNICO propósito de obtener datos de hemograma 
(componentes de su sangre como plaquetas y glóbulos rojos). Es importante aclarar que no se tomara ninguna 
información personal como su nombre o dirección o cualquier otra información de enfermedades pasadas. 
Usted puede rechazar en cualquier momento la inclusión de estos exámenes. 
 
Con el uso de su suero puede suceder que en el futuro se obtengan nuevos productos, exámenes o 
descubrimientos los cuales tienen potencial valor comercial. Los donantes de tejidos, en este caso el suero 
extraído de su sangre, no retienen ningún derecho de propiedad sobre esos productos. Por lo tanto, usted no 
recibiría ningún beneficio económico de esos productos, exámenes o descubrimientos. 
Los resultados del estudio realizado con su muestra serán usados únicamente con propósitos de investigación y 
usted no conocerá el resultado de dichas pruebas.  
 
Riesgos y Beneficios 
No se prevén riesgos asociados con este estudio. Como este no es un estudio sobre tratamiento, usted no recibirá 
ningún beneficio directo por su participación. Nosotros no podemos garantizarle  que usted recibirá algún 
beneficio de este estudio. 
 
Privacidad 
Su privacidad será protegida al máximo posible. La información resultante de este estudio podría ser publicada. 
Nosotros no publicaremos su nombre, dirección o cualquier otra información que lo pueda ligar o identificar a 
usted con los resultados de esta investigación. 
 
Gasto de Tiempo 
Una vez se obtenga la muestra de sangre para realizar sus exámenes médicos, su participación en este estudio no 
requerirá de tiempo adicional para usted. 
 
Pagos 




A quien llamar por preguntas: Usted puede llamar a Carolina Cárdenas al 317 3004517 a cualquier hora si 
tiene alguna pregunta sobre el estudio. 
 
Paciente  
Cuando yo firmo este formato, significa que el estudio de investigación me ha sido explicado en un lenguaje 
que yo entiendo. Si yo decido participar, yo recibiré una copia de esta información y de un resumen del estudio. 
Yo tendré la oportunidad de hacer preguntas sobre el estudio. Mis preguntas deberán ser respondidas a 
satisfacción antes que yo firme este formato. Yo puedo decidir no participar en el estudio o puedo renunciar a 
él en cualquier momento. 
 
Yo sé que se evaluará en este estudio. Yo también se lo bueno y lo malo (riesgos y beneficios) que podría pasar 
si yo hago parte de este estudio. Yo sé que puedo dejar de ser parte de esta investigación sin dejar de recibir mi 
atención médica usual. 
Marque los que considere pertinentes: 
 
Yo consiento en que mi muestra____o exámenes clínicos ___sean usados para esta investigación. 
 
Yo NO consiento en que mi muestra___o exámenes clínicos___sea usados para esta investigación.  
 
Yo consiento que mi muestra sea guardada para otras investigaciones: SI_____  NO ______ 
 
 
   
Nombre del Paciente  
 
 
 Fecha de Nacimiento   
Firma del Paciente  
 
 




 Ciudad de Residencia 




PEDIATRIC ASSENT FORM 
Flesch–Kincaid Readability Scores: 6.0 
 
Heterogeneity of Vector Exposure Alters Dengue Virus Transmission and Disease Risk Patterns 
 
Description of the Study   
Mosquitoes carry dengue virus.  The purpose of this study is to look for virus and other molecules in the blood 
that are made when a person becomes sick. These molecules, called antibodies, are made by the body to protect 
against being sick.   
 
Your child is being asked to participate in a study about dengue virus.  Mosquitoes in your area carry this virus.  
When they bite people, this can cause a person to become sick with dengue.  The data from this study will help 
to better control the mosquito population.  It will also help us to understand how and when the body makes 
the molecules to protect against getting sick. 
 
This study will test your child’s blood for virus to see if he or she has the virus.  We will also see if he or she has 
the molecules to protect against getting sick.  Study staff will take blood two times.  The first time will be today, 
if you want your child to take part in the study.  The second time will be in six months.   
 
Possible Benefits 
There is no benefit to you or your child for being in this study.  The benefit of being in this study is the benefit 
of the community.  It will also help guide mosquito control efforts and help people who get sick with dengue.     
 
Possible Risks 
The risk of side effects from drawing blood is small.  Your child may have pain when the needle goes into the 
skin.  Some people have a little bruising after the blood is taken.    
 
Costs 
There is no cost to be in this study.   
 
Privacy 
Your child’s privacy will be protected to the extent legally possible.  Information from this study may be 
published.  We will not publish your name or your child’s name, address, or other information that would 
identify you or your child or link you or your child to antibody results.   
 
Contacting Study Personnel 
You can call the study staff if you have questions about the study.  You can also contact the study staff if you 
want your child to stop being part of the study.  The contact information is: 
(Insert site-specific investigator contact information.) 
 
Consent 
This study staff has been explained to me, and I freely consent to join this study.  I understand the following: 
 
• There are small risks from getting a blood draw. 
• There are no direct benefits to me from being in this study. 
• I may refuse to join or may drop out at any time. 
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Printed Name of Participant 
 
 
 Date of Birth    
Signature of Participant or Consenting Parent  Date/Time  
Street Address  
 
 
 Barrio, City 
Printed Name of Person Conducting Consent 
Interview 
 






CONSENTIMIENTO INFORMADO PEDIATRICO (SPANISH) 
 
Factores Determinantes de Diversidad Viral y Ecología de la Transmisión del Virus del Dengue en 
Colombia 
Descripción 
Usted está invitado para participar en un estudio de investigación sobre el dengue y su vector. Nosotros 
planeamos estudiar los serotipos de dengue y los anticuerpos en contra del virus y de la saliva del vector 
encontradas en su sangre. 
 
Procedimientos 
A usted se le ha solicitado un examen de sangre para confirmar la infección por el virus del dengue. Nos gustaría 
que nos diera su permiso para estudiar el suero RESTANTE O QUE SOBRE de la realización de dicho examen. 
Ese suero sobrante normalmente es eliminado. Este estudio de investigación no cambiará su tratamiento médico. 
SI ESTAS EMBARASADA NO SERAS INCLUIDA EN ESTE ESTUDIO. 
 
Después de completar nuestros exámenes iniciales, quisiéramos guardar el suero sobrante para hacer futuras 
investigaciones sobre el dengue. Ese suero sería congelado y almacenado con un número o CÓDIGO y NO SE 
INCLUIRA SU NOMBRE. En cualquier momento del estudio usted puede retirarse, y en ese caso su suero 
sería desechado. 
 
Al mismo tiempo, quisiéramos su permiso para acceder a los resultados de otros exámenes que se pidieron junto 
con en examen de confirmación del dengue, con el UNICO propósito de obtener datos de hemograma 
(componentes de su sangre como plaquetas y glóbulos rojos). Es importante aclarar que no se tomara ninguna 
información personal como su nombre o dirección o cualquier otra información de enfermedades pasadas. 
Usted puede rechazar en cualquier momento la inclusión de estos exámenes. 
 
Con el uso de su suero puede suceder que en el futuro se obtengan nuevos productos, exámenes o 
descubrimientos los cuales tienen potencial valor comercial. Los donantes de tejidos, en este caso el suero 
extraído de su sangre, no retienen ningún derecho de propiedad sobre esos productos. Por lo tanto, usted no 
recibiría ningún beneficio económico de esos productos, exámenes o descubrimientos. 
Los resultados del estudio realizado con su muestra serán usados únicamente con propósitos de investigación y 
usted no conocerá el resultado de dichas pruebas.  
 
Riesgos y Beneficios 
No se prevén riesgos asociados con este estudio. Como este no es un estudio sobre tratamiento, usted no recibirá 
ningún beneficio directo por su participación. Nosotros no podemos garantizarle  que usted recibirá algún 
beneficio de este estudio. 
 
Privacidad 
Su privacidad será protegida al máximo posible. La información resultante de este estudio podría ser publicada. 
Nosotros no publicaremos su nombre, dirección o cualquier otra información que lo pueda ligar o identificar a 
usted con los resultados de esta investigación. 
 
Gasto de Tiempo 
Una vez se obtenga la muestra de sangre para realizar sus exámenes médicos, su participación en este estudio no 





Usted no recibirá pago alguno por participar en este estudio. 
 
A quien llamar por preguntas: Usted puede llamar a Carolina Cárdenas al 317 3004517 a cualquier hora si 
tiene alguna pregunta sobre el estudio. 
 
Paciente  
Cuando yo firmo este formato, significa que el estudio de investigación me ha sido explicado en un lenguaje 
que yo entiendo. Si yo decido participar, yo recibiré una copia de esta información y de un resumen del estudio. 
Yo tendré la oportunidad de hacer preguntas sobre el estudio. Mis preguntas deberán ser respondidas a 
satisfacción antes que yo firme este formato. Yo puedo decidir no participar en el estudio o puedo renunciar a 
él en cualquier momento. 
 
Yo sé que se evaluará en este estudio. Yo también se lo bueno y lo malo (riesgos y beneficios) que podría pasar 
si yo hago parte de este estudio. Yo sé que puedo dejar de ser parte de esta investigación sin dejar de recibir mi 
atención médica usual. 
 
Marque los que considere pertinentes: 
 
Yo consiento en que mi muestra _______ o exámenes clínicos _________ sean usados para esta investigación. 
 
Yo NO consiento en que mi muestra ______ o exámenes clínicos_____ sea usados para esta investigación.  
 
Yo consiento que mi muestra sea guardada para otras investigaciones: SI_____  No ______ 
 
 
   
Nombre del Paciente  
 
 
 Fecha de Nacimiento   




Firma del Paciente o Acudiente  
 
 




 Ciudad de Residencia 







CENTERS FOR DISEASE CONTROL AND PREVENTION  




ADULT AND PEDIATRIC CLINICAL LABORATORY REFERENCE RANGES 
 
Adult American Board of Internal Medicine Clinical Laboratory Reference Values* 
(Eryth) Erythrocytes 4.2–5.9 ×106/μL 
(Hct)  Hematocrit  female: 37%–47%  
   male: 42%–50% 
(Hb)  Hemoglobin female: 12–16 g/dL 
   male: 14–18 g/dL 
(Plt)  Platelets 150,000–450,000/μL 
(Leu)  Leukocytes  4.0–11.0 ×103/μL 
(Neut)  Neutrophils  50%–70% 
(Lymph) Lymphocytes 30%–45% 
(Mono)  Monocytes 0–6% 
(Eos)  Eosinophils  0–3% 
(Baso)  Basophils  0–1% 
 
Pediatric Clinical Laboratory Reference Values† 
(Eryth) Erythrocytes  Age    ×103/μL 
 0–30 days   4.1–6.7 
 1 month   3.0–5.4 
 2–6 months   2.7–4.5 
 7 months–2 years 3.7–5.3 
 3–6 year  3.9–5.3 
 7–12 years  4.0–5.2 
 13–18 years   female  4.1–5.1       male  4.5–5.3  
 ≥19 years   female 4.2–5.4       male  4.7–6.0 
 
(Hct) Hematocrit Age    % 
 0–30 days   44–70 
 1 month   32–42 
 2–6 months   29–41 
 7 months–2 years 33–39 
 3–6 years   34–40 
 7–12 years  35–45 
 13–18 years  female 36–45         male  37–49 
 ≥19 years   female 36–46          male 41–53 
 
(Hb) Hemoglobin Age    g/dL 
 0–30 days   15.0–22.0 
 1 month   10.5–14.0 
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 2–6 months   9.5–13.5 
 7 months–2 years  10.5–14.0 
 3–6 years  11.5–14.5 
 7–12 years  11.5–15.5 
 13–18 years  female 12.0–16.0       male  13.0–16.0 
 ≥19 years   female 12.0–16.0      male  13.5–17.5 
 
 
(Plt) Platelets Age, sex inclusive 150,000–450,000/μL 
 
(Leu) Leukocytes Age    ×103/μL 
 0–30 days   9.1–34.0 
 1 month   5.0–19.5 
 2–11 months   6.0–17.5 
 1–6 years   5.0–14.5 
 7–12 years  5.0–14.5 
 13–18 years   4.5–13.5 
 ≥19 years   4.5–11.0 
 
 
  Neutrophils Lymphocytes Monocytes Eosinophils Basophils 
Age  (Neut) (%)  (Lymph) (%)    (Mono) (%)   (Eos) (%)  (Baso) (%)  
0–30 days  32–67  25–37    0–9   0–2  0–1  
1 month  20–46  28–84    0–7   0–3  0–1  
2–11 months  20–48  34–88    0–5   0–3  0–1  
1–6 years  37–71  17–67   0–5   0–3  0–1  
7–12 years  33–76  15–61    0–5   0–3  0–1  





†From: Andropoulos DB. Pediatric Normal Laboratory Values. In Gregory's Pediatric Anesthesia (eds G. A. 




COLOMBIA SEROPREVALENCE SURVEY SAS CODE 
 
****************************************** 
proc printto print=myprint; 
proc printto log=mylog; 
proc format; 
  value agecat 
           1 = '<1' 
           2 = '1-9' 
           3 = '10-17' 
           4 = '18-29' 
           5 = '30-39' 
           6 = '40-49' 
           7 = '50-64' 
           8 = '65+'; 
  value agetwo 
           0 = '<18' 
           1 = '18+'; 
  value serodenv 
           0 = 'DENV neg' 
           1 = 'DENV1 pos' 
           2 = 'DENV2 pos' 
           3 = 'DENV3 pos' 
           4 = 'DENV4 pos' 
           5 = 'DENV1,DENV2 pos' 
           6 = 'DENV1,DENV3 pos' 
           7 = 'DENV1,DENV4 pos' 
           8 = 'DENV2,DENV3 pos' 
           9 = 'DENV2,DENV4 pos' 
          10 = 'DENV3,DENV4 pos' 
          11 = 'DENV1,DENV2,DENV3 pos' 
          12 = 'DENV1,DENV3,DENV4 pos' 
          13 = 'DENV2,DENV3,DENV4 pos'; 
 value combdenv 
           0 = 'DENV neg' 
           1 = 'DENV1 pos, only' 
           2 = 'DENV2 pos, only' 
           3 = 'DENV3 pos, only' 
           4 = 'DENV4 pos, only' 
           5 = 'combined DENV'; 
  value pos 
           0 = 'negative' 
           1 = 'positive'; 
  value multipos 
           0 = 'mono inf' 
           1 = 'multi inf'; 
  value yesno 
           0 = 'no' 
           1 = 'yes'; 
  value sex 
           0 = 'female'  
           1 = 'male'; 
  value denvpos 
           -1 = 'missing' 
            0 = 'negative' 
            1 = 'positive'; 
  value cities 
            1 = 'OCAÑA' 
            2 = 'PATIOS' 
            3 = 'OTHER'; 
  value response 
            1 = 'missing data' 
            2 = 'data available'; 
  value singcomb 
            0 = 'denv neg' 
            1 = 'denv single positive' 
            2 = 'denv multi positive'; 
  value sympdays 
            0 = '<4 days ill' 
            1 = '4+ days'; 
 value serology 
            0 = 'missing' 
            1 = 'IgM pos' 
            2 = 'IgG pos' 
            3 = 'IgM & IgG pos'; 
data disser; 
  set new.new_jen_data; 
  if denvpos = . then delete; 






*  change character to numeric 
*  reset . to blank 
************************************; 
if DAYSSX = '.' then DAYSSX = ' '; 
DAYSSX_n = DAYSSX*1; 
******************************* 
*  agecat variable 
*******************************; 
  if age lt 1 then agecat = 1; 
  if age ge 1 and age lt 10 then agecat = 2; 
  if age ge 10 and age lt 18 then agecat = 3; 
  if age ge 18 and age lt 30 then agecat = 4; 
  if age ge 30 and age lt 40 then agecat = 5; 
  if age ge 40 and age lt 50 then agecat = 6; 
  if age ge 50 and age lt 65 then agecat = 7; 
  if age ge 65 then agecat=8; 
**************************************** 
*  dichotomous age 
****************************************; 
  if age lt 18 then agetwo = 0; 
  if age ge 18 then agetwo = 1; 
*********************************** 
*  fix error in denv2 
***********************************; 
  if denv2 = 2 then denv2 = 1; 
********************************** 
*  serotype DENV 
**********************************; 
serodenv = 0; 
  if denvpos = . then serodenv = .; 
  if denv1 = 1 then serodenv=1; 
  if denv2 = 1  then serodenv=2; 
  if denv3 = 1 then serodenv=3; 
  if denv4 = 1 then serodenv=4; 
  if denv1 = 1 and (denv2 = 1 or denv2 = 2) 
then serodenv=5; 
  if denv1 = 1 and denv3 = 1 then 
serodenv=6; 
  if denv1 = 1 and denv4 = 1 then 
serodenv=7; 
  if denv2 = 1 and denv3 = 1 then 
serodenv=8; 
  if denv2 = 1 and denv4 = 1 then 
serodenv=9; 
  if denv3 = 1 and denv4 = 1 then 
serodenv=10; 
  if denv1 = 1 and denv2 = 1 and denv3 = 1 
then serodenv=11; 
  if denv1 = 1 and denv3 = 1 and denv4 = 1 
then serodenv=12; 
  if denv2 = 1 and denv3 = 1 and denv4 = 1 
then serodenv=12; 
********************************* 
*  combdenv 
*********************************; 
combdenv = 0; 
  if denvpos = . then combdenv=.; 
  if denv1 = 1 then combdenv=1; 
  if denv2 = 1 or denv2 = 2 then 
combdenv=2; 
  if denv3 = 1 then combdenv=3; 
  if denv4 = 1 then combdenv=4; 
  if serodenv ge 5 then combdenv=5; 
*************************************** 
*  neg, single pos, comb pos 
***************************************; 
  if combdenv = 0 then sing_comb = 0; 
  if combdenv ge 1 and combdenv le 4 then 
sing_comb = 1; 
  if combdenv eq 5 then sing_comb = 2; 
************************************** 
*  sex variable 
**************************************; 
  if sex = 'F' then sex = 0; 
  if sex = 'M' then sex = 1; 
************************************* 
*  fix denvpos and denv 
*************************************; 
  if denvpos = . then denvpos = -1; 
  if denv1 = . then denv1 = -1; 
  if denv2 = . then denv2 = -1; 
  if denv3 = . then denv3 = -1; 
116 
 
  if denv4 = . then denv4 = -1; 
************************************* 
*  cities variable 
*************************************; 
if (city = 'ABREGO' or city = 'BOGOTA' or 
city = 'CHICANOTA' or    
 city = 'COCHIRA' or city = 
'CONVENCION' or city = 'CUCUTA' or        
city = 'EL CARMEN' or city = 
'GONZALES' or city = 'GUAMALITO' or     
 city = 'HACARI' or city = 'LA 
ESPERANZA' or city = 'LA PLAYA' or   
 city = 'RIO CESAR' or city = 'SAN 
PABLO' or city = 'TARRA' or  
 city = 'TEORAMA') then cities = 3;  
if city = 'OCAÑA' then cities = 1;            
if city = 'PATIOS' then cities = 2;    
************************************** 
*  response rate information 
**************************************; 
if denvpos = -1 then sero_response = 1; 
if denvpos ge 0 then sero_response = 2; 
if admit = . then clin_response = 1; 
if admit ge 0 then clin_response = 2;  
if rbc = . then blood_response = 1; 
if rbc ge 0 then blood_response = 2; 
************************************* 
*  fix gingbleed 
*************************************; 
  if gingbleed = -1 then gingbleed = .; 
**************************************** 
*  serology 
****************************************; 
  serology = 0; 
  if igm = 1 then serology = 1; 
  if igg = 1 then serology = 2; 
  if igm = 1 and igg = 1 then serology = 3; 
************************************* 
*  admit 
**************************************; 
  if admit = 2 then admit = 1; 
data no_miss_denv; 
  set disser; 
  if denvpos = -1 then delete; 
data no_miss_all; 
  set no_miss_denv; 
  if admit = . then delete; 
run; 
data single; 
  set disser; 
  if combdenv = 5 then delete; 
data positive; 
  set disser; 
  if denvpos = 0 then delete; 
************************************** 
*  single or multiple pos 
**************************************; 
  multi_pos = 0; 
  if serodenv ge 5 then multi_pos = 1; 
************************************** 
*  symptom days 
**************************************; 
  symp_days = 0; 
  if dayssx ge 4 then symp_days=1; 
data complete; 
  set positive; 
  if vomit = . then delete; 
run; 
/* 
proc contents position data=disser; 
*/ 
proc freq data=disser; 
  tables serodenv; 
  tables agecat; 
  tables sex; 
  tables lepto; 
  tables serodenv; 
  tables combdenv; 
  tables serology; 
  tables agecat*denvpos; 
  tables sex*denvpos; 
  tables city; 
  tables city*denvpos; 
  tables serology*denvpos; 
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  tables city*serodenv; 
  tables lepto*denvpos; 
  tables serodenv*denvpos; 
  tables combdenv*denvpos; 
  format serodenv serodenv. agecat agecat. 
denvpos denvpos. sex sex. 
         serology serology. combdenv 
combdenv.; 
run; 
proc means data=disser; 
  var age; 
run; 
proc sort data=disser; 
  by denvpos; 
run; 
proc means data=disser; 
  class denvpos; 
  var age; 
  format denvpos denvpos.; 
run; 
proc freq data=complete; 
  tables multi_pos; 
run; 
proc sort data=complete; 
  by sex; 
run; 
proc freq data=complete; 
  tables sex*multi_pos/all fisher; 
  format sex sex. multi_pos multipos.; 
run;  
/* 
proc logistic data=positive; 
  model multi_pos = sex; 
  format multi_pos multipos. sex sex.; 
run; 
*/ 
proc sort data=complete; 
  by vomit; 
run; 
proc freq data=complete; 
  tables vomit*multi_pos/all; 
  format multi_pos multipos. vomit yesno.; 
run; 
/*  
proc logistic data=positive; 
  model multi_pos = vomit; 
  format multi_pos multipos. vomit yesno.; 
run; 
*/ 
proc sort data=complete; 
  by symp_days; 
run; 
proc freq data=complete; 
  tables symp_days*multi_pos/all; 
  format symp_days sympdays. multi_pos 
multipos.; 
run;  
proc sort data=complete; 
  by myalgia; 
run; 
proc freq data=complete; 
  tables myalgia*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by retropain; 
run; 
proc freq data=complete; 
  tables retropain*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by jntpain; 
run; 
proc freq data=complete; 
  tables jntpain*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by rash; 
run; 
proc freq data=complete; 
  tables rash*multi_pos/all; 




proc sort data=complete; 
  by abdpain; 
run; 
proc freq data=complete; 
  tables abdpain*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by ha; 
run; 
proc freq data=complete; 
  tables ha*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by larvae; 
run; 
proc freq data=complete; 
  tables larvae*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by diarrhea; 
run; 
proc freq data=complete; 
  tables diarrhea*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by diarrhea; 
run; 
proc freq data=complete; 
  tables diarrhea*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by fever; 
run; 
proc freq data=complete; 
  tables fever*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by gingbleed; 
run; 
proc freq data=complete; 
  tables gingbleed*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by agetwo; 
run; 
proc freq data=complete; 
  tables agetwo*multi_pos/all; 
  format multi_pos multipos. agetwo agetwo.; 
run; 
proc sort data=complete; 
  by icterus; 
run; 
proc freq data=complete; 
  tables icterus*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by hyperemia; 
run; 
proc freq data=complete; 
  tables hyperemia*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by OLIGUR; 
proc freq data=complete; 
  tables oligur*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by petech; 
proc freq data=complete; 
  tables petech*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
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  by nosebleed; 
proc freq data=complete; 
  tables nosebleed*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by hypotn; 
proc freq data=complete; 
  tables hypotn*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by tachy; 
proc freq data=complete; 
  tables tachy*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by bednet; 
proc freq data=complete; 
  tables bednet*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by admit; 
proc freq data=complete; 
  tables admit*multi_pos/all; 




*  response information 
*******************************************; 
proc freq data=disser; 
  tables sero_response clin_response 
blood_response; 
  tables sero_response*clin_response; 
  tables sero_response*blood_response; 
  tables blood_response*clin_response; 








*  all data including missing 
********************************************
**; 
proc means data=disser; 
    var age DENVPOS DENV1 DENV2 
DENV3 DENV4 IGM IGG LEPTO rbc 
PLT  
          HB HCT WBC NEUT EOS LYMPH 
MONO BASO DAYSSX_n;  
  title 'all data including missing'; 
proc means data=no_miss_all; 
  var age DENVPOS DENV1 DENV2 
DENV3 DENV4 IGM IGG LEPTO PLT  
          HB HCT WBC NEUT EOS LYMPH 
MONO DAYSSX_n;  
  title 'complete data'; 
proc means data=no_miss_denv; 
  var rbc baso plt; 
  title 'data for rbc, baso, plt - missing 
denvpos taken out only';  
proc freq data=no_miss_all; 
   tables sex city cities dayssx_n ADMIT 
DENVCLASS FEVER MYALGIA 
GINGBLEED         
          VOMIt ICTERUS RETROPAIN 
JNTPAIN HYPEREMIA RASH OLIGUR 
PETECH DIARRHEA NOSEBLEED 
ABDPAIN HA                          
          HYPOTN TACHY BEDNET 
LARVAE LARVLOC DENVPOS DENV1 
DENV2 DENV3 DENV4 agecat; 
  format agecat agecat. denvpos denv1 denv2 
denv3 denv4 denvpos. cities cities.;     
  title 'complete data';                        
run; 
/* 
proc means data=disser; 
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  var age DENVPOS DENV1 DENV2 
DENV3 DENV4 IGM IGG LEPTO RBC 
PLT  
          HB HCT WBC NEUT EOS LYMPH 
MONO BASO DAYSSX_n;  
  title 'data including missing denvpos'; 
proc freq data=disser; 
   tables sex city dayssx_n ADMIT 
DENVCLASS FEVER MYALGIA 
GINGBLEED         
          VOMIt ICTERUS RETROPAIN 
JNTPAIN HYPEREMIA RASH OLIGUR 
PETECH DIARRHEA NOSEBLEED 
ABDPAIN HA                          
          HYPOTN TACHY BEDNET 
LARVAE LARVLOC DENVPOS DENV1 
DENV2 DENV3 DENV4 agecat cities; 
  format agecat agecat. denvpos denv1 denv2 




*  frequencies according to denvpos 
including combined denv 
***************************************; 
proc sort data=no_miss_all; 
  by denvpos; 
run; 
proc freq data=no_miss_all; 
  tables (sex cities)*denvpos/chisq; 
  format denvpos pos. cities cities.; 
  title 'complete data'; 
run; 
proc ttest data=no_miss_all; 
  class denvpos; 
  var age HB HCT WBC NEUT EOS 
LYMPH MONO; 
  format denvpos pos.; 
  title 'complete data'; 
run; 
proc sort data=no_miss_denv; 
  by denvpos; 
proc ttest data=no_miss_denv; 
  class denvpos; 
  var rbc plt baso; 
  format denvpos pos.; 
  title 'data for rbc, baso, and plt - missing 
denvpos taken out'; 
proc freq data=no_miss_all; 
  tables (cities FEVER MYALGIA 
GINGBLEED         
          VOMIt ICTERUS RETROPAIN 
JNTPAIN HYPEREMIA RASH OLIGUR 
PETECH DIARRHEA NOSEBLEED 
ABDPAIN HA                          
          HYPOTN TACHY BEDNET 
LARVAE)*denvpos/chisq; 
  format denvpos pos. cities cities.; 
  title 'complete data'; 
run; 
proc sort data=no_miss_all; 
  by sex; 
run; 
proc freq data=no_miss_all; 
  tables sex*denvpos/all; 
  format sex sex. denvpos pos.; 
run;  
proc logistic data=no_miss_all; 
  model denvpos = sex; 
  format denvpos pos. sex sex.; 
run; 
proc sort data=no_miss_all; 
  by vomit; 
run; 
proc freq data=no_miss_all; 
  tables vomit*denvpos/all; 
  format denvpos pos. vomit yesno.; 
run;  
proc logistic data=no_miss_all; 
  model denvpos = vomit; 
  format denvpos pos. vomit yesno.; 
run; 
******************************************** 




proc sort data=no_miss_all; 
  by sing_comb; 
run; 
proc freq data=no_miss_all; 
  tables (sex cities)*sing_comb/chisq; 
  format sing_comb singcomb. cities cities.; 
  title 'complete data - single and multiple 
DENV pos'; 
run; 
proc anova data=no_miss_all; 
   class sing_comb; 
 model age=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean age'; 
run; 
proc anova data=no_miss_all; 
   class sing_comb; 
 model hb=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean hb'; 
run; 
proc anova data=no_miss_all; 
   class sing_comb; 
 model hct=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean hct'; 
run; 
proc anova data=no_miss_all; 
   class sing_comb; 
 model wbc=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean wbc'; 
run; 
proc anova data=no_miss_all; 
   class sing_comb; 
 model neut=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean neut'; 
run; 
proc anova data=no_miss_all; 
   class sing_comb; 
 model eos=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean eos'; 
run; 
proc anova data=no_miss_all; 
   class sing_comb; 
 model lymph=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean lymph'; 
run; 
proc anova data=no_miss_all; 
   class sing_comb; 
 model mono=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean mono'; 
run; 
proc sort data=no_miss_denv; 




proc anova data=no_miss_denv; 
   class sing_comb; 
 model rbc=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean rbc'; 
run; 
proc anova data=no_miss_denv; 
   class sing_comb; 
 model plt=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean platelet'; 
run; 
proc anova data=no_miss_denv; 
   class sing_comb; 
 model baso=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 






*  frequencies according to denvpos only 
singular 
***************************************; 
proc sort data=single; 
  by denvpos; 
run; 
proc freq data=single; 
  tables (sex city hood)*denvpos/chisq; 
  format denvpos pos.; 
  title 'frequencies according to singular 
denvpos'; 
run; 
proc ttest data=single; 
  class denvpos; 
  var age RBC PLT HB HCT WBC NEUT 
EOS LYMPH MONO BASO; 
  format denvpos pos.; 
  title 'ttest by covariates according to 
singular denvpos'; 
run; 
proc freq data=single; 
  tables (FEVER MYALGIA GINGBLEED         
          VOMIt ICTERUS RETROPAIN 
JNTPAIN HYPEREMIA RASH OLIGUR 
PETECH DIARRHEA NOSEBLEED 
ABDPAIN HA                          
          HYPOTN TACHY BEDNET 
LARVAE)*denvpos/chisq; 
  format denvpos pos. FEVER MYALGIA 
GINGBLEED         
          VOMIt ICTERUS RETROPAIN 
JNTPAIN HYPEREMIA RASH OLIGUR 
PETECH DIARRHEA NOSEBLEED 
ABDPAIN HA                          
          HYPOTN TACHY BEDNET 
LARVAE yesno.; 







*  frequencies according to combdenv 
singular individual denv1-4 
***************************************; 
proc sort data=single; 
  by combdenv; 
run; 
proc freq data=single; 
  tables (sex city hood)*combdenv/chisq; 
  format combdenv combdenv.; 
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  title 'frequencies according to singular 
denvpos'; 
run; 
proc anova data=single; 
   class combdenv; 
 model age=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean age'; 
run; 
proc anova data=single; 
   class combdenv; 
 model rbc=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean rbc'; 
run; 
proc anova data=single; 
   class combdenv; 
 model plt=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean plt'; 
run; 
proc anova data=single; 
   class combdenv; 
 model hb=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean hb'; 
run; 
proc anova data=single; 
   class combdenv; 
 model hct=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean hct'; 
run; 
proc anova data=single; 
   class combdenv; 
 model wbc=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean wbc'; 
run; 
proc anova data=single; 
   class combdenv; 
 model neut=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean neut'; 
run; 
proc anova data=single; 
   class combdenv; 
 model eos=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean eos'; 
run; 
proc anova data=single; 
   class combdenv; 
 model lymph=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 





proc anova data=single; 
   class combdenv; 
 model mono=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean mono'; 
run;  
proc anova data=single; 
   class combdenv; 
 model baso=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean baso'; 
run;  
proc freq data=single; 
  tables (FEVER MYALGIA GINGBLEED         
          VOMIt ICTERUS RETROPAIN 
JNTPAIN HYPEREMIA RASH OLIGUR 
PETECH DIARRHEA NOSEBLEED 
ABDPAIN HA                          
          HYPOTN TACHY BEDNET 
LARVAE)*combdenv/chisq; 
  format combdenv combdenv. FEVER 
MYALGIA GINGBLEED         
          VOMIt ICTERUS RETROPAIN 
JNTPAIN HYPEREMIA RASH OLIGUR 
PETECH DIARRHEA NOSEBLEED 
ABDPAIN HA                          
          HYPOTN TACHY BEDNET 
LARVAE yesno.; 






*  frequencies according to individual denv1-
4 among positives only 
***************************************; 
proc sort data=positive; 
  by combdenv; 
run; 
proc freq data=positive; 
  tables (sex city hood)*combdenv/chisq; 
  format combdenv combdenv.; 
  title 'frequencies according to singular 
denvpos, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model age=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean age, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model rbc=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean rbc, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model plt=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean plt, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model hb=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
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format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean hb, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model hct=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean hct, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model wbc=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean wbc, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model neut=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean neut, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model eos=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean eos, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model lymph=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean lymph, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model mono=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean mono, positives only'; 
run;  
proc anova data=positive; 
   class combdenv; 
 model baso=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean baso, positives only'; 
run;  
proc freq data=positive; 
  tables (FEVER MYALGIA GINGBLEED         
          VOMIt ICTERUS RETROPAIN 
JNTPAIN HYPEREMIA RASH OLIGUR 
PETECH DIARRHEA NOSEBLEED 
ABDPAIN HA                          
          HYPOTN TACHY BEDNET 
LARVAE)*combdenv/chisq; 
  format combdenv combdenv. FEVER 
MYALGIA GINGBLEED         
          VOMIt ICTERUS RETROPAIN 
JNTPAIN HYPEREMIA RASH OLIGUR 
PETECH DIARRHEA NOSEBLEED 
ABDPAIN HA HYPOTN TACHY 
BEDNET LARVAE yesno.; 
title 'frequencies according to singular 





proc freq data=disser; 
  tables agecat denvpos denv1 denv2 denv3 
denv4 serodenv combdenv; 
  format agecat agecat. serodenv serodenv. 
combdenv combdenv.; 
run; 
proc freq data=disser; 
   tables city*denvpos; 
   tables sex*denvpos; 
run; 
proc sort data=disser; 
   by denvpos; 
run; 
proc means; 
  class denvpos; 
  var age rbc plt hb hct wbc neut eos lymph 
mono baso; 
run; 
proc freq data=disser; 
  tables denvpos*(serodenv combdenv); 




proc freq data=disser; 
  tables denv2*(denv1 denv3 denv4 
serodenv); 
  format serodenv serodenv.; 
run; 
*/ 
proc sort data=disser; 
  by combdenv; 
run; 
proc means data=disser; 
  class combdenv; 
  var age rbc plt hb hct wbc neut eos lymph 
mono baso; 
format combdenv combdenv.; 
run; 
proc freq data=disser; 
  tables combdenv*sex; 
format combdenv combdenv.; 
/* 
proc univariate freq data=disser; 





options ls=80 ps=60 nocenter; 
libname new 'c:\jennifer\data'; 
options FORMCHAR="|----|+|---+=|-/\<>*"; 
filename myprint 'c:\jennifer\prog\jen6.lst'; 
filename mylog 'c:\jennifer\prog\jen6.log'; 
proc printto print=myprint; 
proc printto log=mylog; 
proc format; 
  value agecat 
           1 = '<1' 
           2 = '1-9' 
           3 = '10-17' 
           4 = '18-29' 
           5 = '30-39' 
           6 = '40-49' 
           7 = '50-64' 
           8 = '65+'; 
  value agetwo 
           0 = '<18' 
           1 = '18+'; 
  value serodenv 
           0 = 'DENV neg' 
           1 = 'DENV1 pos' 
           2 = 'DENV2 pos' 
           3 = 'DENV3 pos' 
           4 = 'DENV4 pos' 
           5 = 'DENV1,DENV2 pos' 
           6 = 'DENV1,DENV3 pos' 
           7 = 'DENV1,DENV4 pos' 
           8 = 'DENV2,DENV3 pos' 
           9 = 'DENV2,DENV4 pos' 
          10 = 'DENV3,DENV4 pos' 
          11 = 'DENV1,DENV2,DENV3 pos' 
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          12 = 'DENV1,DENV3,DENV4 pos' 
          13 = 'DENV2,DENV3,DENV4 pos'; 
 value combdenv 
           0 = 'DENV neg' 
           1 = 'DENV1 pos, only' 
           2 = 'DENV2 pos, only' 
           3 = 'DENV3 pos, only' 
           4 = 'DENV4 pos, only' 
           5 = 'combined DENV'; 
  value pos 
           0 = 'negative' 
           1 = 'positive'; 
  value multipos 
           0 = 'mono inf' 
           1 = 'multi inf'; 
  value yesno 
           0 = 'no' 
           1 = 'yes'; 
  value sex 
           0 = 'female'  
           1 = 'male'; 
  value denvpos 
           -1 = 'missing' 
            0 = 'negative' 
            1 = 'positive'; 
  value cities 
            1 = 'OCAÑA' 
            2 = 'PATIOS' 
            3 = 'OTHER'; 
  value response 
            1 = 'missing data' 
            2 = 'data available'; 
  value singcomb 
            0 = 'denv neg' 
            1 = 'denv single positive' 
            2 = 'denv multi positive'; 
  value sympdays 
            1 = '<4 days ill' 
            2 = '4+ days'; 
  value altage 
            1 = '<1 yr' 
            2 = '1 yr' 
            3 = '2-11 yrs' 
            4 = '12-18 yrs' 
            5 = '19-44 yrs' 
            6 = '45+ yrs'; 
  value serology 
            0 = 'missing' 
            1 = 'IgM pos' 
            2 = 'IgG pos' 
            3 = 'IgM & IgG pos'; 
  value highlow 
            0 = 'high' 
            1 = 'low'; 
  value lowhigh 
            0 = 'low' 
            1 = 'high'; 
  value symptoms 
            0 = 'no symptoms' 
            1 = '<4 days ill' 
            2 = '4+ days'; 
data disser; 
  set new.new_jen_data; 
  if denvpos = . then delete; 
************************************ 
*  change character to numeric 
*  reset . to blank 
************************************; 
if DAYSSX = '.' then DAYSSX = ' '; 
DAYSSX_n = DAYSSX*1; 
******************************* 
*  agecat variable 
*******************************; 
  if age lt 1 then agecat = 1; 
  if age ge 1 and age lt 10 then agecat = 2; 
  if age ge 10 and age lt 18 then agecat = 3; 
  if age ge 18 and age lt 30 then agecat = 4; 
  if age ge 30 and age lt 40 then agecat = 5; 
  if age ge 40 and age lt 50 then agecat = 6; 
  if age ge 50 and age lt 65 then agecat = 7; 
  if age ge 65 then agecat=8; 
**************************************** 




  if age lt 18 then agetwo = 0; 
  if age ge 18 then agetwo = 1; 
****************************************** 
*  altage 
******************************************; 
  if age lt 1 then altage = 1; 
  if age ge 1 and age lt 2 then altage = 2; 
  if age ge 2 and age lt 12 then altage = 3; 
  if age ge 12 and age lt 19 then altage = 4; 
  if age ge 19 and age lt 45 then altage = 5; 
  if age ge 45 then altage = 6; 
*********************************** 
*  fix error in denv2 
***********************************; 
  if denv2 = 2 then denv2 = 1; 
********************************** 
*  serotype DENV 
**********************************; 
serodenv = 0; 
  if denvpos = . then serodenv = .; 
  if denv1 = 1 then serodenv=1; 
  if denv2 = 1  then serodenv=2; 
  if denv3 = 1 then serodenv=3; 
  if denv4 = 1 then serodenv=4; 
  if denv1 = 1 and (denv2 = 1 or denv2 = 2) 
then serodenv=5; 
  if denv1 = 1 and denv3 = 1 then 
serodenv=6; 
  if denv1 = 1 and denv4 = 1 then 
serodenv=7; 
  if denv2 = 1 and denv3 = 1 then 
serodenv=8; 
  if denv2 = 1 and denv4 = 1 then 
serodenv=9; 
  if denv3 = 1 and denv4 = 1 then 
serodenv=10; 
  if denv1 = 1 and denv2 = 1 and denv3 = 1 
then serodenv=11; 
  if denv1 = 1 and denv3 = 1 and denv4 = 1 
then serodenv=12; 
  if denv2 = 1 and denv3 = 1 and denv4 = 1 
then serodenv=12; 
********************************* 
*  combdenv 
*********************************; 
combdenv = 0; 
  if denvpos = . then combdenv=.; 
  if denv1 = 1 then combdenv=1; 
  if denv2 = 1 or denv2 = 2 then 
combdenv=2; 
  if denv3 = 1 then combdenv=3; 
  if denv4 = 1 then combdenv=4; 
  if serodenv ge 5 then combdenv=5; 
*************************************** 
*  neg, single pos, comb pos 
***************************************; 
  if combdenv = 0 then sing_comb = 0; 
  if combdenv ge 1 and combdenv le 4 then 
sing_comb = 1; 
  if combdenv eq 5 then sing_comb = 2; 
************************************** 
*  sex variable 
**************************************; 
  if sex = 'F' then sex = 0; 
  if sex = 'M' then sex = 1; 
************************************* 
*  fix denvpos and denv 
*************************************; 
  if denvpos = . then denvpos = -1; 
  if denv1 = . then denv1 = -1; 
  if denv2 = . then denv2 = -1; 
  if denv3 = . then denv3 = -1; 
  if denv4 = . then denv4 = -1; 
************************************* 
*  cities variable 
*************************************; 
if (city = 'ABREGO' or city = 'BOGOTA' or 
city = 'CHICANOTA' or    
 city = 'COCHIRA' or city = 
'CONVENCION' or city = 'CUCUTA' or        
city = 'EL CARMEN' or city = 
'GONZALES' or city = 'GUAMALITO' or     
 city = 'HACARI' or city = 'LA 
ESPERANZA' or city = 'LA PLAYA' or   
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 city = 'RIO CESAR' or city = 'SAN 
PABLO' or city = 'TARRA' or  
 city = 'TEORAMA') then cities = 3;  
if city = 'OCAÑA' then cities = 1;            
if city = 'PATIOS' then cities = 2;    
************************************** 
*  response rate information 
**************************************; 
if denvpos = -1 then sero_response = 1; 
if denvpos ge 0 then sero_response = 2; 
if admit = . then clin_response = 1; 
if admit ge 0 then clin_response = 2;  
if rbc = . then blood_response = 1; 
if rbc ge 0 then blood_response = 2; 
************************************* 
*  fix gingbleed 
*************************************; 
  if gingbleed = -1 then gingbleed = .; 
  if gingbleed = 2 then gingbleed = 1; 
**************************************** 
*  serology 
****************************************; 
  serology = 0; 
  if igm = 1 then serology = 1; 
  if igg = 1 then serology = 2; 
  if igm = 1 and igg = 1 then serology = 3; 
******************************************** 
*  indicator variables for denv 
********************************************; 
denv_one = 0; 
if denv1 = 1 then denv_one = 1; 
denv_two = 0; 
if denv2 = 1 then denv_two = 1; 
denv_three = 0; 
if denv3 = 1 then denv_three = 1; 
denv_four = 0; 
if denv4 = 1 then denv_four = 1; 
denv_comb = 0; 
if serodenv ge 5 then denv_comb = 1; 
sing_denv = 0; 
if serodenv ge 1 and serodenv lt 5 then 
sing_denv = 1; 
multi_denv = 0; 
if serodenv ge 5 then multi_denv = 1; 
******************************************* 
*  indicator variable for cities 
********************************************; 
  city1 = 0; 
  if cities = 1 then city1 = 1; 
  city2 = 0; 
  if cities = 2 then city2 = 1; 
************************************** 
*  symptom days                      * 
**************************************; 
  if dayssx_n eq . then symp_days = 0; 
  if dayssx_n ge 0 and dayssx_n lt 6 then 
symp_days=1; 
  if dayssx_n ge 6 then symp_days=2; 
**************************************** 
*  symptom days cut at the median = 3 days 
****************************************; 
  if dayssx_n ge 0 and dayssx_n lt 4 then 
sympdays2 = 1; 
  if dayssx_n ge 4 then sympdays2 = 2; 
****************************************** 
*  account for missing 
*****************************************; 
  sympdays3 = sympdays2; 
  if dayssx_n = . then sympdays3 = 0; 
******************************************** 
*  indicator variables 
********************************************; 
  symptom1 = 0; 
  if sympdays3 = 1 then symptom1 = 1; 
  symptom2 = 0; 
  if sympdays3 = 2 then symptom2 = 1; 
********************************************
***; 
*  note:  rbc missing 126 
********************************************; 
/* 
  if rbc lt 5.0 then rbc2 = 1; 





*  plt cut at 100 (approx median) with 0 = plt 
gt 100 
********************************************; 
  if plt ge 0 and plt lt 100 then plt2 = 1; 
  if plt ge 100 then plt2 = 0; 
******************************************** 
*  HB cut at 13 (approx median) with 0 = 
13+ 
********************************************; 
  if hb ge 0 and hb lt 13 then hb2 = 1; 
  if hb ge 13 then hb2 = 0; 
******************************************** 
*  hct cut at 40 (median) with 0 = hct ge 40 
********************************************; 
   if hct ge 0 and hct lt 40.0 then hct2 = 1; 
   if hct ge 40.0 then hct2 = 0; 
******************************************** 




  if wbc ge 0 and wbc lt 4.0 then wbc2 = 1; 
  if wbc ge 4.0 then wbc2 = 0; 
  if wbc ge 0 and wbc le 5.0 then wbc3 = 1; 
  if wbc gt 5.0 then wbc3 = 0; 
******************************************** 
*  alternate designation of case status for 
wbc2 
********************************************; 
  if wbc2 = 1 then wbc_alt = 0; 
  if wbc2 = 0 then wbc_alt = 1; 
********************************************
********** 
*  neut cut at 55 (median) with 0 = neut ge 
55 
********************************************; 
  if neut ge 0 and neut lt 55 then neut2 = 1; 
  if neut ge 55 then neut2 = 0; 
*************************** 
*  note:  EOS missing 56 
***************************; 
******************************************** 
*  lymph cut at 40.0 (median) with 0 = 
lymph ge 40.0 
********************************************; 
  if lymph ge 0 and lymph lt 40.0 then 
lymph2 = 1; 
  if lymph ge 40.0 then lymph2 = 0; 
******************************************* 
*  note:  mono missing 115 
*******************************************; 
******************************************** 
*  note:  baso missing 126 
********************************************; 
*********************************** 
*  subset data to principal components data 
set 
*  continuous variables clinical plus age 
**************************************; 
data principal; 
  set disser; 




*  signs and symptoms for combdenv 
*******************************************; 
proc freq data=disser; 
  tables myalgia gingbleed vomit icterus 
retropain jntpain hyperemia 
         rash oligur petech diarrhea nosebleed 
abdpain ha hypotn tachy; 
 format myalgia gingbleed vomit icterus 
retropain jntpain hyperemia 
         rash oligur petech diarrhea nosebleed 
abdpain ha hypotn  
         tachy yesno.; 
run; 
proc freq data=disser; 
  tables (myalgia gingbleed vomit icterus 
retropain jntpain hyperemia 
         rash oligur petech diarrhea nosebleed 
abdpain ha hypotn  
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         tachy)*combdenv; 
  format combdenv combdenv. myalgia 
gingbleed vomit icterus retropain jntpain 
hyperemia 
         rash oligur petech diarrhea nosebleed 
abdpain ha hypotn  




*  means of clinical variables by denv pos or 
neg 
********************************************; 
proc sort data=disser; 
  by denvpos; 
run; 
proc means data=disser; 
  var dayssx_n plt hb hct wbc neut lymph age 
rbc; 
run; 
proc ttest data=disser; 
  class denvpos; 
  var dayssx_n plt hb hct wbc neut lymph age 
rbc; 
  format denvpos denvpos.; 
run; 
proc sort data=disser; 
  by combdenv; 
run; 
proc anova data=disser; 
  class combdenv; 
  model plt = combdenv; 
     means combdenv; 
    means combdenv/lsd; 
  format combdenv combdenv.; 
run; 
proc anova data=disser; 
  class combdenv; 
  model hb = combdenv; 
     means combdenv; 
    means combdenv/lsd; 
  format combdenv combdenv.; 
run; 
proc anova data=disser; 
  class combdenv; 
  model hct = combdenv; 
     means combdenv; 
    means combdenv/lsd; 
  format combdenv combdenv.; 
run; 
proc anova data=disser; 
  class combdenv; 
  model wbc = combdenv; 
     means combdenv; 
    means combdenv/lsd; 
  format combdenv combdenv.; 
run; 
proc anova data=disser; 
  class combdenv; 
  model neut = combdenv; 
     means combdenv; 
    means combdenv/lsd; 
  format combdenv combdenv.; 
run; 
proc anova data=disser; 
  class combdenv; 
  model lymph = combdenv; 
     means combdenv; 
    means combdenv/lsd; 
  format combdenv combdenv.; 
run; 
******************************************** 
*  analysis of denv1 and wbc                   * 
********************************************; 
proc freq data=disser; 
  tables combdenv*wbc_alt; 
format combdenv combdenv. wbc_alt 
lowhigh.; 
proc freq data=disser; 
  tables agetwo*wbc_alt; 
  tables sex*wbc_alt; 
  tables symp_days*wbc_alt; 
  tables sympdays3*wbc_alt; 
  tables cities*wbc_alt; 
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  format wbc_alt lowhigh. agetwo agetwo. sex 
sex.  cities cities. 
         sympdays3 symptoms.; 
proc sort data=disser; 
  by combdenv; 
proc anova data=disser; 
  class combdenv; 
  model wbc = combdenv; 
     means combdenv; 
    means combdenv/lsd; 
  format combdenv combdenv.; 
run; 
proc sort data=disser; 
  by sympdays3; 
run; 
proc anova data=disser; 
  class sympdays3; 
  model wbc = sympdays3; 
     means sympdays3; 
    means sympdays3/lsd; 
  format sympdays3 symptoms.; 
run; 
proc logistic data=disser; 
  model wbc_alt(event='low') = denv_one 
denv_two denv_three denv_four 
denv_comb; 
  format wbc_alt lowhigh. denv_one 
denv_two denv_three denv_four denv_comb 
pos.; 
  title 'model of wbc and denv'; 
run; 
*********************************** 
*  adjust for other variables 
***********************************; 
proc logistic data=disser; 
  model wbc_alt(event='low') = agetwo; 
  format wbc_alt lowhigh. denv_one 
denv_two denv_three denv_four denv_comb 
pos. agetwo agetwo.; 
  title 'crude odds ratio for age covariate'; 
run; 
proc logistic data=disser; 
  model wbc_alt(event='low') = sex; 
  format wbc_alt lowhigh. denv_one 
denv_two denv_three denv_four denv_comb 
pos. sex sex.; 
  title 'crude odds ratio for sex covariate'; 
run; 
proc logistic data=disser; 
  model wbc_alt(event='low') = sympdays2; 
  format wbc_alt lowhigh. denv_one 
denv_two denv_three denv_four denv_comb 
pos. sympdays2 sympdays.; 
  title 'crude odds ratio for sympdays 
covariate'; 
run; 
proc logistic data=disser; 
  model wbc_alt(event='low') = symp_days; 
  format wbc_alt lowhigh. denv_one 
denv_two denv_three denv_four denv_comb 
pos. sympdays2 sympdays.; 
  title 'crude odds ratio for sympdays 
covariate'; 
run; 
proc logistic data=disser; 
  model wbc_alt(event='low') = symptom1 
symptom2; 
  format wbc_alt lowhigh. denv_one 
denv_two denv_three denv_four denv_comb 
pos. symp_days sympdays.; 
  title 'crude odds ratio for sympdays 
covariate'; 
run; 
proc logistic data=disser; 
  model wbc_alt(event='low') = city1 city2; 
  format wbc_alt lowhigh. denv_one 
denv_two denv_three denv_four denv_comb 
pos.; 
  title 'crude odds ratio for cities covariate'; 
run; 
proc logistic data=disser; 
  model wbc_alt(event='low') = denv_one 




  format wbc_alt lowhigh. denv_one 
denv_two denv_three denv_four denv_comb 
pos. agetwo agetwo.; 
  title 'model of wbc and denv adjust for age'; 
run; 
proc logistic data=disser; 
  model wbc_alt(event='low') = denv_one 
denv_two denv_three denv_four denv_comb 
sex; 
  format wbc_alt lowhigh. denv_one 
denv_two denv_three denv_four denv_comb 
pos. sex sex.; 
  title 'model of wbc and denv adjust for sex'; 
run; 
proc logistic data=disser; 
  model wbc_alt(event='low') = denv_one 
denv_two denv_three denv_four denv_comb 
symp_days; 
  format wbc_alt lowhigh. denv_one 
denv_two denv_three denv_four denv_comb 
pos.; 
  title 'model of wbc and denv adjust for 
symptom days'; 
run; 
proc logistic data=disser; 
  model wbc_alt(event='low') = denv_one 
denv_two denv_three denv_four denv_comb 
symptom1 symptom2; 
  format wbc_alt lowhigh. denv_one 
denv_two denv_three denv_four denv_comb 
pos. symp2days sympdays.; 




*  model with all covariates 
********************************************; 
proc logistic data=disser; 
  model wbc_alt(event='low') = denv_one 
denv_two denv_three denv_four denv_comb 
symptom1 symptom2 
agetwo sex; 
  format wbc_alt lowhigh. denv_one 
denv_two denv_three denv_four denv_comb 
pos. symp2days sympdays.; 




*  principal components analysis on 
continuous data 
********************************************; 
proc corr data=principal; 
title 'principal components analysis'; 
run; 
proc princomp data=principal; 
run; 
proc factor data=principal simple corr; 
run; 
******************************************** 
*  analysis of IgM, IGG, IgM and IgG by 
days symptomology 
********************************************; 
*  check distribution of clinical variables 
********************************************; 
/* 
proc univariate freq data=disser; 
  var RBC PLT HB HCT WBC NEUT EOS 
LYMPH MONO BASO; 
run; 
proc univariate freq data=disser; 
  var hb; 
run; 
*/ 
proc sort data=disser; 
  by denvpos; 
proc means data=disser; 
  class denvpos; 
  var dayssx_n; 
  format denvpos denvpos.; 
  title 'analysis of IgM, IGG, IgM and IgG by 






proc sort data=disser; 
  by denvpos igm; 
proc means data=disser; 
  by igm; 
  class denvpos; 
  var dayssx_n; 
  format denvpos denvpos. igm pos.; 
run; 
proc sort data=disser; 
  by denvpos igg; 
proc means data=disser; 
  by igg; 
  class denvpos; 
  var dayssx_n; 




proc sort data=disser; 
  by denvpos serology; 
run; 
proc freq data=disser; 
  tables denvpos serology; 
  format denvpos denvpos. serology serology.; 
proc freq data=disser; 
  tables denvpos serology; 
  format denvpos denvpos. serology serology.;   
proc means data=disser; 
  by denvpos; 
  class serology; 
  var dayssx_n; 
  format denvpos denvpos. serology serology.; 
run; 
proc anova data=disser; 
  by denvpos; 
  class serology; 
  model dayssx_n = serology; 
     means serology; 
    means serology/lsd; 




*  tables plt2 hb2 hct2 wbc2 neut2 lymph2 
******************************************; 
proc freq data=disser; 
  tables combdenv*plt2; 
  tables combdenv*hb2; 
  tables combdenv*hct2; 
  tables combdenv*wbc2; 
  tables sing_comb*wbc2; 
  tables combdenv*wbc3; 
  tables combdenv*wbc_alt; 
  tables combdenv*neut2; 
  tables combdenv*lymph2; 
  format combdenv combdenv. sing_comb 
singcomb. plt2 hb2 hct2 wbc2 neut2 lymph2 
highlow. wbc_alt         highlow.; 
run; 
******************************************** 
*  logistic regression 
********************************************; 
proc logistic data=disser; 
  model plt2(event='low') = denv_one 
denv_two denv_three denv_four 
denv_comb; 
  format plt2 highlow. denv_one denv_two 
denv_three denv_four denv_comb pos.; 
  title 'model of plt and denv'; 
run; 
proc logistic data=disser; 
  model hb2(event='low') = denv_one 
denv_two denv_three denv_four 
denv_comb; 
  format hb2 highlow. denv_one denv_two 
denv_three denv_four denv_comb pos.; 
  title 'model of hb and denv'; 
run; 
proc logistic data=disser; 
  model hct2(event='low') = denv_one 




  format hct2 highlow. denv_one denv_two 
denv_three denv_four denv_comb pos.; 
  title 'model of hct and denv'; 
run; 
proc logistic data=disser; 
  model neut2(event='low') = denv_one 
denv_two denv_three denv_four 
denv_comb; 
  format neut2 highlow. denv_one denv_two 
denv_three denv_four denv_comb pos.; 
  title 'model of neut and denv'; 
run; 
proc logistic data=disser; 
  model lymph2(event='low') = denv_one 
denv_two denv_three denv_four 
denv_comb; 
  format lymph2 highlow. denv_one 
denv_two denv_three denv_four denv_comb 
pos.; 
  title 'model of lymph and denv'; 
run; 
endsas; 
proc logistic data=disser; 
  model wbc2(event='high') = denv_one 
denv_two denv_three denv_four 
denv_comb; 
  format wbc2 highlow. denv_one denv_two 
denv_three denv_four denv_comb pos.; 
  title 'model of wbc and denv'; 
run; 
proc logistic data=disser; 
  model wbc3 = denv_one denv_two 
denv_three denv_four denv_comb; 
  format wbc3 highlow. denv_one denv_two 
denv_three denv_four denv_comb pos.; 
  title 'model of wbc and denv'; 
run; 
proc logistic data=disser; 
  model wbc_alt(event='low') = denv_one 
denv_two denv_three denv_four 
denv_comb; 
  format wbc_alt lowhigh. denv_one 
denv_two denv_three denv_four denv_comb 
pos.; 
  title 'model of wbc and denv'; 
run; 
proc logistic data=disser; 
  model wbc2 = sing_denv multi_denv; 
  format wbc2 highlow. denv_one denv_two 
denv_three denv_four denv_comb  
              sing_denv multi_denv pos.; 
  title 'model of wbc and denv'; 
run; 
proc logistic data=disser; 
  model plt2 = sing_denv multi_denv; 
  format wbc2 highlow. denv_one denv_two 
denv_three denv_four denv_comb  
              sing_denv multi_denv pos.; 
  title 'model of wbc and denv'; 
run; 
proc logistic data=disser; 
  model hb2 = sing_denv multi_denv; 
  format wbc2 highlow. denv_one denv_two 
denv_three denv_four denv_comb  
              sing_denv multi_denv pos.; 
  title 'model of wbc and denv'; 
run; 
proc logistic data=disser; 
  model hct2 = sing_denv multi_denv; 
  format wbc2 highlow. denv_one denv_two 
denv_three denv_four denv_comb  
              sing_denv multi_denv pos.; 
  title 'model of wbc and denv'; 
run; 
proc logistic data=disser; 
  model neut2 = sing_denv multi_denv; 
  format wbc2 highlow. denv_one denv_two 
denv_three denv_four denv_comb  
              sing_denv multi_denv pos.; 
  title 'model of wbc and denv'; 
run; 
proc logistic data=disser; 
  model lymph2 = sing_denv multi_denv; 
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format wbc2 highlow. denv_one denv_two 
denv_three denv_four denv_comb  
              sing_denv multi_denv pos.; 
  title 'model of wbc and denv'; 
run; 
proc logistic data=disser; 
  model neut2 = denv_one denv_two 
denv_three denv_four denv_comb; 
  format neut2 highlow. denv_one denv_two 
denv_three denv_four denv_comb pos.; 
  title 'model of neut and denv'; 
run; 
proc logistic data=disser; 
  model lymph2 = denv_one denv_two 
denv_three denv_four denv_comb; 
  format lymph2 highlow. denv_one 
denv_two denv_three denv_four denv_comb 
pos.; 




*  construct logistic regression models 
********************************************; 
data no_miss_denv; 
  set disser; 
  if denvpos = -1 then delete; 
data no_miss_all; 
  set no_miss_denv; 
  if admit = . then delete; 
run; 
data single; 
  set disser; 
  if combdenv = 5 then delete; 
data positive; 
  set disser; 
  if denvpos = 0 then delete; 
************************************** 
*  single or multiple pos 
**************************************; 
  multi_pos = 0; 
  if serodenv ge 5 then multi_pos = 1; 
************************************** 
*  symptom days 
**************************************; 
  symp_days = 0; 
  if dayssx ge 4 then symp_days=1; 
data complete; 
  set positive; 
  if vomit = . then delete; 
run; 
proc univariate freq data=positive; 
  var age; 
title 'for denv positive only'; 
run; 
proc freq data=positive; 
  tables agecat altage; 
  format agecat agecat. altage altage.; 
run; 
proc means data=positive; 
  var age; 
run; 
proc freq data=positive; 
  tables sex city; 
  format sex sex.; 
run;  
proc freq data=positive; 
  tables multi_pos; 
  format multi_pos multipos.; 
run; 
proc freq data=positive; 
  tables multi_pos*serodenv; 





proc contents position data=disser; 
*/ 
proc freq data=disser; 
  tables serodenv; 
  tables agecat; 
  tables sex; 
  tables agecat*denvpos; 
137 
 
  tables city; 
  tables city*denvpos; 
  tables city*serodenv; 
  format serodenv serodenv. agecat agecat. 
denvpos denvpos. sex sex.; 
run; 
proc freq data=complete; 
  tables multi_pos; 
run; 
proc sort data=complete; 
  by sex; 
run; 
proc freq data=complete; 
  tables sex*multi_pos/all fisher; 
  format sex sex. multi_pos multipos.; 
run;  
/* 
proc logistic data=positive; 
  model multi_pos = sex; 
  format multi_pos multipos. sex sex.; 
run; 
*/ 
proc sort data=complete; 
  by vomit; 
run; 
proc freq data=complete; 
  tables vomit*multi_pos/all; 
  format multi_pos multipos. vomit yesno.; 
run; 
/*  
proc logistic data=positive; 
  model multi_pos = vomit; 
  format multi_pos multipos. vomit yesno.; 
run; 
*/ 
proc sort data=complete; 
  by symp_days; 
run; 
proc freq data=complete; 
  tables symp_days*multi_pos/all; 
  format symp_days sympdays. multi_pos 
multipos.; 
run;  
proc sort data=complete; 
  by myalgia; 
run; 
proc freq data=complete; 
  tables myalgia*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by retropain; 
run; 
proc freq data=complete; 
  tables retropain*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by jntpain; 
run; 
proc freq data=complete; 
  tables jntpain*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by rash; 
run; 
proc freq data=complete; 
  tables rash*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by abdpain; 
run; 
proc freq data=complete; 
  tables abdpain*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by ha; 
run; 
proc freq data=complete; 
  tables ha*multi_pos/all; 




proc sort data=complete; 
  by larvae; 
run; 
proc freq data=complete; 
  tables larvae*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by diarrhea; 
run; 
proc freq data=complete; 
  tables diarrhea*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by diarrhea; 
run; 
proc freq data=complete; 
  tables diarrhea*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by fever; 
run; 
proc freq data=complete; 
  tables fever*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by gingbleed; 
run; 
proc freq data=complete; 
  tables gingbleed*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by agetwo; 
run; 
proc freq data=complete; 
  tables agetwo*multi_pos/all; 
  format multi_pos multipos. agetwo agetwo.; 
run; 
proc sort data=complete; 
  by icterus; 
run; 
proc freq data=complete; 
  tables icterus*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by hyperemia; 
run; 
proc freq data=complete; 
  tables hyperemia*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by OLIGUR; 
proc freq data=complete; 
  tables oligur*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by petech; 
proc freq data=complete; 
  tables petech*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by nosebleed; 
proc freq data=complete; 
  tables nosebleed*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by hypotn; 
proc freq data=complete; 
  tables hypotn*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by tachy; 
proc freq data=complete; 
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  tables tachy*multi_pos/all; 
  format multi_pos multipos.; 
run; 
proc sort data=complete; 
  by bednet; 
proc freq data=complete; 
  tables bednet*multi_pos/all; 




*  response information 
*******************************************; 
proc freq data=disser; 
  tables sero_response clin_response 
blood_response; 
  tables sero_response*clin_response; 
  tables sero_response*blood_response; 
  tables blood_response*clin_response; 




*  frequencies with complete data 
********************************************; 
******************************************** 
*  all data including missing 
********************************************; 
proc means data=disser; 
    var age DENVPOS DENV1 DENV2 
DENV3 DENV4 IGM IGG LEPTO rbc 
PLT HB HCT WBC NEUT EOS LYMPH 
MONO BASO DAYSSX_n;  
  title 'all data including missing'; 
proc means data=no_miss_all; 
  var age DENVPOS DENV1 DENV2 
DENV3 DENV4 IGM IGG LEPTO PLT  
HB HCT WBC NEUT EOS LYMPH 
MONO DAYSSX_n;  
  title 'complete data'; 
proc means data=no_miss_denv; 
  var rbc baso plt; 
  title 'data for rbc, baso, plt - missing 
denvpos taken out only';  
proc freq data=no_miss_all; 
   tables sex city cities dayssx_n ADMIT 
DENVCLASS FEVER MYALGIA 
GINGBLEED VOMIt ICTERUS 
RETROPAIN JNTPAIN HYPEREMIA 
RASH OLIGUR PETECH DIARRHEA 
NOSEBLEED ABDPAIN HA            
HYPOTN TACHY BEDNET LARVAE 
LARVLOC DENVPOS DENV1 DENV2 
DENV3 DENV4 agecat; 
  format agecat agecat. denvpos denv1 denv2 
denv3 denv4 denvpos. cities cities.;     
  title 'complete data';                        
run; 
/* 
proc means data=disser; 
  var age DENVPOS DENV1 DENV2 
DENV3 DENV4 IGM IGG LEPTO RBC 
PLT HB HCT WBC NEUT EOS LYMPH 
MONO BASO DAYSSX_n;  
  title 'data including missing denvpos'; 
proc freq data=disser; 
   tables sex city dayssx_n ADMIT 
DENVCLASS FEVER MYALGIA 
GINGBLEED VOMIT ICTERUS 
RETROPAIN JNTPAIN HYPEREMIA 
RASH OLIGUR PETECH DIARRHEA 
NOSEBLEED ABDPAIN HA                          
HYPOTN TACHY BEDNET LARVAE 
LARVLOC DENVPOS DENV1 DENV2 
DENV3 DENV4 agecat cities; 
  format agecat agecat. denvpos denv1 denv2 




*  frequencies according to denvpos 
including combined denv 
***************************************; 
proc sort data=no_miss_all; 
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  by denvpos; 
run; 
proc freq data=no_miss_all; 
  tables (sex cities)*denvpos/chisq; 
  format denvpos pos. cities cities.; 
  title 'complete data'; 
run; 
proc ttest data=no_miss_all; 
  class denvpos; 
  var age HB HCT WBC NEUT EOS 
LYMPH MONO; 
  format denvpos pos.; 
  title 'complete data'; 
run; 
proc sort data=no_miss_denv; 
  by denvpos; 
proc ttest data=no_miss_denv; 
  class denvpos; 
  var rbc plt baso; 
  format denvpos pos.; 
  title 'data for rbc, baso, and plt - missing 
denvpos taken out'; 
proc freq data=no_miss_all; 
  tables (cities FEVER MYALGIA 
GINGBLEED VOMIt ICTERUS 
RETROPAIN JNTPAIN HYPEREMIA 
RASH OLIGUR PETECH DIARRHEA 
NOSEBLEED ABDPAIN HA                          
HYPOTN TACHY BEDNET 
LARVAE)*denvpos/chisq; 
  format denvpos pos. cities cities.; 
  title 'complete data'; 
run; 
proc sort data=no_miss_all; 
  by sex; 
run; 
proc freq data=no_miss_all; 
  tables sex*denvpos/all; 
  format sex sex. denvpos pos.; 
run;  
proc logistic data=no_miss_all; 
  model denvpos = sex; 
  format denvpos pos. sex sex.; 
run; 
proc sort data=no_miss_all; 
  by vomit; 
run; 
proc freq data=no_miss_all; 
  tables vomit*denvpos/all; 
  format denvpos pos. vomit yesno.; 
run;  
proc logistic data=no_miss_all; 
  model denvpos = vomit; 
  format denvpos pos. vomit yesno.; 
run; 
******************************************** 
*  single, multiple denv positive 
********************************************; 
proc sort data=no_miss_all; 
  by sing_comb; 
run; 
proc freq data=no_miss_all; 
  tables (sex cities)*sing_comb/chisq; 
  format sing_comb singcomb. cities cities.; 
  title 'complete data - single and multiple 
DENV pos'; 
run; 
proc anova data=no_miss_all; 
   class sing_comb; 
 model age=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean age'; 
run; 
proc anova data=no_miss_all; 
   class sing_comb; 
 model hb=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 





proc anova data=no_miss_all; 
   class sing_comb; 
 model hct=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean hct'; 
run; 
proc anova data=no_miss_all; 
   class sing_comb; 
 model wbc=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean wbc'; 
run; 
proc anova data=no_miss_all; 
   class sing_comb; 
 model neut=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean neut'; 
run; 
proc anova data=no_miss_all; 
   class sing_comb; 
 model eos=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean eos'; 
run; 
proc anova data=no_miss_all; 
   class sing_comb; 
 model lymph=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean lymph'; 
run; 
proc anova data=no_miss_all; 
   class sing_comb; 
 model mono=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean mono'; 
run; 
proc sort data=no_miss_denv; 
  by sing_comb; 
run; 
proc anova data=no_miss_denv; 
   class sing_comb; 
 model rbc=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean rbc'; 
run; 
proc anova data=no_miss_denv; 
   class sing_comb; 
 model plt=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 
  title 'Unadjusted ANOVA (sing_comb), 
mean platelet'; 
run; 
proc anova data=no_miss_denv; 
   class sing_comb; 
 model baso=sing_comb; 
    means sing_comb; 
    means sing_comb/lsd; 
format sing_comb singcomb.; 








*  frequencies according to denvpos only 
singular 
***************************************; 
proc sort data=single; 
  by denvpos; 
run; 
proc freq data=single; 
  tables (sex city hood)*denvpos/chisq; 
  format denvpos pos.; 
  title 'frequencies according to singular 
denvpos'; 
run; 
proc ttest data=single; 
  class denvpos; 
  var age RBC PLT HB HCT WBC NEUT 
EOS LYMPH MONO BASO; 
  format denvpos pos.; 
  title 'ttest by covariates according to 
singular denvpos'; 
run; 
proc freq data=single; 
  tables (FEVER MYALGIA GINGBLEED         
VOMIt ICTERUS RETROPAIN 
JNTPAIN HYPEREMIA RASH OLIGUR 
PETECH DIARRHEA NOSEBLEED 
ABDPAIN HA HYPOTN TACHY 
BEDNET LARVAE)*denvpos/chisq; 
  format denvpos pos. FEVER MYALGIA 
GINGBLEED VOMIt ICTERUS 
RETROPAIN JNTPAIN HYPEREMIA 
RASH OLIGUR PETECH DIARRHEA 
NOSEBLEED ABDPAIN HA                          
HYPOTN TACHY BEDNET LARVAE 
yesno.; 







*  frequencies according to combdenv 
singular individual denv1-4 
***************************************; 
proc sort data=single; 
  by combdenv; 
run; 
proc freq data=single; 
  tables (sex city hood)*combdenv/chisq; 
  format combdenv combdenv.; 
  title 'frequencies according to singular 
denvpos'; 
run; 
proc anova data=single; 
   class combdenv; 
 model age=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean age'; 
run; 
proc anova data=single; 
   class combdenv; 
 model rbc=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean rbc'; 
run; 
proc anova data=single; 
   class combdenv; 
 model plt=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 





proc anova data=single; 
   class combdenv; 
 model hb=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean hb'; 
run; 
proc anova data=single; 
   class combdenv; 
 model hct=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean hct'; 
run; 
proc anova data=single; 
   class combdenv; 
 model wbc=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean wbc'; 
run; 
proc anova data=single; 
   class combdenv; 
 model neut=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean neut'; 
run; 
proc anova data=single; 
   class combdenv; 
 model eos=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean eos'; 
run; 
proc anova data=single; 
   class combdenv; 
 model lymph=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean lymph'; 
run; 
proc anova data=single; 
   class combdenv; 
 model mono=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean mono'; 
run;  
proc anova data=single; 
   class combdenv; 
 model baso=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean baso'; 
run;  
proc freq data=single; 
  tables (FEVER MYALGIA GINGBLEED         
VOMIt ICTERUS RETROPAIN 
JNTPAIN HYPEREMIA RASH OLIGUR 
PETECH DIARRHEA NOSEBLEED 
ABDPAIN HA HYPOTN TACHY 
BEDNET LARVAE)*combdenv/chisq; 
  format combdenv combdenv. FEVER 
MYALGIA GINGBLEED VOMIt 
ICTERUS RETROPAIN JNTPAIN 
HYPEREMIA RASH OLIGUR PETECH 
DIARRHEA NOSEBLEED ABDPAIN HA                          
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HYPOTN TACHY BEDNET LARVAE 
yesno.; 






*  frequencies according to individual denv1-
4 among positives only 
***************************************; 
proc sort data=positive; 
  by combdenv; 
run; 
proc freq data=positive; 
  tables (sex city hood)*combdenv/chisq; 
  format combdenv combdenv.; 
  title 'frequencies according to singular 
denvpos, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model age=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean age, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model rbc=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean rbc, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model plt=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean plt, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model hb=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean hb, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model hct=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean hct, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model wbc=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean wbc, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model neut=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean neut, positives only'; 
run; 
proc anova data=positive; 
145 
 
   class combdenv; 
 model eos=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean eos, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model lymph=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean lymph, positives only'; 
run; 
proc anova data=positive; 
   class combdenv; 
 model mono=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean mono, positives only'; 
run;  
proc anova data=positive; 
   class combdenv; 
 model baso=combdenv; 
    means combdenv; 
    means combdenv/lsd; 
format combdenv combdenv.; 
  title 'Unadjusted ANOVA (combdenv), 
mean baso, positives only'; 
run;  
proc freq data=positive; 
  tables (FEVER MYALGIA GINGBLEED         
VOMIt ICTERUS RETROPAIN 
JNTPAIN HYPEREMIA RASH OLIGUR 
PETECH DIARRHEA NOSEBLEED 
ABDPAIN HA HYPOTN TACHY 
BEDNET LARVAE)*combdenv/chisq; 
  format combdenv combdenv. FEVER 
MYALGIA GINGBLEED VOMIt 
ICTERUS RETROPAIN JNTPAIN 
HYPEREMIA RASH OLIGUR PETECH 
DIARRHEA NOSEBLEED ABDPAIN HA                          
HYPOTN TACHY BEDNET LARVAE 
yesno.; 
  title 'frequencies according to singular 
denvpos, positives only'; 
run; 
endsas; 
proc freq data=disser; 
  tables agecat denvpos denv1 denv2 denv3 
denv4 serodenv combdenv; 
  format agecat agecat. serodenv serodenv. 
combdenv combdenv.; 
run; 
proc freq data=disser; 
   tables city*denvpos; 
   tables sex*denvpos; 
run; 
proc sort data=disser; 
   by denvpos; 
run; 
proc means; 
  class denvpos; 
  var age rbc plt hb hct wbc neut eos lymph 
mono baso; 
run; 
proc freq data=disser; 
  tables denvpos*(serodenv combdenv); 




proc freq data=disser; 
  tables denv2*(denv1 denv3 denv4 
serodenv); 
  format serodenv serodenv.; 
run; 
*/ 
proc sort data=disser; 
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  by combdenv; 
run; 
proc means data=disser; 
  class combdenv; 
  var age rbc plt hb hct wbc neut eos lymph 
mono baso; 
format combdenv combdenv.; 
run; 
proc freq data=disser; 
  tables combdenv*sex; 
format combdenv combdenv.; 
/* 
proc univariate freq data=disser; 








COLOMBIA SEROPREVALENCE SURVEY RAW DATA 
SEX AGE MUNICIPALITY DENV DENV1 DENV2 DENV3 DENV4 IGM IGG LEPTO DATEDRAW ERYTH PLT HB HCT LEU NEUT EOS LYMPH MONO BASO DPO ADMIT MYALGIA GINGBLEED VOMIT ICTERUS RETROPAIN JNTPAIN HYPEREMIA RASH OLIGUR PETECH DIARRHEA NOSEBLEED ABDPAIN HA HYPOTN TACHY
F 9 OCAÑA 1 1 0 0 0 0 0 0 11/05/13 4.4 108 11.5 36.2 1.7 72.3 0.6 21.8 4.5 0.8 . . . . . . . . . . . . . . . . . .
F 9 SAN PABLO 1 0 1 0 0 0 0 0 11/24/13 5.7 13 16.0 47.9 5.5 66.4 1.2 26.5 5.1 0.8 . . . . . . . . . . . . . . . . . .
M 10 PATIOS 1 0 0 1 1 0 1 0 12/12/13 . 110 12.9 41.0 2.7 57.0 . 43.0 . . 4 1 0 0 1 0 0 1 0 0 0 0 0 0 0 1 0 0
M 10 PATIOS 0 0 0 0 0 . . 0 04/07/14 . 142 11.8 37.0 7.2 20.0 6.0 74.0 . . 7 0 0 0 1 0 0 0 0 1 0 0 0 0 0 1 0 0
F 10 PATIOS 1 0 1 0 0 0 1 0 12/03/13 . 137 11.0 36.0 4.0 16.0 5.0 79.0 . . 6 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
F 10 PATIOS 1 0 1 0 0 0 1 0 09/24/13 . 71 14.0 44.1 4.9 20.0 . 80.0 . . 5 1 1 0 1 0 1 1 0 0 0 0 0 0 0 1 0 0
M 10 PATIOS 0 0 0 0 0 . . 0 03/31/14 . 86 11.8 37.0 2.6 40.0 2.0 58.0 . . 3 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
M 10 PATIOS 0 0 0 0 0 . . 0 04/07/14 . 145 11.7 38.0 1.7 30.0 . 70.0 . . 2 1 0 0 1 0 1 1 0 0 0 0 0 0 0 1 0 0
F 10 OCAÑA 0 0 0 0 0 0 0 0 12/01/13 4.7 110 12.5 38.1 3.6 78.2 3.3 20.0 3.8 0.2 . . . . . . . . . . . . . . . . . .
M 10 CONVENCION 0 0 0 0 0 0 0 0 12/16/13 5.1 178 13.8 41.1 7.6 21.0 1.3 72.2 5.1 0.4 . . . . . . . . . . . . . . . . . .
M 10 TEORAMA 1 0 1 0 0 0 1 0 02/19/14 5.4 72 14.6 43.7 3.9 43.1 0.1 38.3 17.7 0.8 . . . . . . . . . . . . . . . . . .
M 11 PATIOS 1 0 0 1 0 0 1 0 12/24/13 . 138 12.1 41.0 1.8 41.0 2.0 57.0 . . 2 1 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
M 11 PATIOS 1 1 0 0 0 0 1 0 10/21/13 . 92 11.7 36.7 4.1 75.0 2.0 23.0 . . 3 1 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0
F 11 CONVENCION 0 0 0 0 0 0 0 0 11/26/13 5.1 96 12.1 37.4 3.6 66.6 1.1 27.3 4.8 0.2 . . . . . . . . . . . . . . . . . .
F 11 OCAÑA 0 0 0 0 0 0 0 0 10/31/13 5.6 159 13.3 41.9 2.5 65.9 1.2 30.3 2.5 0.1 . . . . . . . . . . . . . . . . . .
F 11 OCAÑA 1 0 1 0 0 0 0 0 01/31/13 4.9 25 14.9 42.4 2.6 77.3 1.8 16.6 4.2 0.1 . . . . . . . . . . . . . . . . . .
M 11 OCAÑA 1 0 1 0 0 0 0 0 10/29/13 4.9 32 13.7 40.9 3.1 72.3 0.9 17.7 8.6 0.5 . . . . . . . . . . . . . . . . . .
M 11 PATIOS 1 1 0 0 0 . . 0 04/24/14 . 140 13.5 44.0 2.3 60.0 . 40.0 . . 4 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
F 11 PATIOS 0 0 0 0 0 0 1 0 10/24/13 . 100 12.9 41.1 2.8 65.0 . 35.0 . . 2 1 1 0 1 0 0 1 0 0 0 0 0 0 1 1 0 0
M 12 PATIOS 0 0 0 0 0 2 2 0 03/27/14 . 95 11.9 37.0 1.8 33.0 2.0 65.0 . . 6 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
M 12 PATIOS 0 0 0 0 0 0 1 0 10/17/13 . 114 11.3 35.4 11.0 37.0 1.0 59.0 3.0 . 3 1 1 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0
M 12 OCAÑA 1 1 0 1 1 0 1 0 03/12/14 5.1 104 15.2 45.0 2.5 58.2 1.5 37.1 2.8 0.4 . . . . . . . . . . . . . . . . . .
F 12 PATIOS 0 0 0 0 0 0 1 0 01/23/14 . 138 13.3 43.0 3.1 30.0 . 70.0 . . 3 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0
F 12 PATIOS 0 0 0 0 0 0 1 0 11/20/13 . 94 12.8 40.0 2.6 46.0 . 54.0 . . 3 0 1 0 1 0 0 0 0 1 0 1 0 1 1 1 0 0
F 12 TARRA 1 1 0 0 0 0 0 0 10/24/13 4.9 29 12.8 39.8 6.7 89.6 2.5 7.2 0.6 0.1 . . . . . . . . . . . . . . . . . .
M 13 PATIOS 0 0 0 0 0 1 1 0 03/14/14 . 102 11.0 36.0 3.9 34.0 1.0 65.0 . . 5 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
F 13 PATIOS 1 0 1 0 0 . . 0 04/13/14 . 139 10.1 35.0 2.3 72.0 . 28.0 . . 4 0 1 0 0 0 1 0 0 0 0 0 0 0 1 1 0 0
M 13 GONZALES 0 0 0 0 0 0 1 0 02/22/14 4.9 106 13.8 39.7 4.5 85.0 0.0 9.0 5.8 0.2 . . . . . . . . . . . . . . . . . .
F 13 PATIOS 0 0 0 0 0 0 1 0 12/28/13 . 71 12.1 39.0 3.0 12.0 2.0 86.0 . . 8 0 1 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0
F 13 PATIOS 0 0 0 0 0 0 1 0 10/21/13 . 114 12.2 38.2 2.2 56.0 5.0 39.0 . . 3 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
M 13 PATIOS 1 0 1 1 0 . . 0 04/01/14 . 149 13.5 43.0 3.6 50.0 . 50.0 . . 3 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 14 PATIOS 0 0 0 0 0 . . 0 04/03/14 . 105 NHR 37.0 3.0 20.0 4.0 76.0 . . 5 0 1 0 1 0 1 1 0 1 0 0 0 0 0 1 0 0
M 14 CONVENCION 1 0 1 0 1 0 0 0 12/30/13 5.8 47 16.0 47.9 5.1 94.1 0.6 2.5 2.5 0.3 . . . . . . . . . . . . . . . . . .
F 14 CONVENCION 0 0 0 0 0 0 0 0 11/26/13 4.3 31 11.8 36.1 9.6 57.2 0.8 31.7 9.2 1.1 . . . . . . . . . . . . . . . . . .
F 14 PATIOS 0 0 0 0 0 . . 0 04/10/14 . 97 12.4 39.0 5.1 25.0 1.0 74.0 . . 5 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
M 14 OCAÑA 1 0 0 0 1 0 0 0 10/22/13 5.3 32 15.3 45.2 4.7 76.9 3.1 15.8 3.8 0.4 . . . . . . . . . . . . . . . . . .
M 14 SAN PABLO 1 0 1 0 0 0 0 0 01/15/14 5.8 49 15.5 48.3 4.9 52.7 3.6 37.0 6.5 0.2 . . . . . . . . . . . . . . . . . .
M 14 PATIOS 1 1 0 0 0 . . 0 04/09/14 . 106 11.6 38.0 2.0 54.0 . 46.0 . . 3 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
M 14 TEORAMA 1 0 1 0 0 0 0 0 11/10/13 5.6 15 16.1 47.8 3.2 87.6 1.1 5.7 4.7 0.9 . . . . . . . . . . . . . . . . . .
F 14 PATIOS 0 0 0 0 0 1 1 0 03/03/14 . 108 12.8 42.0 2.7 37.0 2.0 61.0 . . 3 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
M 14 PATIOS 0 0 0 0 0 0 1 0 09/13/13 . 152 13.7 42.9 3.0 34.0 6.0 60.0 . . 4 0 1 0 1 0 1 1 0 1 0 0 0 0 0 1 0 0
M 14 TEORAMA 1 0 1 0 0 0 0 0 11/21/13 5.0 40 13.2 42.4 4.6 49.2 2.6 45.7 2.5 0.0 . . . . . . . . . . . . . . . . . .
M 14 PATIOS 0 0 0 0 0 0 1 0 01/10/14 . 112 14.3 45.0 4.7 45.0 2.0 53.0 . . 3 0 1 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0
F 15 OCAÑA 0 0 0 0 0 0 0 0 10/23/13 5.0 36 14.0 40.9 4.6 72.9 1.6 23.1 2.4 0.0 . . . . . . . . . . . . . . . . . .
F 15 OCAÑA 1 0 1 0 0 0 0 0 12/22/13 5.3 19 14.6 45.4 4.3 42.4 2.4 47.7 7.5 0.0 . . . . . . . . . . . . . . . . . .
M 15 OCAÑA 1 0 1 0 0 0 1 0 03/18/14 5.1 120 14.4 42.6 8.2 40.9 1.1 46.8 11.0 0.2 . . . . . . . . . . . . . . . . . .
M 15 PATIOS 0 0 0 0 0 0 1 0 09/27/13 . 106 14.8 46.2 4.3 39.0 2.0 59.0 . . 3 0 0 0 0 0 1 1 0 1 0 0 0 0 0 1 0 0
M 15 PATIOS 1 1 1 1 0 0 1 0 10/03/13 . 110 13.0 40.0 1.3 52.0 . 48.0 . . 3 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
F 15 OCAÑA 0 0 0 0 0 0 0 0 10/21/13 5.6 25 15.7 46.3 3.9 88.1 1.6 8.7 1.4 0.2 . . . . . . . . . . . . . . . . . .
M 15 PATIOS 0 0 0 0 0 0 1 0 10/30/13 . 74 14.2 44.9 3.3 35.0 1.0 64.0 . . 3 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
F 15 PATIOS 1 0 1 0 0 . . 0 04/10/14 . 88 39.4 12.0 1.8 69.0 . 31.0 . . 4 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
M 15 OCAÑA 0 0 0 0 0 0 0 0 12/30/13 5.7 43 15.3 46.4 4.7 82.5 1.2 12.5 3.7 0.1 . . . . . . . . . . . . . . . . . .
M 16 PATIOS 0 0 0 0 0 0 1 0 10/24/13 . 119 14.0 44.2 3.7 30.0 . 70.0 . . 3 0 1 0 0 0 1 1 0 1 0 0 0 0 1 1 0 0
F 16 PATIOS 1 1 0 0 0 0 1 0 10/30/13 . 110 13.8 45.3 11.3 38.0 . 62.0 . . 3 0 1 0 1 0 0 1 0 0 0 0 0 0 1 1 0 0
M 16 ABREGO 0 0 0 0 0 0 0 0 11/07/13 5.7 42 16.3 49.8 4.1 86.7 1.1 10.4 1.8 0.0 . . . . . . . . . . . . . . . . . .
M 16 PATIOS 0 0 0 0 0 . . 0 04/23/14 . 126 11.9 40.0 3.1 50.0 1.0 49.0 . . 3 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
F 16 PATIOS 0 0 0 0 0 0 1 1 09/27/13 . 106 13.8 43.9 2.6 63.0 8.0 29.0 . . 3 0 1 0 0 0 0 1 0 0 0 0 0 0 1 1 0 0
F 16 PATIOS 1 0 1 0 0 . . 0 04/24/14 . 100 11.7 37.0 2.1 72.0 . 28.0 . . 2 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0
M 16 PATIOS 1 0 0 1 0 0 1 0 . 121 15.1 48 3.4 71.0 4.0 25.0 . . 2 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
F 16 OCAÑA 0 0 0 0 0 0 0 0 12/06/13 4.8 75 13.3 40.5 1.8 84.6 1.7 10.1 3.3 0.3 . . . . . . . . . . . . . . . . . .
M 17 PATIOS 1 0 0 0 1 . . 0 04/22/14 . 109 14.3 44.0 3.6 62.0 1.0 37.0 . . 3 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
F 17 ABREGO 0 0 0 0 0 0 0 0 10/30/13 5.1 90 12.4 39.8 3.2 86.0 2.0 11.3 0.6 0.1 . . . . . . . . . . . . . . . . . .
F 17 OCAÑA 1 1 0 0 0 0 0 0 03/05/14 4.1 73 12.1 35.2 2.3 81.4 3.1 9.7 5.7 0.1 . . . . . . . . . . . . . . . . . .
F 17 OCAÑA 0 0 0 0 0 0 0 0 12/19/13 4.7 118 13.1 40.8 4.6 59.8 1.7 33.1 5.0 0.4 . . . . . . . . . . . . . . . . . .
F 17 PATIOS 1 1 0 0 0 0 1 0 10/17/13 . 96 12.9 42.7 2.8 46.0 2.0 52.0 . . 2 1 1 0 0 0 1 0 0 1 0 0 0 0 1 1 0 0
M 18 OCAÑA 0 0 0 0 0 0 0 0 11/06/13 4.2 137 12.5 37.9 8.8 91.9 1.1 4.3 1.8 0.9 . . . . . . . . . . . . . . . . . .
F 19 ABREGO 1 1 0 0 0 0 0 0 11/29/13 5.3 38 15.6 44.5 8.0 46.4 1.8 41.3 9.1 1.4 . . . . . . . . . . . . . . . . . .
F 19 TEORAMA 0 0 0 0 0 0 0 0 11/09/13 4.8 15 13.7 41.8 3.0 70.4 0.8 25.6 3.2 0.0 . . . . . . . . . . . . . . . . . .
F 19 OCAÑA 1 0 1 0 0 0 0 0 11/08/13 4.7 118 13.7 41.6 2.8 84.8 0.9 10.2 4.0 0.1 . . . . . . . . . . . . . . . . . .
M 19 PATIOS 1 0 0 1 0 0 1 0 01/11/14 . 132 14.0 43.0 2.6 38.0 . 62.0 . . 6 0 1 0 0 0 0 1 0 0 0 0 1 0 0 1 0 0




SEX AGE MUNICIPALITY DENV DENV1 DENV2 DENV3 DENV4 IGM IGG LEPTO DATEDRAW ERYTH PLT HB HCT LEU NEUT EOS LYMPH MONO BASO DPO ADMIT MYALGIA GINGBLEED VOMIT ICTERUS RETROPAIN JNTPAIN HYPEREMIA RASH OLIGUR PETECH DIARRHEA NOSEBLEED ABDPAIN HA HYPOTN TACHY
M 1 PATIOS 0 0 0 0 0 . . 0 04/10/14 . 81 11.1 38.0 6.1 16.0 . 84.0 . . 3 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0
M 1 OCAÑA 0 0 0 0 0 0 0 0 11/25/13 5.3 127 13.6 41.6 2.7 78.8 0.9 18.4 1.8 0.1 . . . . . . . . . . . . . . . . . .
F 1 OCAÑA 1 0 0 1 0 0 0 0 11/10/13 4.9 23 13.2 39.4 5.6 47.0 0.4 49.1 3.4 0.1 . . . . . . . . . . . . . . . . . .
M 1 PATIOS 1 0 1 0 1 . . 0 04/01/14 . 132 10.2 33.0 6.1 27.0 1.0 72.0 . . 3 0 0 0 1 0 0 0 0 1 0 0 0 0 0 1 0 0
M 1 OCAÑA 0 0 0 0 0 0 0 0 11/05/13 4.3 17 10.8 32.1 4.0 43.1 1 44.8 10.8 0.3 . . . . . . . . . . . . . . . . . .
F 1 OCAÑA 0 0 0 0 0 0 0 0 11/10/13 4.8 70 14.1 42.5 3.1 74.0 0.8 19.8 5.1 0.3 . . . . . . . . . . . . . . . . . .
M 1 PATIOS 1 0 1 0 0 0 1 0 01/28/14 . 130 38.1 12.0 4.0 10.0 1.0 89.0 . . 3 0 1 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0
F 1 HACARI 0 0 0 0 0 0 0 0 10/19/14 4.3 147 11.4 35.0 3.7 80.1 1.8 15.5 2.6 0.0 . . . . . . . . . . . . . . . . . .
M 1 PATIOS 0 0 0 0 0 0 1 0 01/29/14 . 144 10.7 35.0 2.5 17.0 . 83.0 . . 2  1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
F 1 LA PLAYA 0 0 0 0 0 0 0 0 02/07/14 4.9 162 12.3 36.7 9.8 17.7 0.0 66.8 14.5 1.0 . . . . . . . . . . . . . . . . . .
M 1 PATIOS 0 0 0 0 0 0 1 0 01/27/14 . 142 10.3 35.0 5.3 24.0 . 76.0 . . 2 0 1 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0
F 1 PATIOS 0 0 0 0 0 1 1 0 02/26/14 . 131 12.6 39.0 8.6 54.0 . 46.0 . . 3 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
M 1 PATIOS 0 0 0 0 0 0 1 0 . . 105 11.9 39.5 5.6 39.0 3.0 58.0 . . 4 0 1 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0
F 2 GUAMALITO 1 0 0 1 0 0 0 0 12/21/13 4.9 151 12.3 38.4 3.5 77.7 0.3 18.9 2.1 1.0 . . . . . . . . . . . . . . . . . .
M 2 PATIOS 0 0 0 0 0 0 1 0 01/05/14 . 62 11.9 37.0 3.1 30.0 3.0 67.0 . . 4 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
M 2 PATIOS 1 0 1 1 0 0 1 0 09/17/14 . 75 12.5 38.0 5.0 42.0 . 58.0 . . 3 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0
F 2 PATIOS 0 0 0 0 0 1 1 0 02/20/14 . 117 11.0 35.0 6.0 17.0 2.0 81.0 . . 9 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
F 3 PATIOS 0 0 0 0 0 0 1 0 09/20/13 . 92 11.2 35.8 2.5 40.0 8.0 52.0 . . 5 1 1 0 0 0 1 0 0 0 0 1 0 0 0 1 0 0
F 3 PATIOS 1 0 0 1 0 1 1 0 03/12/14 . 99 10.0 33.0 3.3 36.0 2.0 62.0 . . 3 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
M 3 SAN PABLO 1 0 0 1 1 0 0 0 01/12/14 5.3 58 13.4 42.5 4.7 64.7 1.5 30.8 2.8 0.2 . . . . . . . . . . . . . . . . . .
M 3 PATIOS 0 0 0 0 0 . . 0 04/01/14 . 124 10.5 34.0 4.0 14.0 1.0 85.0 . . 4 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
F 3 PATIOS 0 0 0 0 0 0 1 0 12/02/13 . 78 9.2 29.0 2.9 27.0 . 73.0 . . 2 1 1 0 0 0 0 1 0 1 0 0 0 0 0 1 0 0
M 3 PATIOS 0 0 0 0 0 0 1 0 01/22/14 . 102 8.7 30.0 5.1 10.0 . 90.0 . . 3 0 1 0 1 0 1 1 0 0 0 0 0 0 0 1 0 0
F 4 PATIOS 1 1 0 0 0 0 1 0 11/18/13 . 144 10.4 32.0 3.0 28.0 . 72.0 . . 3 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0
M 4 PATIOS 0 0 0 0 0 2 1 0 03/22/14 . 149 12.9 41.0 4.8 56.0 . 44.0 . . 4 1 1 0 0 0 1 0 0 0 0 0 0 0 1 1 0 0
F 4 PATIOS 1 0 1 0 1 . . 0 04/21/14 . 174 10.6 36.0 3.8 21.0 . 79.0 . . 3 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
M 4 ABREGO 0 0 0 0 0 0 0 0 11/21/13 5.4 57 13.6 41.4 9.6 45.9 0.7 51.3 2.0 0.1 . . . . . . . . . . . . . . . . . .
M 5 TEORAMA 1 0 1 0 0 0 0 0 11/05/13 5.9 33 13.9 43.2 5.5 66.3 0.7 25.2 7.7 0.1 . . . . . . . . . . . . . . . . . .
F 5 PATIOS 0 0 0 0 0 0 1 0 11/24/13 . 144 11.3 37.0 9.8 21.0 1.0 76.0 2.0 . 7 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
F 5 PATIOS 1 1 0 0 0 1 0 0 02/04/14 . 133 13.3 41.0 2.7 34.0 . 66.0 . . 3 0 1 0 1 0 0 0 0 1 0 0 1 0 1 1 0 0
F 5 OCAÑA 0 0 0 0 0 0 0 0 10/20/13 5.0 115 13.4 40.9 2.2 60.8 2.4 33.1 3.6 0.1 . . . . . . . . . . . . . . . . . .
F 5 OCAÑA 0 0 0 0 0 0 0 0 10/28/13 5.0 19 12.2 38.7 12.2 88.6 0.6 9.6 1.1 0.1 . . . . . . . . . . . . . . . . . .
M 5 PATIOS 0 0 0 0 0 0 1 0 01/10/14 . 128 9.7 31.0 4.1 32.0 2.0 66.0 . . 3 0 1 0 0 0 0 1 0 0 0 0 0 0 1 1 0 0
F 5 PATIOS 0 0 0 0 0 1 1 0 02/24/14 . 109 10.2 34.0 4.7 32.0 1.0 67.0 . . 6 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
M 5 PATIOS 1 1 0 0 0 0 1 0 11/05/13 . 83 11.5 35.8 3.7 29.0 . 71.0 . . 4 1 1 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0
M 5 OCAÑA 0 0 0 0 0 0 0 0 12/29/13 4.2 84 12.3 35.6 2.6 71.5 1.6 25.5 1.3 0.1 . . . . . . . . . . . . . . . . . .
F 5 CUCUTA 1 0 1 0 0 . . 0 04/29/14 . 145 11.8 39.0 4.8 26.0 . 74.0 . . 5 1 1 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0
M 6 PATIOS 1 0 1 0 0 . . 0 04/09/14 . 128 10.9 36.0 2.7 21.0 1.0 77.0 1.0 . 6 0 1 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0
M 6 PATIOS 1 0 0 1 0 2 1 0 03/24/14 . 142 11.2 37.0 4.6 35.0 12.0 53.0 . . 2 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
M 7 PATIOS 1 0 0 1 0 0 1 0 11/15/13 . 133 11.4 36.0 1.4 30.0 . 70.0 . . 4 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
M 7 PATIOS 0 0 0 0 0 0 1 0 01/01/14 . 95 11.7 38.0 1.0 35.0 3.0 62.0 . . 2 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
M 7 PATIOS 1 0 0 1 0 0 1 0 01/29/14 . 125 10.5 35.0 6.1 14.0 . 86.0 . . 6 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
M 7 PATIOS 1 0 0 1 0 0 1 0 01/28/14 . 101 13.5 42.0 3.7 32.0 . 68.0 . . 3 0 1 0 1 0 1 0 0 0 0 0 0 0 1 1 0 0
F 7 OCAÑA 0 0 0 0 0 0 0 0 03/18/14 4.2 125 12.1 36.1 3.8 11.1 3.1 77.7 7.5 0.6 . . . . . . . . . . . . . . . . . .
F 7 PATIOS 0 0 0 0 0 0 1 0 10/24/13 . 70 11.4 38.3 3.4 31.0 6.0 63.0 . . 5 1 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0
F 7 PATIOS 1 0 1 0 0 0 1 0 10/18/13 . 96 11.8 37.5 2.9 66.0 4.0 30.0 . . 4 0 0 0 1 0 0 0 0 1 0 1 1 1 1 1 0 0
M 7 OCAÑA 0 0 0 0 0 0 0 0 10/13/13 4.2 129 12.3 36.4 3.7 90.1 1.5 6.9 1.3 0.2 . . . . . . . . . . . . . . . . . .
F 7 PATIOS 0 0 0 0 0 0 1 0 12/08/13 . 80 11.7 37.0 4.0 20.0 19.0 60.0 1.0 . 6 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0
M 7 PATIOS 0 0 0 0 0 0 1 0 09/13/13 . 137 11.2 35.6 2.5 47.0 12.0 41.0 . . 4 0 1 0 1 0 0 0 0 0 0 0 1 0 0 1 0 0
M 7 CHICANOTA 1 1 0 0 0 0 1 0 11/04/13 . 110 11.9 39.2 5.4 14.0 1.0 84.0 1.0 . 3 0 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0
F 8 PATIOS 1 1 1 0 0 1 1 0 02/08/14 . 99 14.3 45.0 2.3 60.0 . 40.0 . . 3 0 1 0 0 0 1 0 0 1 0 0 0 0 0 1 0 0
M 8 PATIOS 0 0 0 0 0 1 1 0 02/27/14 . 138 12.7 41.0 4.1 27.0 8.0 65.0 . . 7 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
F 8 PATIOS 1 0 0 1 0 0 1 0 12/17/13 . 128 11.7 37.0 3.1 44.0 . 56.0 . . 4 1 1 0 1 1 0 0 0 1 1 1 0 0 1 1 0 0
F 8 PATIOS 1 0 1 0 1 . . 0 04/15/14 . 131 11.4 37.0 3.0 67.0 . 33.0 . . 3 0 1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0
F 8 PATIOS 0 0 0 0 0 0 1 0 09/22/13 . 153 11.1 37.0 2.6 40.0 2.0 54.0 4.0 . 4 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
M 8 OCAÑA 0 0 0 0 0 0 0 0 10/22/13 5.2 110 14.1 41.2 2.8 63.2 2.9 25.9 7.9 0.1 . . . . . . . . . . . . . . . . . .
M 8 PATIOS 1 1 0 0 0 0 1 0 10/02/13 . 122 10.9 35.3 2.0 50.0 8.0 42.0 . . 3 1 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0
F 8 PATIOS 1 0 1 0 0 0 1 0 10/19/14 . 127 13.0 40.0 2.5 62.0 2.0 36.0 . . 2 1 0 0 1 0 1 1 0 0 0 0 0 1 0 1 0 0
M 8 PATIOS 0 0 0 0 0 . . 0 04/13/14 . 125 12.9 5.0 2.9 40.0 4.0 56.0 . . 3 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0
M 8 SAN PABLO 0 0 0 0 0 0 0 0 01/30/14 4.5 142 13.0 35.6 6.3 88.1 4.1 6.5 1.3 0.0 . . . . . . . . . . . . . . . . . .
M 9 PATIOS 1 0 1 0 1 . . 0 04/12/14 . 161 11.8 38.0 3.0 55.0 . 45.0 . . 3 1 1 0 1 0 1 0 0 1 0 0 0 0 1 1 0 0
F 9 PATIOS 1 0 0 0 1 0 1 0 10/21/13 . 122 11.8 37.3 3.4 44.0 . 56.0 . . 2 0 1 0 0 0 0 1 0 0 0 0 0 0 1 1 0 0
M 9 PATIOS 1 0 1 0 0 0 1 0 10/02/13 . 126 12.5 38.4 3.0 56.0 6.0 38.0 . . 2 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
F 9 PATIOS 1 0 1 0 0 0 1 0 09/24/13 . 134 13.5 42.9 2.9 61.0 3.0 36.0 . . 4 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
F 9 PATIOS 1 1 0 0 0 0 1 0 10/07/13 . 127 12.3 41.8 3.8 35.0 4.0 61.0 . . 8 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0
M 9 PATIOS 1 0 0 0 1 0 1 0 10/22/13 . 135 12.1 36.7 2.6 59.0 1.0 40.0 . . 2 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
M 9 OCAÑA 1 0 0 1 0 0 0 0 01/04/13 4.8 127 12.8 40.6 3.3 92.1 1.4 4.9 1.5 0.1 . . . . . . . . . . . . . . . . . .
M 9 PATIOS 1 0 1 1 1 0 1 0 01/01/14 . 118 11.4 37.0 1.8 55.0 3.0 42.0 . . 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 9 OCAÑA 0 0 0 0 0 0 0 0 12/10/13 4.9 101 13.9 41.9 4.3 52.0 1.6 40.1 6.3 0.0 . . . . . . . . . . . . . . . . . .
M 9 PATIOS 0 0 0 0 0 0 1 0 11/13/13 . 72 10.5 35.0 2.2 56.0 . 44.0 . . 5 1 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0




SEX AGE MUNICIPALITY DENV DENV1 DENV2 DENV3 DENV4 IGM IGG LEPTO DATEDRAW ERYTH PLT HB HCT LEU NEUT EOS LYMPH MONO BASO DPO ADMIT MYALGIA GINGBLEED VOMIT ICTERUS RETROPAIN JNTPAIN HYPEREMIA RASH OLIGUR PETECH DIARRHEA NOSEBLEED ABDPAIN HA HYPOTN TACHY
M 20 OCAÑA 1 1 0 0 0 0 0 0 02/03/14 5.1 184 14.8 45.0 2.9 55.5 0.3 29.5 14.4 0.3 . . . . . . . . . . . . . . . . . .
M 21 PATIOS 1 0 1 0 0 . . 0 04/13/14 . 129 14.0 43.0 7.7 69.0 2.0 29.0 . . 3 0 1 0 1 0 1 1 0 0 0 0 1 0 0 1 0 0
M 21 PATIOS 1 0 0 1 0 0 1 1 12/12/13 . 112 13.4 43.0 2.8 22.0 2.0 76.0 . . 6 1 1 0 1 0 0 1 0 0 0 0 0 0 1 0 0 0
M 22 OCAÑA 0 0 0 0 0 0 0 0 12/02/13 3.9 70 13.2 37.7 4.2 79.7 0.6 17.8 1.7 0.2 . . . . . . . . . . . . . . . . . .
F 22 OCAÑA 0 0 0 0 0 0 0 0 11/05/13 3.8 147 12.2 37.8 4.2 72.2 2.9 21.6 2.7 0.6 . . . . . . . . . . . . . . . . . .
M 22 EL CARMEN 1 0 0 1 0 0 0 0 12/31/13 5.3 161 14.5 45.3 2.7 83.2 1.5 11.3 3.3 0.7 . . . . . . . . . . . . . . . . . .
M 22 COCHIRA 1 0 1 0 0 0 0 0 02/06/14 5.9 12 19.1 53.3 7.3 22.5 2.8 63.8 10.4 0.5 . . . . . . . . . . . . . . . . . .
M 23 PATIOS 1 0 0 0 1 0 1 0 11/05/13 . 63 14.2 43.6 2.3 63.0 . 37.0 . . 4 1 1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0
M 23 PATIOS 1 0 0 0 1 . . 0 04/29/14 . 129 14.5 45.0 4.3 73.0 2.0 23.0 2.0 . 3 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
M 23 TEORAMA 0 0 0 0 0 0 0 0 11/26/13 5.5 41 16.2 49.2 7.0 83.7 1.4 12.9 1.9 0.1 . . . . . . . . . . . . . . . . . .
M 24 PATIOS 0 0 0 0 0 0 1 0 01/11/14 . 121 14.7 45.0 4.6 77.0 . 23.0 . . 3 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
F 25 PATIOS 1 1 0 0 0 0 1 0 09/27/13 . 134 10.0 33.1 2.0 32.0 6.0 62.0 . . 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 25 PATIOS 1 0 0 0 1 0 1 0 01/15/14 . 80 11.6 38.0 2.3 44.0 9.0 46.0 1.0 . 4 1 1 0 1 0 0 0 0 1 0 0 0 0 0 1 0 0
M 26 PATIOS 1 0 1 0 0 . . 0 04/12/14 . 40 13.1 45.0 3.2 58.0 . 42.0 . . 3 1 1 0 0 0 1 1 0 0 0 0 0 0 1 1 0 0
M 26 RIO CESAR 0 0 0 0 0 0 0 0 12/04/13 4.3 72 12.7 38.5 4.6 83.0 3.6 8.6 4.5 0.3 . . . . . . . . . . . . . . . . . .
F 27 OCAÑA 1 0 0 1 0 0 0 0 02/09/14 4.5 26 14.5 41.8 2.0 47.9 2.3 37.7 11.5 0.6 . . . . . . . . . . . . . . . . . .
F 28 ABREGO 0 0 0 0 0 0 0 0 11/28/13 5.0 78 12.7 38.6 1.6 56.9 1.7 39.0 2.4 0.0 . . . . . . . . . . . . . . . . . .
M 28.0 OCAÑA 0 0 0 0 0 0 0 0 12/03/13 4.9 191 14.0 41.0 7.6 76.5 6.4 14.0 3.0 0.1 . . . . . . . . . . . . . . . . . .
M 28 LA ESPERANZA 0 0 0 0 0 0 1 0 02/22/14 6.0 48 17.9 52.9 1.9 25.3 0.6 63.1 10.1 0.9 . . . . . . . . . . . . . . . . . .
F 28 TEORAMA 0 0 0 0 0 0 1 0 02/23/14 4.4 58 12.9 37.3 2.4 25.8 0.4 63.6 8.1 2.1 . . . . . . . . . . . . . . . . . .
F 30 PATIOS 1 0 0 0 1 0 1 0 01/11/14 . 132 12.5 39.0 5.2 64.0 2.0 34.0 . . 3 0 1 0 1 0 0 1 0 0 0 0 0 0 1 1 0 0
F 30 OCAÑA 0 0 0 0 0 0 0 0 10/26/13 4.6 112 13.2 41.6 2.0 75.1 2.4 20.7 1.8 0.0 . . . . . . . . . . . . . . . . . .
M 31 TEORAMA 1 0 1 0 0 0 0 0 12/19/13 6.5 11 17.7 54.6 4.9 63.5 2.9 26.4 7.0 0.2 . . . . . . . . . . . . . . . . . .
M 31 OCAÑA 1 1 0 0 0 0 0 0 12/19/13 6.0 66 18.1 55.6 3.1 69.0 1.0 23.7 6.1 0.2 . . . . . . . . . . . . . . . . . .
F 31 TEORAMA 1 0 1 0 0 0 1 0 02/23/14 4.4 9 13.3 39.9 2.3 20.7 2.6 66.0 7.9 2.8 . . . . . . . . . . . . . . . . . .
M 31 OCAÑA 0 0 0 0 0 0 0 0 12/30/13 5.6 94 15.6 44.9 2.4 64.8 3.2 25.4 6.3 0.3 . . . . . . . . . . . . . . . . . .
M 32 OCAÑA 0 0 0 0 0 0 0 0 12/02/13 5.5 88 15.8 47.5 6.0 83.2 1.8 11.2 2.7 1.1 . . . . . . . . . . . . . . . . . .
F 33 PATIOS 1 0 0 0 1 1 1 0 02/26/14 . 126 12.0 38.0 2.4 58.0 2.0 40.0 . . 4 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
M 33 PATIOS 1 0 1 0 0 0 1 1 09/30/13 . 117 12.6 38.8 4.4 85.0 . 15.0 . . 3 0 1 0 1 0 1 1 0 0 0 0 1 0 1 1 0 0
F 33 OCAÑA 1 1 0 0 0 0 0 0 01/28/14 4.5 38 15.4 41.7 4.1 65.0 1.5 31.0 2.3 0.2 . . . . . . . . . . . . . . . . . .
M 34 TEORAMA 0 0 0 0 0 0 0 0 11/21/13 5.1 44 14.8 43.8 4.5 58.7 4.5 34.3 2.4 0.1 . . . . . . . . . . . . . . . . . .
F 34 GUAMALITO 1 0 0 1 0 0 0 0 01/14/14 4.5 41 13.5 40.0 1.8 87.2 0.4 11.1 1.2 0.1 . . . . . . . . . . . . . . . . . .
M 34 SAN PABLO 1 1 0 0 0 0 0 0 01/20/14 5.4 94 15.9 47.0 1.5 81.1 0.3 16.0 2.3 0.3 . . . . . . . . . . . . . . . . . .
F 35 PATIOS 0 0 0 0 0 0 1 0 12/21/13 . 78 12.3 34.0 7.6 26.0 . 74.0 . . 6 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
M 35 OCAÑA 0 0 0 0 0 0 0 0 12/12/13 4.8 53 13.0 39.4 11.4 91.2 1.2 2.0 1.7 3.9 . . . . . . . . . . . . . . . . . .
F 36 PATIOS 1 0 0 1 0 0 1 0 10/12/13 . 123 12.2 40.6 5.4 38.0 1.0 61.0 . . 5 0 1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0
M 36 OCAÑA 0 0 0 0 0 0 0 0 10/18/13 5.4 51 15.6 46.7 2.6 80.7 4.1 10.1 4.8 0.3 . . . . . . . . . . . . . . . . . .
M 36 PATIOS 0 0 0 0 0 0 1 0 11/08/13 . 112 11.0 35.0 5.9 75.0 2.0 22.0 1.0 . 5 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
M 37 PATIOS 1 0 0 1 0 0 1 0 11/18/13 . 32 13.8 42.0 5.9 81.0 . 19.0 . . 2 1 1 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0
F 37 SAN PABLO 1 0 1 0 1 0 0 0 01/17/13 4.8 55 14.8 41.5 9.6 32.8 5.4 55.1 5.8 0.9 . . . . . . . . . . . . . . . . . .
M 37 SAN PABLO 1 0 1 1 0 0 0 0 01/15/14 5.9 16 16.3 50.8 4.6 55.3 1.3 33.0 9.7 0.7 . . . . . . . . . . . . . . . . . .
F 38 PATIOS 0 0 0 0 0 0 1 0 11/18/13 . 80 11.6 39.0 4.4 21.0 2.0 77.0 . . 3 0 1 0 1 0 0 1 0 0 0 0 0 0 1 1 0 0
M 38 BOGOTA 0 0 0 0 0 0 0 0 02/28/14 4.7 90 15.2 44.0 2.6 37.8 2.4 49.2 9.2 1.4 . . . . . . . . . . . . . . . . . .
F 41 PATIOS 1 1 0 0 0 0 1 0 09/14/13 . 98 12.4 39.4 2.5 53.0 5.0 40.0 2.0 . 4 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
M 43 PATIOS 0 0 0 0 0 0 1 0 12/04/13 . 145 13.5 45.0 3.6 57.0 . 43.0 . . 4 0 1 0 0 0 1 0 0 1 0 0 0 0 1 0 0 0
M 43 PATIOS 0 0 0 0 0 0 1 0 12/04/13 . 145 13.5 45.0 3.6 37.0 1.0 62.0 . . 4 0 1 0 0 0 1 0 0 1 0 0 0 0 1 0 0 0
M 43 PATIOS 0 0 0 0 0 0 1 0 09/16/13 . 109 14.2 42.6 2.1 54.0 2.0 44.0 . . 5 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
M 45 PATIOS 1 0 0 1 0 0 1 0 10/12/13 . 150 15.6 48.8 3.4 50.0 5.0 45.0 . . 5 0 1 0 1 0 0 0 0 0 0 1 0 0 0 1 0 0
M 45 OCAÑA 0 0 0 0 0 0 0 0 11/03/13 6.1 128 17.5 52.5 4.0 73.3 2.1 20.1 4.3 0.2 . . . . . . . . . . . . . . . . . .
M 46 OCAÑA 0 0 0 0 0 0 0 0 12/25/13 4.8 119 13.4 40.3 5.2 86.4 1.2 8.6 3.6 0.2 . . . . . . . . . . . . . . . . . .
M 47 PATIOS 0 0 0 0 0 0 1 0 01/31/14 . 123 16.1 52.0 3.3 25.0 . 75.0 . . 4 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
M 48 PATIOS 1 0 1 0 0 0 1 0 01/05/14 . 86 15.5 50.0 3.6 36.0 6.0 56.0 2.0 . 4 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
F 49 OCAÑA 0 0 0 0 0 0 0 0 10/28/13 4.6 33 12.5 38.2 2.0 85.2 3.0 8.7 2.8 0.3 . . . . . . . . . . . . . . . . . .
F 50 PATIOS 0 0 0 0 0 1 1 0 02/20/14 . 125 11.5 38.0 5.6 74.0 . 26.0 . . 2 0 1 0 0 0 1 0 0 0 0 0 1 0 0 1 0 0
F 51 GUAMALITO 0 0 0 0 0 0 0 0 01/19/14 4.2 137 11.9 39.0 5.0 52.4 5.4 36.9 5.2 0.1 . . . . . . . . . . . . . . . . . .
M 51 PATIOS 1 0 0 1 0 0 1 0 12/28/13 . 130 . 38.0 7.4 73.0 . 27.0 . . 8 0 1 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0
F 52 PATIOS 0 0 0 0 0 0 1 0 01/05/14 . 86 14.4 43.0 2.1 55.0 1.0 44.0 . . 4 1 1 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0
M 54 OCAÑA 0 0 0 0 0 0 0 0 12/02/13 4.4 129 12.9 39.7 3.5 81.0 2.6 13.2 2.1 1.1 . . . . . . . . . . . . . . . . . .
M 54 OCAÑA 0 0 0 0 0 0 1 0 03/19/14 5.6 58 16.2 47.2 5.0 43.4 2.6 44.0 9.1 0.9 . . . . . . . . . . . . . . . . . .
M 55 OCAÑA 0 0 0 0 0 0 0 0 11/23/13 5.1 125 15.8 46.8 3.1 69.4 1.5 23.7 5.1 0.3 . . . . . . . . . . . . . . . . . .
F 56 EL CARMEN 0 0 0 0 0 0 0 0 12/03/13 4.4 24 12.1 36.0 1.7 78.6 1.3 16.6 3.1 0.4 . . . . . . . . . . . . . . . . . .
M 57 PATIOS 1 0 1 0 0 . . 0 04/29/14 . 109 8.8 30.0 9.0 91.0 . 9.0 . . 3 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
M 59 OCAÑA 0 0 0 0 0 0 0 0 12/16/13 5.2 76 16.2 46.3 3.5 68.5 1.5 27.6 2.3 0.1 . . . . . . . . . . . . . . . . . .
M 61 PATIOS 1 0 1 0 0 . . 0 03/31/14 . 123 12.4 40.0 5.3 59.0 . 41.0 . . 6 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0
F 62 PATIOS 1 0 1 1 0 . . 0 03/29/14 . 97 11.6 37.0 3.8 62.0 2.0 36.0 . . 4 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
M 65 SAN PABLO 1 0 1 0 0 0 0 0 01/18/14 4.5 66 14.1 41.5 3.8 38.4 5.2 45.4 8.2 2.8 . . . . . . . . . . . . . . . . . .
F 73 OCAÑA 0 0 0 0 0 0 0 1 10/17/13 4.3 20 14.0 42.2 7.6 71.9 1.1 22.0 3.7 1.3 . . . . . . . . . . . . . . . . . .
F 76 PATIOS 0 0 0 0 0 1 1 0 02/05/14 . 119 11.0 39.0 4.7 74.0 . 26.0 . . 4 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0
M 77 PATIOS 0 0 0 0 0 0 1 0 12/26/13 . 148 10.2 32.0 5.1 62.0 1.0 37.0 . . 3 0 1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0
F 80 PATIOS 1 0 0 1 0 1 1 0 02/09/14 . 124 12.1 39.0 5.7 65.0 . 35.0 . . 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
F 82 PATIOS 1 0 1 0 0 . . 0 04/15/14 . 123 9.3 31.0 10.5 85.0 . 15.0 . . 2 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0
F 85 OCAÑA 0 0 0 0 0 0 0 0 11/02/13 5.1 49 14.5 43.3 11.4 94.5 1.6 2.2 0.9 0.8 . . . . . . . . . . . . . . . . . .
F 87 PATIOS 1 0 0 1 0 2 2 0 03/25/14 . 123 10.8 35.0 6.0 75.0 . 25.0 . . 3 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 1
F 92 PATIOS 0 0 0 0 0 . . 0 03/28/14 . 67 11.9 38.0 4.2 84.0 . 16.0 . . 3 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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POST-EBOLA VIRUS DISEASE STUDY CONSENT FORM 
 
POST-EBOLA SYNDROME: INVESTIGATING THE CLINICAL PROFILE OF PAIN AND DISABILITY AMONG 
SURVIVORS OF EBOLA VIRUS DISEASE IN BOMI COUNTY, LIBERIA 
 
Principal Investigator: Christopher Mores  
Co-investigator: Jennifer Giovanni  
 
Description:  You are a survivor of Ebola virus disease.  Since you left the ETU, you have told us that you 
have pain, tiredness, and sadness.  In February, I examined your body and asked you questions about your 
health.  Now I ask your permission to do another physical exam and to ask you more questions about your 
health.  The purpose of the physical exam and the questions is to learn where your body hurts, how your life 
has changed, and how nurses and doctors can learn about post-Ebola syndrome in people who survived Ebola. 
 
Procedures:  I will look at parts of your body, including your hands and feet, your neck, and your muscles.  I 
will press on them to ask if they hurt.  I will touch parts of your skin and ask you if you feel pain.  I will ask 
you to move your arms and to walk.  I will also take your blood pressure and ask you questions about how 
you feel.  I will ask you if it is easy or hard to farm, to cook, and to walk in your village.  I will ask how you 
got Ebola. 
 
The examination will not go inside your body.  I will not take your blood.   
 
Risks and benefits:  There is no risk to your body or health by being a part of this study.  There is no benefit 
to you or your body by being part of this study.  There is no treatment for Ebola or the pains people have 
when they survive Ebola.  You will not get any treatment by being part of this study.  The information I get 
from you will help nurses and doctors understand why survivors of Ebola have pain and tiredness.  This will 
help us understand how to take care of people who survive Ebola in the future. 
 
Privacy:  You name will not be given to any person.  The name of your village will not be given to any 
person.  I know your name and village, and I will keep it private for just me.  Information about how you got 
Ebola, your treatment, and the pain you have will be published.  I will not give any information that will tell 
people who you are. 
 
Time:  This exam and the questions will take about 1 hour. 
  
Payment:  You will not get money for being in this study. 
 
If you have questions:  You can call me, Jennifer, on my Liberia mobile.  The number is +231 88 618 7306.  
When I am in America, you can call me on my American mobile.  The number in America is +001 310 948 
2366. 
 
Participant:  I am signing this form because the study was told to me in a language I understand.  I know that 
I will be asked questions about my body and when I had Ebola.  I do not have to be in this study.  If I want to 
152 
 
be in this study, I will have a copy of this paper.  I know there is no treatment for Ebola.  I know my name 
and village name will not be given to anyone. 
 
Photos (“snaps”):  I may ask to take snaps of your exam.  I will not take pictures of your face.  If the snaps are 
used in the research, your name and face will not be in the snap. 
 
By putting your name or mark below: 
 
It is okay for snaps of me to be taken and published.  _________________________    
 
It is NOT okay for snaps of me to be taken and published.  _________________________  
 
_____________________________________ __________________________________ 
Your Name or Mark   Your Date of Birth or Age 
 
_________________   ____________________ 
Date of Exam   Your Mobile Number 
 
_____________________________________ 
Witness Printed Name or Mark   
 
_____________________________________ ___________________________ 
Signature of Nurse Doing Your Exam  Liberian Nursing License Number 









FIELD INVESTIGATION NOTES, LIBERIA, JUNE 2015  
 
 
Cross-checking notes from survivor interviews with retained prescription medications 
from pharmacy in Monrovia. 




HISTORY AND PHYSICAL EXAMINATION, HUSBAND, LIBERIA, 2015 
 
General appearance is that of a well-appearing, 40 year-old, muscular African male. Posture is erect; appears 
thin for height/weight. Demeanor, facial expressions appropriate to clinical setting. Maintains eye contact. 
Intellect congruent w/ educational level. A&O x 3. Immediate, recent, remote memory intact.  
 
PMI: (1) 2009 admission for blood transfusion s/t malaria, (2) 2003 surgery for repair of LLL bisection of 
tibialas anterior during the civil war.  
MEDICATIONS: None.  
ALLERGIES: Cotrimoxazole; reports acute, intense dermal itching.  
FAMILY HISTORY: Older brother with diabetes. Mother has chronic lower back pain. No h/o HTN or 
vascular disease.  
SKIN/NAILS: Integument smooth, intact. Soft, warm to touch. No edema, rashes. Nails firm, clean, smooth. 
Hands calloused, appropriate to occupation. No clubbing, cyanosis. Lateral aspect of RLL significant for 1-inch 
open lesion, circular in appearance. Patient states it is a recent wound r/t farming. Borders pink with evidence 
of epithelial regeneration. No pus or exudate with palpation.  
HEAD AND NECK: General appearance is normal cephalic shape proportional to body. Hair closely shaven. 
Facial features symmetrical, appropriately placed. No pain reported upon palpation of skull. Lymph nodes, 
thyroid not palpated; no masses, swelling observed.  
EYES: Eyelids are smooth, lashes appropriately placed. PERRLA. Conjunctivae pale w/o exudates; sclerae moist, 
white with intermittent brown coloration. Lacrimal ducts moist without tearing. Cornea smooth, transparent 
w/ symmetric light reflex. Six cardinal positions of gaze (CN III, IV, VI) intact w/ smooth movement. No 
nystagmus. Fundoscopic exam not performed.  
Peripheral fields not equal. Right eye has normal confrontation, peripheral visual fields, and distal acuity. 
Left eye has decreased confrontation, marked distal acuity deficit with inability to discern the number of 
fingers presented. Left peripheral deficits: inferior and superior ≈ 45 ̊ from transverse plane, nasal ≈ 30 ̊ 
from sagittal plane, and temporal ≈ 60 ̊ from sagittal plane.  
ENT  
Ears: Pinnae symmetrical, appropriately placed on head. No pain upon palpation. Sensation equal 
bilaterally. Internal exam not performed.  
Nose: No discharge, obstruction. Septum is midline. Nares symmetrical, clear, patent. Internal exam, 
smelling test for CN I not performed.  
Mouth/pharynx: Lips dry, brown, symmetrical. Mucosa moist, pink, w/o lesions. Teeth present, clean; 
gums well-attached to dentitia. No pain with mastication. Swallow normal. Internal exam not performed.  
THORAX AND LUNGS: Respirations unlabored, smooth. No cough, pain with normal/deep respiration. No 
boney abnormalities. Movement symmetrical w/ respiratory excursion. No use of accessory muscles. No audible 
rhonchi, wheezes or rubs. Jugular, carotid pulsations not visible. Auscultation, percussion not performed.  
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CARDIOVASCULAR: RRR. No gallop, rub, or murmur.  
ABDOMEN: Integument smooth, intact w/o lesions, color congruent w/ rest of body; normal hair distribution. 
Soft, flat, bowel sounds audible x 4 quadrants. Nontender to light, deep palpation. BS, liver not examined. 
MUSCULOSKELETAL: Posture is erect and stable in sitting, standing, walking positions. Vertebral column 
straight w/o visible lordosis, kyposis. Head appears midline between shoulders. Muscle mass, tone equal 
bilaterally. Joints are defined w/o edema. Patient has full ROM of bilateral knees but demonstrates pain at 
extremes of flexion/extension. ROM of shoulders limited by pain at extension above shoulder level. Grip, UE 
strength strong, equal bilaterally; however, arthralgia of wrist, elbow, and shoulder joints made assessment 
difficult. Patient has extreme sensitivity to palpation over the lumbo-sacral area; retracts from slight pressure. 
From L3-L5, pain ascends the vertebral column to T7-T9. Patient indicates severe pain from C1-C7 with 
limited ROM of head in all four directions. Pain is concentrated over the splenius capitus and occipitalis muscles 
with a visible pain response upon palpation. For emphasis, the patient experiences relief from pain only when 
all the joints are in their most neutral positions without motion.  Patient denies myalgias, although the muscle 
fibers in immediate proximity to the joints are mildly painful. In fact, it is the arthralgias that fatigue him, not 
muscular fatigue. All joints, including the fingers and toes, are painful, limiting the ability to perform DALYs, 
especially farming. When discussing his pain, the patient becomes visibly saddened.  
NEUROLOGIC  
Mental status: The patient is alert, attentive, and oriented. Speech is clear and fluent with good repetition, 
comprehension, and recall.  
Motor: Patient moves all extremities. Coordination, accuracy of movement equal bilaterally, upper, lower. 
Gait even w/ alternating arm movement. No loss of balance. No tremor, abnormal or extraneous 
movements. Gait is steady with normal step, base, arm swing, and turning. Heel and toe walking are 
normal.  
Reflexes: Not examined.  
Sensory: Grossly normal to light touch, pressure. Senses are intact in fingers and toes. No neuropathy or 
paraesthesia.  
Cranial Nerves  
CN II: Visual fields are full to confrontation.  
CN III, IV, VI: At primary gaze, there is no eye deviation. When the patient is looking to the left, the right eye 
does not adduct. When the patient is looking up, the right eye does not move up as well as the left. She develops 
horizontal diplopia in all directions of gaze especially when looking to the left. Convergence is impaired.  
CN V: Corneal responses intact bilaterally. Facial sensations intact on right side. Tactile sensation diminished 
over the three branches.  
CN VII: Face is symmetric with normal eye closure and smile.  
CN VII: Hearing is normal with to whispering. Answers questions appropriately.  
CN IX, X: Not examined.  
CN XI: Head turning intact.  
CN XII: Not examined.  
GENITOURINARY: Not examined. Patient states he occasionally awakens with an erection of height and firmness 
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